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The interest on crystal forms of APIs arises from the different properties, as such as solubility, dissolution rate, 
and bioavailability which they exhibit. A strategy to improve the properties of compound, is the formation of 
cocrystal involving API and a coformer. In this PhD project, a cocrystal screening of cosmetic API allantoin and 
some coformers of cosmetic interest was performed. The screening was preceded by statistical analysis of 
possible cocrystals of allantoin using CSD- materials. Potentially, allantoin can be involved in cocrystal 
formation with the selected coformers. Nevertheless, experimental results disagree with the statistical analysis 
and no cocrystal were obtained. The unique known crystalline form of DL-allantoin has been shown to be 
extremely stable and not available to make interaction with other molecules.  
The PhD thesis is focused mainly on quantitative method of API crystalline forms via X-Ray Powder Diffraction 
because the high request of the pharmaceutical companies to establish the quantity of polymorphic impurities 
or partially recrystallization of amorphous. These information are fundamental to guarantee the quality and 
efficacy of the drug product during and after the manufacturing process. The polymorph of the drug product 
must be qualitatively and quantitatively evaluated to monitor the potential transition of the polymorphic form in 
another. Therefore, the development of solid-state quantitative analysis method is essential for control 
products’ stability. X-Ray Powder Diffraction (XRPD) is the main technique applied for qualitative and 
quantitative determination of the polymorphs.  
The systematic and accidental errors, which may impact the analysis, have been studied to avoid such errors 
during the analysis. As evidenced also during the real case of quantitative analysis investigated, the 
preparation of homogeneous calibration standards, is extremely challenging for solid-state mixtures, but it is 
fundamental to achieve satisfactory results.  
In the PhD thesis different approaches of quantitative analysis are reported: univariate, multivariate method 
with or without internal standard. 
Frequently, the content of a crystal form is precisely quantified in a wide range with construction of a calibration 
curve and it is possible to reach the low weight fraction of 1%.  
I presented the example of quantification of a polymorphic impurity (paracetamol form II) in the commercial 
preparation of Tachifludec which contains paracetamol form I. The main issue in univariate method is the 
identification of a specific peak of the analyte among the several peaks due to the excipients which can 
interfering with the analyte. Although a specific peak was present, its intensity was not sufficient for 
quantification of low percentage (< 15%). The presence of several peaks due to the formulation was overcome 
by applying the standard addition method (SAM) and the tachifludec formulation was spiked with paracetamol 
form II. The data were evaluated by univariate and multivariate method NAS and the best results were obtained 
with the application of the multivariate method NAS. These approaches were also evaluated in the case of 
mixture amorphous-crystalline. Two different standards were used: mixtures of α-lactose 
monohydrate/amorphous lactose and α-lactose monohydrate/Hydroxy propyl methyl cellulose (HPMC). In the 
last case it was studied the potential use of stable amorphous surrogate as Hydroxypropyl methyl cellulose 
(HPMC) instead to the unstable real amorphous in crystallinity degree determination. The univariate analysis 
was applied to five different peaks of α-lactose monohydrate but only two signals gave satisfactory results with 
R2 values. It is worth noting that the α-lactose monohydrate is affected by preferential orientation, which 
significantly decreases the reliability of the calibration curve. Even in these cases, multivariate method 
achieved the best results succeeding into overcoming of inhomogeneity problem that mostly affects the 
univariate analysis.  
The novel XRPD quantification method based on the whole pattern Direct derivation (DD) based on intensity–
composition equation was applied to determine crystallinity degree of binary mixture containing HPMC as 
amorphous and monohydrate α-lactose in percentage ≤ 15% w/w. The quantification method was evaluated 
in three scenarios: method a) the unit cell parameters of the crystalline form are available, method b) the 
structural information is unknown, but the patterns of pure crystalline and amorphous references are available, 
and method c) only the mixtures’ patterns are available. The obtained results in the three different scenarios 
evidence comparable and reasonable relative errors (<20%) in methods a and b, while in method c the 
crystalline degree was underestimated with relative errors ranged up to 40%. Method a and b achieved more 
accurate results than method c because it was possible to better describe the crystalline phase with a high 




evaluate the analysis of highly potent compounds. In this last case an accurate quantification was achieved 
removing the matrix effect by subtracting the Kapton® film signal from the total signal. 
Finally, I evaluated three different methods: autoscale, USP and direct derivation (DDQM), for the crystallinity 
degree determination of three sample (Test 02, Test 03, and Test 04) of formulation containing highly potent 
API deposited on catheter balloon. To evaluate the best approach for the quantification of the drug coated 
balloon (DCB) the three methods were assessed with mixtures on HPMC and α-lactose monohydrate analysed 
in the same way into a glass capillary. The quantification of the DCB samples presented several difficulties: 1) 
the amount of powder for each samples was around 10-15mg so it was impossible add an internal standard, 
2) the filling of the capillary is particularly challenging; 3) the preparation of known samples is prevented by the 
absence of suitable amount of amorphous and crystalline references precluding the assessment of the 
precision and accuracy of the methods; 4) the nature of API itself because it is highly potent and it has non-
stoichiometric hydrate behaviour, so the crystal structure can slightly change from sample to sample.  
The three quantitative methods gave different quantification of the crystalline material. With the autoscale 
method, all the DCB samples showed crystallinity degree comparable to the crystalline reference, however the 
difference plot was very noisy because of the mismatch of the crystalline peak positions in the reference and 
the samples, so it was not considered reliable. The USP method required a correction factor based on the 
100% crystalline reference and gave a crystallinity around the 81%-97%, while the DDQM gave a crystallinity 
between 59%-71%. The results of USP method and DDQM method are not comparable between them but 
they are consistent inside the method. Both methods agree to determine the sample Test 03 as the most 
crystalline sample and the other sample Test 02 and Test 04 with a comparable crystallinity degree. 
Nevertheless, the DDQM method was considered the best method to estimate the crystallinity degree of 
formulation onto DCB because of the directly determination without application of a correct factor needed for 
the USP method and of the possible application of Pawley function and hence determination of the changing 







CHAPTER 1  
CRYSTAL FORMS 
1 POLYMORPHISM IMPORTANCE IN PHARMACEUTICAL FIELD 
The term polymorphism derived from the Greek words polus (πολύ) meaning much/many and morphẽ (μορφή) 
meaning form, in chemistry it denotes the physical phenomenon consisting, essentially, in the possibility of a 
compound to exist in different crystalline forms. Crystals are characterized by the order arrangement of the 
atoms in the three dimensions. Usually they are described by a structural unit, called unit cell, which is repeated 
regularly in three dimensions in space 1,2. In polymorphs the same atoms or molecules are arranged differently 
in the unit cell, yielding to different crystal phases. Crystalline solids are usually very stable, have a well-defined 
melting point value and often exhibit different behavior in different measurement directions, i.e., they are 
generally anisotropic. Compounds can exist as amorphous solid, which is characterized by highest density of 
imperfections, and it is commonly described as a liquid with a very high density. Amorphous compounds are 
less stable than crystalline solids and do not present melting point. Generally, they show hygroscopic behavior, 
i.e., absorb water from the atmosphere in ambient humidity conditions, and they are isotropic, which means 
they have the same physical properties in all directions. Alongside amorphous and crystalline polymorphs, 
several different crystal forms related to a target compound are studied. We can distinguish solvates or 
pseudo-polymorphs which commonly appear during the polymorph screening, salts and cocrystal, as 
represented in Figure 1 and described following.  
 
 
Figure 1. Solid-state forms 
 
Polymorphism phenomenon and the study of the different crystal forms is extremely important in industry, 
especially in pharmaceutical. Guideline for the investigation, determination, development, manufacturing, and 
control of the different crystal structures of a new drug are issued by ICH (International Conference on 
Harmonization) and FDA (Food and Drug Administration). These organizations underline the importance to 
study polymorphism and solvate formation of new drug and to control this phenomenon during the whole 
process because of differences in forms could affect the quality and performance of the new drug products. 3,4  
ICH Q6 provides guidance on how and when the polymorphic forms should be investigated and controlled also 
considering the impact of the polymorph on the performance of the relevant final drug product (solid or liquid 
dosage) (Figure 4). 3 The first step is to conduct a polymorph screening to find out all the multiple crystalline 
forms of the new drug, extremely probable considering the statistic. In fact, Stahly G.P., in his paper reveals 
that 90% of organic compounds exist as amorphous and multiple crystalline forms and about 50% of molecules 
has solvates and hydrated forms. 5 In the mid1990s, polymorph screening was proposed as procedure to find 
the form with the most advantageous bioavailability. The goal of polymorph screening is to find all potential 




dosage products. 6 The guideline does not report a procedure for the polymorph screening which needs to be 
tailored on the properties of the target molecule. Several techniques can be used to obtain new crystal form 
as such as crystallization by shock colling, evaporation, precipitation, vapor diffusion, slurry (suspension 
equilibrium), crystallization from melt, humidity induced transformation, sublimation, desolvation, salting out, 
pH change, lyophilization, etc.1 Once polymorphs had been identified and isolated, their characterization shall 
be carried out by single crystal (SCXRD) and powder (XRPD) X-Ray diffraction, thermal analysis as differential 
scanning calorimetry (DSC) and thermogravimetric analysis (TGA), microscopy, solid-state nuclear magnetic 
resonance (SSNMR), infrared (IR) spectroscopy and Raman one.  
X-Ray diffraction is the main technique for the study of polymorphism. The XRPD diffractogram of crystalline 
phase is characterized by sharp peaks, while amorphous phase gives only a halo. Hence, XRPD readily 
distinguishes between crystalline and amorphous phases. Additionally, XRPD pattern is characteristic of each 
crystalline phase, as a fingerprint of the crystalline structure. In fact, United States Pharmacopeia (USP) 
reports XRPD as leading technique for identification of the crystalline phases. In addition to qualitative phase 
analysis, USP also indicates XRPD for quantitative phase analysis of crystalline fractions. X-Ray diffraction 
allows the determination of the crystalline structure giving information about the unit cell parameters and the 
position of the atoms. On the other hand, when the crystal structure is known it is possible to calculate XRD 
pattern with corrected position and intensity (devoid of preferred orientation). Single crystal X-Ray diffraction 
is the principal technique for solving crystalline structures, but it requires a single crystal with suitable size, not 
always available, alternatively even powder XRD is able to determine the crystalline structure. However, it is 
more challenging due to reflection overlap, hard background determination and possible preferred orientation 
phenomenon, especially for organic compounds, which have large lattice, and low symmetry and scattering 
properties. 7,8  
Other useful techniques for the polymorph characterization are FT-IR and FT-Raman spectroscopy, whose 
spectra are molecular structure fingerprint and are sensitive to conformation and environment as such as 
different interactions. FT-IR and FT-Raman are complementary technique because FT-IR is based on 
absorption of infrared light by molecule that changes a dipole moment (asymmetric mode), while FT-Raman 
is based on scattering of laser radiation due to change in the polarization of the molecule (symmetric mode). 9 
Both qualitative and quantitative analysis can be performed using FT-IR and FT-Raman spectroscopy.  
Other powerful but lesser-known technique is SSNMR, based on the resonance frequency of nuclei (13C, 15N, 
31P, 25Mg, and 23Na) in a strong magnetic field. It is complex and highly cost technique, though it gives wide 
structural and dynamic information about both crystalline and amorphous materials and even formulations. 
Among all, it provides information about crystalline structure, solid state chemical reactivity, interaction 
between API (active pharmaceutical ingredient) and excipients, and it can be used in quantification analysis. 
9–11  
Differential scanning calorimetry (DSC) and thermalgravimetric analysis (TGA)  are destructive techniques that 
investigate the thermal behavior of compounds. DSC measures the different heat absorbed or released by 
analyzing the temperature difference between reference (empty pan) and sample during heating and cooling. 
The temperature and energy involved in melting, crystallization, solid-solid reaction, and evaporation events 
can be easily determined. TGA measures the change in mass of a sample during a heating cycle. It is useful 
in the solvates and hydrates study and in determination of their stoichiometric and stability. Microscopic 
techniques are used to evaluate the morphology, shape, and particle size of the crystalline (Figure 2). 
Additionally, polarized light microscopy (PLM) studies the different optical properties of materials and it can 
mainly be used to readily discriminate between amorphous and crystalline materials, because amorphous 
phase (isotropic) propagates light in the same way in all directions and completely extinguished the light, while 







Figure 2. Image of prism crystal by optical 
microscopy  
Figure 3. Image of crystalline phase by PLM 
 
A combination of several techniques is usually recommended to obtain suitable and deep characterization of 
drug substance. Physical characterization is a crucial aspect of evaluating the performance, efficacy, and 
stability of materials under development and of selecting the best polymorph for the drug product. Properties, 
as such as solubility, stability, and melting point, of the new crystalline forms impact differently on quality of 
the drug product depending on the intended dosage form. The polymorphic form is important in dosage choice, 
the manufacturing process, and formulation.6 In pharmaceutical practice, the solid phase is the widely 
preferred phase for the easiness of handle and its stability and the compliance of the patient. The 
administration of drug products occurs commonly via oral dosing, in which solid state of the ingredients 
significantly affect the performance. 12,13 Lipinski et al. point out that in oral administered drug with a dose of 1 
mg/kg and solubility greater than 65 ug/mL absorption is unaffected, while solubility less than 10 ug/mL limits 
absorption. 14 Hence, ICH requires control of drug substance polymorph in case of solid dosage form and liquid 
containing undissolved drug substance to avoid adverse effect on drug product performance and quality. 3 The 
strategy of control, such as appropriate tests and acceptance criteria are determined case by case. Byrn et al. 
provide different flow charts for different common types of solid (polymorphs, solvates, amorphous). Generally, 
when single polymorph is routinely produced from manufacturing process, they recommend a qualitative test 
to differentiate and control the form, e.g., XRPD or DSC. Otherwise, when the manufacturing process provides 
mixture of forms, quantitative tests are needed to determinate the composition, in particular, limit test should 
be performed to control the presence of particular form below acceptable amount.15 Furthermore, control of 
polymorph of APIs is necessary after manufacturing of the drug product because of possible changes in its 
crystal form, such as amorphization, crystallization, polymorphic transition or alteration in chemical composition 
(desolvation or salt-free base/acid transition) can occurred during the process or the storage. Several stresses 
undergo during the manufacturing process of drug product for example mechanical stress (e.g. milling, 
compression), thermal stress (e.g. freezing, drying, melting) and interaction with other components, may 
induce phase transition. 1 In case of a drug substance sensitive to polymorphic alteration, its stability should 
be monitored during its production and storage to assure reproducibly and stability of the final product. 
Especially, the check of drug polymorph is crucial in case of high risk of adverse effect in efficacy and quality 
of formulation. Nevertheless, the entity of the tests and acceptance criteria should be assessed on a case-by-
case basis, considering the characteristic of the drug. 16 FDA reports that concern about the polymorph in the 
drug product is not in needed “if the most thermodynamically stable polymorphic form is used or the same form 
is used in a previously approved product of the same dosage form” and it estimates that “Drug product 
performance testing (e.g., dissolution testing) can generally provide adequate control of polymorph ratio 
changes for poorly soluble drugs […] Only in rare cases would polymorphic form characterization in the drug 






Figure 4. Flow of drug substance polymorph evaluation based on ICH and FDA guideline 
 
The formation of different polymorphs is primarily lead by the kinetic and thermodynamic of the system. In fact, 
polymorphs are solid phases with distinct Gibbs free energy, enthalpy, and entropy due to the definite 
molecular interactions in crystal lattices. It is worth noting that the difference of free energy between 
polymorphs are small, 90% of polymorphs differ by less than 4 kJ/mol (or 1 kcal/mol), however, the structural 
difference between the polymorphs and the resulting different free energy lead to different properties, such as 
stability and solubility. 6,13,17 Additionally, polymorphs present differences in other several properties, as such 
as dissolution rate, compressibility, and handling, that can drastically affect the properties of pharmaceutical 
product and its manufacturing process. In Table 1 are set out thoroughly all the different properties that differ 
among crystal forms1,18–20.  
 
Table 1. Different physical properties of polymorphs 
Packing properties Molar volume and density  
Refractive index 
Conductivity: electrical and thermal 
Thermodynamic properties Hygroscopicity 
Melting and sublimation temperatures  
Internal or structural energy 
Enthalpy 
Heat capacity  
Entropy  
Free Energy and Chemical Potential 
Thermodynamic Activity  
Vapor Pressure  
Solubility 
Spectroscopic properties Electronic state transitions  
Vibrational state transitions  
Nuclear spin state transitions 
Kinetic properties Dissolution rate 
Rates of solid-state reactions 
Stability 




Mechanical properties Tensile strength  
Compressibility, tabletting 
Handling, flow, and blending 
 
In the formulation of a pharmaceutical product the physical-chemical stability, solubility, and bioavailability of 




Generally, the most stable crystalline form (lowest free energy) leads the choice of the pharmaceutical industry 
for drug products thanks to its stability. The possibility of interconversion between the various forms can have 
very serious consequences on the life of a product. The risk of significant impact on product performance due 
to polymorph transition is high for poorly soluble and unstable drug substance. 12 Despite their poor stability, 
amorphous and metastable solids have attracted the attention of pharmaceutical industries because, thanks 
to their high free energy, they have higher solubility and dissolution rate, which give medical benefits as 
bioavailability and drug delivery. These properties could be used to increase the absorption and performance 
of poorly soluble drugs. In fact, poor bioavailability of drug substance (<20%) can result poorly controlled 
pharmacological effects, and poorly controlled toxic effects. 12 Generally, different polymorphs show different 
solubility less than 10 times, while largest difference (up to several hundred times) is observed between 
amorphous and crystalline phases. Solvates are always less soluble in the solvation solvent, thus, hydrates 
are less soluble in water than the anhydrous solid. 12,21 As demonstrated by Kobayashi at al., the solubility of 
anhydrous Form I and III of carbamazepine is 1.5–1.6 times more soluble that dihydrate form. 22 
Therefore, the research and characterization of the crystal forms of a molecule, such polymorphs, salts, 
solvates or cocrystals, expand the choice of the most suitable solid form for the development of a new drug 
and has relevant implications in the manufacturing. The desired crystal form is chosen also taking into account 
all the manufacturing process, in fact, another critical factor of developability is the ability to scale-up the 
manufacturing of the selected crystal form. The manufacturing process of drug substance and product should 
be reproducible and with a reasonable cost. 12 The knowledge of the solid-state properties of APIs in the first 
steps of drug development, avoids problems related to their production and optimize the drug product 
manufacturing process.  
The pharmaceutical companies invest wide resources, time, and cost, to deeply study and develop drug 
products, hence they are concerned to protect their own inventions by patent. Additionally, the polymorphism 
is potentially of great business-wise importance for pharmaceutical industry thanks to the patentability of the 
crystalline forms, which show the three requirements for US patent: utility, novelty, and non-obviousness. The 
potential difference in properties of different polymorphs allows to claim the crystal form in patent. In recent 
years, increasingly economic and regulatory pressure, the cost of the discovery of even more rare new drugs, 
and the constantly expiration of drugs’ patents has led the pharmaceutical industry to focus on patents’ lifecycle 
of their existing drug products. Typically, pharmaceutical companies implement the strategy of claiming new 
crystalline form usually 4-6 years after the issue of the original patent to extend its protection. 23  
Concluding, the polymorph screening of pharmaceutical compounds and the characterization of the crystal 
forms of the APIs lead to choose the best crystal form for the pharmaceutical formulation and constitute a 
strategic patent defense tool for drugs .24,25. 
 
2 CRYSTAL FORMS 
2.1 Polymorphs 
Polymorphism occurs when compounds with the same chemical composition arrange atoms or molecules in 
different crystalline structures characterized by long range order with different inter- and intra-molecular 
interaction network and consequently different level of free energy and solid-state stability, that makes them 
desirable for active pharmaceutical ingredients. 17 Cruz-Cabeza et al. report that polymorphism is independent 
of most molecular properties except for chirality and flexibility of the molecules. 17 Crystalline form can be stand 
out in configurational and conformational polymorphs related to flexibility of the molecules. Configurational 
polymorphs, called also packing polymorphisms, have different crystalline structure with distinct molecular 
interaction networks but equivalent molecule conformation. Typically, conformational polymorphism occurs 
with molecules with rigid conformation, for instance carbamazepine that exists in four different polymorphs 
with equivalent molecular conformation, hydrogen bond network and consequently similar free energy 
(difference within 0.7 kcal/mol). 26 Contrarily, in conformational polymorphism the molecules show multiple 
conformations, the flexibility of the molecular structure allows manifold interaction, different packing, and 
various crystalline structures. An example of conformational polymorph is ritonavir form I and II, which 
respectively show the molecule in cis and trans conformation around carbamate bond. The different molecular 




resulting in different properties, as such as morphology and solubility. In case of ritonavir, the forms have 
divergent solubility affecting their performance and additionally different morphology, form I has plate-like 
shape while form II shows acicular shape. 27  
To describe the thermodynamic relationship of polymorphs, we can consider a dimorphic system with form A 
and B in isobaric condition. The pair of polymorphs can form an enantiotropic or monotropic system. In an 
enantiotropic system, a reversible transition between polymorphs A and B exists at define temperature before 
the melting points of both polymorphs. At this transition point (Tt) the free energy of the two polymorphs is 
equal GA = GB and they undergo solid-solid transition (Figure 5 right side).  
In the case of monotropic system, only one of the polymorphs is stable in all the temperature, that is 
characterized by the lowest free energy value below the melting point of both polymorphs. As reported in left 
side of Figure 5, the free energy of polymorph B is always lower than one of polymorph A GB < GA. 19,28 
The polymorph with the lower free energy (higher melting temperature) is the thermodynamic stable form. The 
metastable form should convert to stable form at any temperature but, the conversion is kinetically avoided. 29  
It is important to establish the stability of the polymorphs. Generally, slurry experiments allow to identify the 
thermodynamic stable polymorph. As the same way, antisolvent diffusion and slow recrystallization are used 
to obtain more stable forms. On the contrary, metastable forms are generally obtained by fast crystallization, 
as such as high supersaturation, precipitation with antisolvent, quench-cooling, and pH change.  
 
Figure 5. Energy-temperature plot for monotropic (left side) and enantiotropic (right side) system. 
An extensive polymorph screening on the target API is important to assure consistent and reproducible 
production of the desired form, and to avoid the appearance of a new polymorph on the late stages of bulk 
drug process development as in the case of ritonavir. 
The occurrence of the more stable and dramatically less soluble form II of ritonavir in batch of more soluble 
form I, affected the effectiveness of the drug product. Production of pure batch of the metastable form I had 
been impossible for the concomitant crystallization of the two forms due to competing kinetic and 
thermodynamic factors which forced the Abbot to rethink to the manufacturing process. 27,30   
 
2.2 Solvates/Hydrates 
Solvates are crystalline form containing into crystal lattice a molecule of solvent, when the solvent is water the 
crystalline form is called hydrate.  
Large number of pharmaceutical compounds are solvates and hydrates, often called pseudo-polymorphs. The 
propensity of API and solvent molecules to crystallize in solvate form depends on their molecular structures 
and tendency to form hydrogen bonds. Water is extremely receptive to form hydrates thanks to its small size 
and propensity to form hydrogen bonds both as donor and acceptor. In fact, a survey of the Cambridge 
Structural Database demonstrated the more frequency of hydrates than solvates with organic solvents, about 




promotes the formation of hydrates. Mostly, hydrates are of great interest in pharmaceutical field due to 
stabilization effect of water and safety concern about organic solvent toxicity, not suitable for drug substance.  
Based on structural aspect of the interaction between water and API, hydrates are classified in three different 
classes. Class I) the water molecules are isolated from other water molecules. Water molecules interact only 
with API through hydrogen bond and van der Waals interactions. Hydrates of class I are identifiable by DSC, 
TGA and infrared spectroscopy. These hydrates show sharp endothermic peak and weight loss in small range 
due to dehydration in DSC and TGA respectively and hydroxyl bands in IR spectroscopy. 6 Class II) water 
molecules interact both with API and adjacent molecules of water. These hydrates are called channel hydrate 
due to the formation along crystallographic axis of channels or layers where water molecules are located. 
Hydrates of class II are divided in channel and planar hydrate based on hydration and dehydration behavior. 
Exposed at high humidity, channel hydrates can host additional water molecules into the channels expanding 
the crystal lattice in all the directions changing the unit cell dimension, this can be observed with the shift of 
crystalline reflection in XRPD pattern. While, in planar hydrates the water molecules are in layers between 
drug molecules and the exposition at high humidity causes expansion of crystal lattice only along an axis. 
Generally, channel hydrates are nonstoichiometric hydrates, while in planar hydrates the amount of water in 
layers change stoichiometrically in accordance with relative humidity. 6 Stochiometric hydrates show 
hydrate/dehydration transition point at critical RH%. In nonstoichiometric hydrates water molecules can move 
into or out of the crystal lattice without occur in solid state transition and the form is stable in a wide range of 
RH%. Figure 6 reports an example of XRPD pattern of nonstoichiometric hydrates, red pattern was collected 
at 60%RH, while collection of the green pattern was performed after stability at 75%RH. The XRPD comparison 
points out the shift in position of the peaks in the range 8-14°2θ and around 20°2θ due to the increased of 
relative crystalline planes while the peaks in the range 14-19°2θ are superimposable. Class III) are metal–ion 
coordinated hydrates in which water molecules form strong ion-water bonds. 31 
 
 
Figure 6. Example of nonstoichiometric hydrate. Red pattern was collected at 60%RHwhile collection of the 
green pattern was performed at 75% RH. 
Different physical, chemical, and mechanical properties are observed between hydrates/solvates and 
anhydrous crystal forms and between hydrates of different stoichiometry. It is worth noting that hydrates are 
less soluble in water than the anhydrous form which are commonly two times more soluble. Additionally, 
mechanical properties of the powder are affected by hydration state, for instance different compressibility of 
anhydrous and dihydrate forms of dibasic calcium phosphate. 32 
Typically, solvates and hydrates arise during slurrying, refluxing, wet granulation, or exposition to solvent 
vapor. Exposure to solvent vapor can also lead to the formation of solvates. Hydration states of a compound 
can be studied by moisture sorption experiments with DVS (Dynamic vapor sorption) analysis or by exposure 
to high humidity. Karl Fisher titration measures the amount of water present in a powder. TGA can measure 
the amount of weight loss during desolvation/dehydration process and in connection with EGA (evolved gas 




DSC. Using at hot stage microscopy desolvation/dehydration can be directly observed. Study of crystalline 
structure by SCXRD allows the determination of the presence of solvent/water, its location in the crystalline 
lattice, the interaction involves and the classification of the hydrates. XRPD, FT-IR and FT-Raman monitors 
the transition of the phases.  
 
2.3 Cocrystal 
Cocrystal is a multicomponent crystal containing within the crystal lattice two or more components in neutral 
and solid state, generally in a stoichiometric ratio, linked via non-ionic interactions, typically hydrogen bond 
interactions, but also van der Waals forces and π–π interactions. Considerable number of APIs potentially can 
form cocrystal because of their propensity to interact through hydrogen bonds. When cocrystal is constitutes 
by an API and the other molecule, named coformer, pharmaceutically acceptable for safety reason, it is labeled 
as pharmaceutical cocrystal. 33 FDA reports “drug products that are designed to contain a new co-crystal are 
considered analogous to a new polymorph of the API. A co-crystal that is composed of two or more APIs (with 
or without additional inactive coformers) will be treated as a fixed-dose combination product and not a new 
single API”. 34  
For safety reason the choice of possible coformers is limited at small group of amino acids, acids, bases, 
nucleotides, or vitamins. However, cocrystals are very attractive for their significantly different physical and 
chemical properties compared to pure starting materials. Cocrystal formation can enhance the performance of 
API, as such as stability, solubility, bioavailability, and efficacy. An example, cocrystal of tramadol and 
celecoxib shows improvement in safety of tramadol and in bioavailability of celecoxib compared to the drugs 
dosing separately. 33 Additionally, cocrystal formation is extremely promising especially for neutral molecules 
with non-ionizable functional groups in which salt formation is not applicable. It was demonstrated that 
cocrystals, as well as salts, may show polymorphism and form various polymorphs and hydrates. Among 
others, carbamazepine-saccharin and carbamazepine-nicotinamide cocrystals have shown two polymorphs 
each other. 35 
Several methods yield to the formation of cocrystal including solid state methods, as such as mechanical 
synthesis (grinding and kneading) and extrusion, solution methods (isothermal slurry conversion, evaporation, 
spray drying, and precipitation), and supercritical fluid methods. 36 
Cocrystal are characterized using SCXRD and SSNMR to define molecular interaction and stoichiometry to 
confirm the cocrystal structure, by thermal analysis DSC and TGA to determine melting point and presence of 
solvent, and spectroscopy FT-IR and FT-Raman.  
 
2.4  Organic Salts 
Several compounds contain ionizable groups and can constitute salt with appropriate ions via acid – base 
reaction. The condition for forming of salt is pKa difference greater than 2 between compound and counter ion. 
Salt formation is important in pharmaceutical industry because is a simple way to change and improve physical 
and chemical properties. The 50% of drug substances in the market are salts. 6 Salts for pharmaceutical 
purpose must include safely counter ions of which toxicity has fully examined. Additionally, safety assessment 
of salt is required for regulatory approval to initiate clinical studies and marketing. 6 
Formation of salts leads to several advantages: poorly soluble drugs may increase solubility and bioavailability, 
taste masking, improvement of physical properties (melting temperature, crystallinity, and hygroscopicity) and 
mechanical ones, augmentation of chemical stability, overcoming of formulation problems (incompatibility with 
excipients), improvement of purity, as such as enantiomeric purity, as in the case of chiral compound 
clopidogrel. Only S enantiomer of clopidogrel shows biological activity additionally R enantiomer has poor 
tolerability, the selective formation of salt of 10- L-camphorsulfonic acid with S enantiomer of clopidogrel 
resolves the racemic mixture. 37 
Nevertheless, the stability and solubility of salts depends on the pH of aqueous solution. The pH value in which 
salt reaches the maximum solubility and the transition in free form occurs is labeled pHmax. Salts resulting 
from weak base are stable at pH values below pHmax, while salts of weak acid are stable at pH higher than 
pHmax. For this reason, in formulation it is fundamental to consider the stability of the salt and its pH solubility 




transition in free form. In solid dosage form, salt with low hygroscopicity and high crystallinity is preferable to 
avoid changes due to interaction with water in excipients and environment. 38 
First, fundamental information to conduct a salt screening is the knowledge of pKa of the drug substance to 
choose suitable counter ions based on their pKa and drug-ion pKa difference. The salts are characterized 
mainly with XRPD and spectroscopy technique, as such as FT-Raman. SCXRD and SSNMR are extremely 
useful to define the crystalline structure and determine the formation of salt or cocrystal. Moreover, dissolution 
testes at different pH to study the pH solubility profile are essential.1 
 
2.5 Amorphous phase 
ICH and FDA define polymorph as different forms of the same drug substance which differ in their physical 
properties and report “Polymorphism may also include solvation or hydration products (also known as pseudo-
polymorphs) and amorphous forms” including amorphous phase in polymorphism phenomenon.  
The amorphous phase is characterized by lack of long-range order. Compared to crystalline phases, it has 
higher molecular energy and greater molecular mobility, so we can say that it has microscopically properties 
of a liquid, with macroscopic mechanical properties of a solid. 
Amorphous phase is characterized by high level of free energy that results in wide solubility and potentially 
greater dissolution rates and oral bioavailability compared to corresponding crystal. Conversely, its high free 
energy involves in chemical and physical instability, as demonstrated by Pikal et al. 39  
The properties of amorphous phase related to its free energy are explained by the free energy versus 
temperature plot (Figure 7). At temperature below of melting temperature (Tm) the solid phase is the 
thermodynamically stable form because of it has lower free energy than the liquid phase while at temperature 
higher than the melting point the liquid phase is stable. Slowly cooling the liquid phase at temperature below 
Tm crystallization can occurred. However, quench colling the liquid, the formation of crystal nuclei can be 
avoided, and the system follow the supercooled liquid line shown in Figure 7. Decreasing the temperature, the 
molecular mobility decreases and the viscosity of liquid increases, until glass transition temperature (Tg) in 
which unstable glassy state forms with amorphous characteristics. Glass transition temperature is a kinetic 
transition, hence Tg depends on the rate of cooling and equilibrium of supercooled liquid. Experimentally, Tg 
can be determined by differential scanning calorimetry (DSC). 6 
 
 
Figure 7. Free energy plot 
 
As reported, amorphous phase can be form by melting the crystal and rapidly cooling the liquid to avoid 
recrystallization, this procedure is called vitrification or quench-cooling. However, amorphous can be formed 
through other methods. Generally, formation of amorphous state requires fast changing, as such as in 




crystal structure. Following some examples of amorphous preparation procedure are reported. Amorphous 
can be formed from solution by inducing a rapid precipitation with use of anti-solvent, swift changing in pH or 
temperature. Amorphization can be promoted by grinding, although its efficacy is disputed for the ambiguous 
distinction between true amorphous solid and microcrystalline powder with particle size ≤ 100 Å, hardly 
distinguishable by main technique XRPD and DSC. 40 The most used amorphization methods are lyophilization 
and spray-drying. In the first case amorphization occurs by rapidly freezing a solution and successively 
sublimination of frozen solution and drying to eliminate residual solvent to obtain highly soluble product. Spray-
drying consists in rapid drying through heat atmosphere of atomized concentrated solution to increase the 
surface area in contact with the hot gas. In this way, it is possible to produce powder with good flow properties 
and spherical particle with desired size, usually small size for inhalation dosage forms.1 
In pharmaceutic field numerous amorphous compounds, both excipient and API, are used. Hence, the study 
of the amorphous phase is important because of its advantageous high solubility and, on the contrary, its 
inconvenient instability. In case of poor soluble drug, the amorphous phase is desirable to enhance solubility, 
bioavailability, and performance of the drug product. For example, amorphous form of the antibiotic novobiocin 
shows solubility rate 70 times greater than its crystalline form. For this reason, amorphous phase is preferable 
because it is readily absorbed and it reaches the therapeutic blood level, in contrast to crystalline form that is 
not effective due to its poor absorption. 41  
Nevertheless, as reported by Fukuoka et al, amorphous phase is generally unstable and it tendentially 
crystallizes. 42 Therefore, crystalline phase is usually preferable despite its low solubility.  
Therefore, it is fundamental characterized amorphous phase to know its crystallization tendency, surface 
chemistry and molecular mobility. Additionally, it is important to quantitatively determine the crystalline fraction 
in largely amorphous substance or formulation to, for instance, avoid dramatically decrease of solubility and 
guarantee the performance of the product. Deeply characterization of amorphous phase requires combination 
of technique, especially XRPD, DSC and DVS. In case of amorphous phase XRPD shows diffusive halo as 
opposed to sharp peaks detected for crystalline materials, XRPD pattern is largely used for amorphous-
crystalline quantitative analysis. 43 DSC gives information about Tg, and crystallization temperature (Tc), 
respectively marked in thermogram by change of the baseline due to change in heat capacity and exothermic 
peak. 44 Amorphous phase has high hygroscopicity, its exposure at high humidity induces absorption of water 
and increase in molecular mobility and potentially crystallization. DVS allows to study the amorphous behavior 
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COCRYSTAL SCREENING OF ALLANTOIN 
1 INTRODUCTION 
1.1 Allantoin 
Allantoin (CAS No. 97-59-6) or 2,5-dioxo-4-imidazolidinyl urea (Figure 1) is 5-membered azaheterocycles 
compound with urea as substituent in position 4th and chiral center in the same position.  
 
 
Figure 1. Allantoin structure 
Allantoin is white, odourless, tasteless, and non-staining powder. Allantoin is amphoteric molecule, soluble in 
hot water, slightly soluble in cold water, glycerine, and propylene glycol, even less soluble in alcohol and 
practically insoluble in non-polar solvents. It can be extracted from some plants, as such as callus of Coffea 
Arabica plant, leaves and apical shoots of the Mertensia maritima plant, or it can be synthesized from carbonyl 
compounds, urea and azaheterocycles. 1 
In the 1960s, numerous relevant studies have been conducted on the dependency on pH of hydrolysis and 
racemization mechanisms of allantoin. Vogels et al. have demonstrated the instability of allantoin in alkaline 
media, where it hydrolyses to urea and glyoxylic acid, while in ordinary conditions it is stable. 2 In addition to 
the reactions of hydrolysis and racemization, allantoin can react with phenol, in the presence of heterogeneous 
catalysts such as mineral acids supported onto solid zeolite, producing ortho/para-hydroxyphenyl hydantoin. 3 
Allantoin can highlight chemo and electrochemiluminescence phenomena decomposing and releasing a 
cyanide radical that react with lucigenin in an alkaline medium.4 By reacting allantoin with glutaraldehyde and 
formaldehyde, many bactericides can be synthesized through condensation reactions. 1 
Allantoin has a chiral center in 4th position and it exists as a racemic mixture of stereoisomers (R) and (S). The 
conversion between the two allantoin enantiomers is catalysed by the enzyme allantoin racemase. Allantoin 
can racemize via two mechanisms SE1 and SE2 which involve a carbanion as an intermediate stabilized by 
tautomerization. Another possible racemization process can happen via SN2 like mechanism through the 
intramolecular attack of primary amide nitrogen at carbonyl carbon (C2 in Figure 1) and the formation of a 
symmetrical bicyclic intermediate.5 Intramolecular racemization proceeds more rapidly in allantoin in anionic 
form than in neutral form.  
Allantoin is a product of purine and protein metabolism. Back in 1838 it has been shown that allantoin results 
from oxidation of uric acid, which is a component of metabolism of the purine nitrogenous bases, adenine and 
guanine, of DNA and RNA. In animals, uric acid is metabolized through various steps mediated by several 
enzymes including the enzyme urate-oxidase. This enzyme catalyses the decomposition of urate, the uric acid 
anion physiologically prevalent, into (S)-allantoin. On the other hand, humans have deficiencies in urate-
oxidase, consequently they cannot decompose urate in (S)-allantoin, therefore high level of urate can cause 
significant disorders such as gout. 6 Studies revealed the presence of allantoin and uric acid in the urine of 
mammals, in some plants and, in small quantities, also in human urine and amniotic fluid. Shestopalov et al. 
support the significance of allantoin in the forming placenta and its synthesis in embryonic tissues. 7  
The conformational study of allantoin neutral form points out the presence of four conformers of allantoin 
differing in the dihedral angles and in the bond lengths. 5 The two most stable conformers are characterized 




energy one. The other two conformers adopt a cis amide bond, and they are referred to as cis-1 and cis-2, the 
latter cis-2 is characterized "scorpion" conformation with the ureic group above the imidazole ring and a torsion 
angle of 21° (Figure 2). Using the Boltzmann statistic and the computed conformer energies, the equilibrium 
population is estimated to be 98.3/1.2/0.4/0.1% (trans-2/trans-1/cis-2/cis-1) at room temperature. 8 Concerning 
the allantoin in anionic form, in that case the most stable conformer is cis-1. Furthermore, it is observed new 
possible conformation named cis-3. The different conformations adopted by allantoin in neutral and acid form 
provide an explanation for the observed dependence on pH of racemization. 5 
 
 
Figure 2. Allantoin conformers in neutral form on the top and Cis-3 anionic allantoin conformer. Kahn, K.; 
Tipton, P. A. Kinetics and Mechanism of Allantoin Racemization. Bioorg. Chem. 2000, 28 (2), 62–72. 
https://doi.org/10.1006/bioo.2000.1162 
To date, only the crystalline form of RS-allantoin is known registered in CSD with the refcode ALATIN. The 
monoclinic crystal structure has space group P21/c and following parameters a = 8.024 Å, b = 5.153 Å, c = 
14.797 Å, α = γ = 90°, β = 93.02° with a molecule in the asymmetric unit with a conformation very similar to 
the trans-2 conformer. 9  
The presence of five hydrogen bond donor sites and three carbonyl oxygens as hydrogen bond acceptors, 
suggests that the structure is characterized by a complex hydrogen bond network. All hydrogen bonds 
observed in the crystal structure, are inter-molecular and are summarized in Table 1. Each allantoin molecule 
forms five hydrogen bonds which correspond to the five hydrogens linked to nitrogen of heterocycle and urea 
substitute (a and b in Figure 3). Figure 3c shows the crystalline packaging of RS-allantoin, it is worth noting 
that the hydrogen bond interactions between the urea groups form a sort of channel along the b axis.  
 
Table 1. Hydrogen bond length calculated by Mercury software 
Hydrogen bond donor Hydrogen bond acceptor Length (Å) 
N4 O2 3.006 (1) 
N2 O1 2.828 (1) 
N3 O3 2.912 (1) 






Figure 3. Hydrogen bonds involving heterocycle N atoms a) and urea N atoms b). Picture c) shows crystalline 
packing seen along axis b 
Allantoin has biological, pharmaceutical, and cosmetic interest. Relevance of the study of this molecule 
resurfaces around 2000 when Gus’kov et al. have shown that allantoin is an important marker of oxidative 
stress and it reduces the genotoxic effect of ultraviolet radiation. 10 Furthermore, allantoin has biological effect 
comparable to that of vitamin C explained also by their similarity in antioxidant properties and hydrolysis 
reactions. 11 
Allantoin has been used as a drug for treatment of rheumatoid arthritis, myocardial infarction, some tumours, 
and its use in cosmetics is increasingly growing. Furthermore, allantoin can be used in agriculture as plant 
growth regulator, fertilizing, component of veterinary antiseptic and as a reagent in the synthesis of DL-5-(4-
hydroxyphenyl) hydantoin, precursor in the enzymatic synthesis of D-(4-hydroxyphenyl) glycine. 7 Allantoin is 
widely used in cosmetic products, it is used in more than 1300 cosmetic products in concentrations up to 2% 
for its keratolytic, moisturizing, soothing and anti-irritating effect on the skin; it promotes the renewal of 
epidermal cells and accelerates the healing of wounds, cuts and scars. 1,12 Furthermore, allantoin stimulates 
and increases the synthesis of pro-collagen, a precursor of collagen. 1 These properties and beneficial effects 
of allantoin make it a suitable molecule for any personal care application. It is fully compatible with most 
cosmetic ingredients and with anionic, cationic, and non-ionic systems. Its use greatly increases the 
performance of each cosmetic preparation, even in small quantities (used up to 2%). It provides relief and 
smooth and healthy appearance to the skin. 13 Allantoin is very effective in the dry state or in suspension but 
it has a limited solubility in water and alcohol, a saturated aqueous solution contains only 0.6% of allantoin. 
For this reason, allantoin has been associated with several molecules, to improve its solubility and effects. 
Several patents, mainly of 1970s, claim the use of allantoin alone or linked to organic and inorganic molecules, 
as such as complexes and salts. 13,14 Some patents claim the production of complexes of allantoin with metals 
such as aluminium, zinc and silver used in the medical field. 15,16 Patent US3932627 claims the formation of 
non-thrombogenic and anti-microbial complex formed by silver heparin and allantoin, it combines the 
antimicrobial properties of silver with the anticoagulant properties of heparin and the capacity of allantoin to 
form a long-lasting coating in polymeric implants used in heart and vascular surgery to replace defective or 




Among the compounds of allantoin with organic molecules, the most studied and used in the cosmetic field 
are compounds with galacturonic acid, glycyrrhetinic acid, polygalacturonic acid, ascorbic acid, panthenol and 
biotin. Safety of ascorbic acid, biotin, glycyrrhetinic acid and panthenol has already been evaluated and 
demonstrated by the Expert Group on the Evaluation of Cosmetic Ingredients (CIR), while galacturonic and 
polygalacturonic acid are sugars, major components of pectin which has been designated by the US Food and 
Drug Administration (FDA) as a safe food additive. 13 Generally, these patents declare increasing in stability 
and solubility of the allantoin. Following, some allantoin derivates presented by these patents are reported. 
Allantoin ascorbate (CAS No. 57448-83-6) is a yellowish-white powder that is soluble in water. 18 Biotin 
allantoin (CAS No. 4492-73-3) is a complex soluble 8% in cold water and very soluble in hot water, containing 
57.1 ± 4% of biotin and 42.9 ± 4% of allantoin. 19 Allantoin panthenol is water-soluble white powder. 20 Allantoin 
with galacturonic acid (CAS No. 5119-24-4) is soluble from 3 to 5% by weight, it is constituted by 41.6 ± 4% of 
allantoin and 58.4 ± 4% of α-D-galacturonic acid. Allantoin with polygalacturonic acid (CAS No. 29659-38-9) 
is a yellowish-white powder that forms a gel in solutions of sodium citrate. Allantoin with glycyrrhetinic acid 
(CAS No. 4572-09-2) in molar ratio 1:1, 1:2 or 1:3 is a yellowish-white powder with an acrid odour soluble in 
propylene glycol and alcohol but not in water, the complex contains 30 ± 2% of allantoin and 70 ± 2% of 
glycyrrhetic acid. 13 Additionally, patent of complexes of allantoin and urocanic acid, glycine and p-
aminobenzoic acid have been issued. 21–24 
Nowadays, Akema fine chemicals is a leading European producer of allantoin offering a wide range of allantoin 
derivatives and preservatives for personal care. The main products are Allantoin, Alphanta, Alcloxa, Aldioxa 
(CAS No. 5579-81-7), Allantoin calcium pantothenate, Alglycera (CAS No. 4572-09-2), and Almeth.  
Alphanta is an allantoin and panthenol derivate with anti-inflammatory, soothing, healing, and moisturizing 
properties. It is suitable in cosmetic products, for hair care, for oral hygiene and for sun screening. 
Alcloxa and Aldioxa are aluminium salts of allantoin that occur as a white powder and combine the astringent 
and antimicrobial properties of aluminium with the anti-irritant, soothing and healing properties of allantoin. 
Particularly, Aldioxa is not soluble in water and alcohol, it is stable in a pH range of 3-8 and on heating up to 
80°C. It is a product that can be incorporated into creams and powders for specific applications including 
antiperspirants (0.2-1%), products for children (0.2-0.3%), anti-acne products (1-2%), products for oral hygiene 
(0.1-2%). 25 Allantoin calcium pantothenate is a complex of allantoin and calcium pantothenate with protective, 
anti-irritant, soothing and moisturizing properties. It is soluble in water and glycerine, slightly soluble in 
propylene glycol and insoluble in oils. It can be used safely as an anti-irritant, wound healing, and conditioning 
agent. It can be incorporated at 0.2-2% in most formulations, especially in sprays, tonics, gels, lotions, creams 
and powders. 26 Alglycera is allantoin complex with glycyrrhetinic acid that maximizes the effectiveness of the 
individual components, it helps normalize the stratum corneum and stimulates the healing of damaged skin. 
Given the low solubility in most solvents, it is applied in solid form as a lotion, cream, paste or powder. 25 
Almeth (Allantoin Acetyl Methionine) is a white powder that synergically combines the protective effect of the 
skin of allantoin with the stimulating effect of the metabolism and donor sulphur of acetyl methionine. The 
complex is soluble in water up to 1%, it is not soluble in alcohol and oils. It finds application in the cosmetic, 
dermatological and hair care fields. 25 
Nevertheless, the patent presents the salt of allantoin but the allantoin lacks of a clear protonation site. 
Additionally, the term 'complex' underlines the chemical association of two or more species linked by inter-
molecular interactions. In some cases, this definition is inaccurate because the term complex in the chemical 
field only indicates metal complexes formed by a transition metal coordinated with a set of ions or molecules. 
The nature of these compounds reported in these patents is unclear. Recently, Puszyńska-Tuszkanow et al. 
have demonstrated the existence of complexes of silver and allantoin. 27 Nevertheless, the solid-state and the 
real composition of all the complexes of allantoin submitted by the patents mentioned above are not fully 
characterized. Moreover, in case of the complex of allantoin with panthenol or other organic molecule the term 






1.2 Cocrystals  
Co-crystal is a stoichiometric multi-component crystal composed by neutral molecular species that exist in the 
solid state under environmental conditions. 28,29  
The formation of cocrystals is mainly based on the supramolecular synthons, transferable connectors that can 
be used to bind molecules with non-covalent interactions such as hydrogen bonds, halogen bonds, π-stacking 
interactions. In the last 30 years, many synthons have been discovered, which can be classified into two macro-
groups: supramolecular homo-synthons, which are composed of identical and complementary functional 
groups; and supramolecular hetero-synthons composed of distinct but complementary functional groups. 30 
Corpinot and Bučar report some examples of supramolecular homo-synthons and supramolecular hetero-
synthons shown in Figure 4.  
 
 
Figure 4. Common homo-synthons supramolecular (a) and supramolecular hetero-synthons (b) (R = H, alkyl; X = 
Br, I). Corpinot and Bučar (2019) 
Numerous crystallographic studies have demonstrated the preferential formation of heteromeric synthons 
compared to the formation of homomeric interactions. 31–35 Generally, synthons are hydrogen bond donors or 
acceptors. and their formation are fundamental in the formation of co-crystal. Although, the presence of 
numerous donor and acceptor hydrogen bond functional groups do not ensure the formation of a cocrystal, it 
is essential to consider the complementarity and the strength of the possible interactions to design the 
cocrystal. 36 In case of multiple interactions between the molecules with different and competing synthons, the 
design of the cocrystal must consider the hierarchy of synthons, i.e., which of the possible synthons are formed 
at the expense of the others, based on their strength as bond acceptors or donors. 
Cocrystal formation is promoted between molecules similar in shape and polarity as demonstrated by analysis 
of cocrystals in the Cocrystal Data Set, a database of co-crystals that contains 974 structures formed by 1949 
molecules. Hence, to predict the Cocrystal formation it is important to have descriptors for shape and polarity. 
The polarity is described by the dipole moment and the ratio of total N and O atoms to the non-hydrogen atoms 
(FNO). While the shape is defined by two parameters: DS/L and DM/L, which are ratio of short (S) medium (M) 
with long (L) axes of rectangular box enclosing molecule. If these values are similar in the two coformers, the 
formation of co-crystal between them will be feasible. Hence, to design co-crystals, it is necessary to 
understand supramolecular synthons to select suitable coformers able to create molecular interactions, and to 





1.3 CSD modules  
The Cambridge Structural Database (CSD) is the leading crystallographic bibliographic, chemical, and 
numerical database of X-ray and neutron diffraction studies of organic and organometallic molecules. It was 
created in 1965 by the Cambridge Crystallographic Data Center (CCDC), whose main purpose is to promote 
chemistry especially crystallography for the public benefit. Originally the number of crystalline structures was 
limited and the database was a paper document circulated to the scientific community through a series of 
volumes called Molecular Structures and Dimension. 38 
The evolution of technology, as such as the advances in data collection and structure solution techniques, and 
the introduction of the standard crystallographic file (CIF) have led to exponential increase in the number of 
crystal structures reported in the CSD database (Figure 5).39  
 
 
Figure 5. Increasing of number of structures published per year in the CSD since 1972 
From the paper file to nowadays, the CSD expanded greatly to contain more than one million crystalline 
structures. The main quality of the CSD is the possibility to browse it for free online via the WebCSD. 
Additionally, it can be easily consulted via Conquest, a paid software.  
In the CSD, each structure is encoded by a specific identification REFCODE of six alphabetic letters, which 
refer to a specific chemical compound, and 2 numbers, which trace further determinations of the same 
structure. 
The information contained within the CSD can be classified into three different groups that describe the 
dimensionality of the content: 1D (bibliographic information), 2D (chemical connectivity), 3D (molecular and 
crystalline structure). 
The CCDC supplies other software and programs of crystallographic interest. Currently, these software are 
available: Mercury, Mogul, Hermes, Isostar, Dash, Gold, enCIFer and CSD Python. 
Mercury was created in 2002. It is useful and high-quality tool for visualization and investigation of crystalline 
structures.  
The main functions of this software include: 
• Reading various file formats of crystalline structures; 
• Viewing in 3D and motion options; 
• Displaying and measure display distances, angles and torsion angles involving atoms, centroids and 
planes; 
• Visualization of elements of symmetry, axes of crystalline cells and crystal in any direction; 




Over the years, the growing interest from both academics and industrial companies, as such as pharmaceutical 
and cosmetic industries, in Crystal Engineering has prompted the development of more and more tools and 
modules within Mercury such as CSD-Community, CSD-System, CSD-Materials and CSD-Discovery. 40 
Between these modules, CSD-Materials is extremely helpful tool to understand and to design materials. 
Specifically, it allows to predict molecular geometry, intermolecular interactions, and crystal packing. Among 
the applications of CSD-Materials, it includes the ability to engineer new compositions, as such as co-crystals 
through searching for suitable packing patterns and the study of similarity between crystal structures.  
CSD Conformer Generator is a module of CSD-Materials that performs conformational analysis of the target 
molecule based on CSD data and 3D molecular structure including all hydrogen atoms. It can minimize 
molecular conformations and generate different conformer subsets according to conformer similarity. 41,42 A 
molecule can adopt different conformation, therefore performing conformational analysis of the target molecule 
is important because of the target molecule conformer can vary in co-crystals with different coformers. CSD 
Conformer Generator identifies the most probable conformers of target molecule and it can generate subsets 
with the different conformers based on data provided by the CSD. 
Other useful application of CSD-Materials is the evaluation of preferred inter- and intra-molecular interactions 
through Hydrogen Bond Propensities module which determines the propensity of the molecule to form 
hydrogen bonds. Hydrogen Bond Propensities leads the evaluation of the presence of polymorphism for the 
target molecule through a statistical analysis of the hydrogen bond models. Statistical model calculates the 
probabilities of the formation of hydrogen bonds between each possible combination of donor or acceptor 
functional groups of given target molecule using the information of the CSD on the frequency of involving of 
functional group in hydrogen bond. Furthermore, the method reports the coordination number, that is number 
of hydrogen bonds that donor or acceptor can form simultaneously. Coordination depends on the dual capacity 
of an atom to be donor and acceptor and on the chemical environment. The determination of coordination 
number is based on the number of observed non-covalent interatomic contacts involving an H atom below a 
specified distance and angle threshold. The propensity and coordination numbers are plotted in Hydrogen 
bond combination plot that displays the potential polymorphs of a given compound. It is mainly used to 
understand which of all polymorphic forms is more stable. 43,44  
Furthermore, the Full Interaction maps (FIM) is a three-dimensional image of the space around the target 
molecule that indicates the interaction preferences of a molecule in a specific conformation. Especially, it 
displays the most likely positions of interaction with specific functional groups such as donors and acceptors 
of hydrogen bonds and hydrophobic groups.  
Summarizing, through this tool it is possible to predict the possible hydrogen bonds for a given molecule, 
evaluate its plausible crystal forms, calculate hydrogen bond propensities for individual donor and acceptor 
groups and perform a comprehensive hydrogen bond analysis on a set of structures. 
Other important tool is Co-Crystal Design, which allows the identification of suitable coformers to form co-
crystal with a certain target molecule with high probability reducing co-crystal screening trials and time.45 
Through Screen by Molecular Complementarity function, this module calculates the probability of two 
molecules, a target and a conformer, to form co-crystal based on a semiquantitative model for the formation 
of co-crystals designed by Fábián. 36 The most significant molecular properties that leads the formation of co-
crystals were identified evaluating a wide range of molecular parameters (in total 131) of each component of 
the co-crystals in the CSD. The statistical analysis of these data reveals the decisive molecular properties for 
crystallization of two molecules are their size and polarity depicted by the molecular descriptors: dipole 
moment, DFNO, DS/L and DM/L. It is important to point out this method is applicable only for neutral 





2 AIM  
Allantoin has wide interest in cosmetic for its several cosmetic applications. Hence, the study of allantoin is of 
great interest for the cosmetic industry. Especially, is of particular concern the study of association of this 
molecule with other compounds with the mainly purpose to improve the features of allantoin particularly its 
poor solubility in water. In fact, several patent of ’60s claim the correlation of allantoin with several other 
compounds of cosmetic interest as such as biotin, acid, ascorbate, etc. 13,18–20 Literature reports several studies 
of allantoin and patents that claims improvements of allantoin characteristics as such as solubility thanks to its 
correlation with other molecules in form of salts and complexes. 14–17,21–24 However, a clear characterization of 
solid-state of these compounds is missing. Their improved characteristic in solubility and stability suggests an 
interaction between these compounds that can be attributed to formation of cocrystal or to interaction of the 
two individual components in solution. The term Co-crystal had not yet been widely realized at the time of the 
publications and the term “complex” had been used to denote this type of crystal structures. 35 Therefore, the 
presence of different properties of these compounds compared to the starting reagents does not exclude the 
formation of co-crystals. Additionally, the presence of urea in the allantoin structure and its propensity to form 
co-crystals support this hypothesis. 46–49 
Preliminary studies have been conducted by group of prof. Evelina Colacino of the University of Montpellier. 
In collaboration prof. Evelina Colacino, the study of possible co-crystal of allantoin is experimentally proceeded 
in PolyCrystalLine laboratories. The first purpose was to understand the real nature Alphanta, a compound of 
allantoin and panthenol commercialized by Akema.  
Furthermore, the study was extended to the screening of allontoin co-crystals especially with cosmetic interest 
molecules. The chosen coformers are D-panthenol, Galacturonic Acid Monohydrate, D-Glucuronic Acid, L-
Ascorbic Acid, and trans-Ferulic Acid. Nevertheless, the list of coformers is extended to evaluate major number 
of compounds. Moreover, the propensity of allantoin to form co-crystal is evaluated using the Mercury CSD-
materials module to study the reactivity of allantoin and identify potential coformers for the formation of co-
crystals of allantoin.   
3 EXPERIMENTAL PROCEDURE 
Allantoin has been evaluated using the Mercury’s application to study its propensity to form cocrystals, 
additionally, the formation of cocrystal of allantoin has been experimentally evaluated. The tested coformers 
are selected on the basis their cosmetic benefit and the co-crystal design results and are D-panthenol (PAN), 
Galacturonic acid monohydrate (GAL), D-Glucuronic acid (DGL), L-ascorbic acid (ASC), Trans-ferulic acid 
(FER), Citric Acid (CIA), DL-Panthenol (DLPAN), L-Lysine (LLYS), L-Tartaric Acid (LTA), Maleic Acid (MEA), 
Urea and 2,5-Dihydroxybenzoic acid (DHB). 
All the experiments have been performed in PolyCrystalLine laboratories, the following co-crystallization 
method were tested: evaporations at 60°C (EvHT), cold precipitation, slurry, melting and experiments of 
mechanochemistry such as grinding and kneading. Grinding and kneading experiments were conducted using 
Retsch MM 200 grinder. All the products were analysed by X-ray diffraction via Rikagu miniflex, the settings 
are reported in appendix A. Thermal methods, especially scanning calorimetric analysis (DSC), on the other 
hand are useful for analysing mixtures composed with the two potential components of the co-crystal to 
evaluate the possible formation of cocrystal by melting. The presence of endothermic peak associated with 
the eutectic fusion immediately followed by an exothermic peak due to the crystallization can indicate the 
formation of the co-crystal. The lack of exothermic crystallization peak indicates that co-crystallization has not 
occurred. 
 
3.1 Reagent and Standards  
Allantoin and the coformer of cosmetic interest D-panthenol, Galacturonic Acid Monohydrate, D-Glucuronic 
Acid, L-Ascorbic Acid and trans-Ferulic Acid were supplied by Evelina Colacino group. DL-panthenol was 
provided by Alfa Aesar (Kandel, Germany). Other coformers: citric acid, L-lysine, L-tartaric acid, DL-Malic acid, 





3.2 Application CSD modules 
3.2.1 CSD Conformer Generator 
Analysis of the feasible conformers of allantoin has been performed using the Mercury’s tool CSD Conformer 
Generator and the structure of allantoin ALATIN. Maximum of ten conformations were considered.50 Figure 6 
reports the four conformers of allantoin obtained by the analysis of CSD Conformer Generator. The results 
evidenced the presence of four possible conformers trans-1 (a), trans-2 (b), cis-1 (c) and cis-2 (d) compatible 
with the literature data for allantoin in neutral form.  
 
Figure 6. Conformers of allantoin by CSD Conformer Generator: a) trans-1 b) trans-2 c) cis-1 d) cis-2 
 
3.2.2 Hydrogen Bond Propensities 
The Hydrogen Bond propensities tool of Mercury has been used to evaluate the propensity of allantoin to form 
hydrogen bond. This tool evaluates the hydrogen bonds formed by the target molecule in its known crystalline 
structures. In case of different polymorphs, the comparison of the hydrogen bond strength can be used to rank 
the stability of the polymorphs. In case of allantoin, only one crystal form is known. However, the study of the 
feasible hydrogen bond is useful to evaluate the possible interaction of the molecule even with another 
molecule. The functional groups of allantoin were classified in donor and acceptor of hydrogen bond and they 
were classified considering their propensity to form hydrogen bond in existing crystal structures. Figure 7 
displays the functional groups classified by the software Mercury in donors and acceptors of hydrogen bond 
highlighted in blue and red, respectively. All the nitrogen of both ureic groups, the substituent in position 4th 
and in azaheterocycle were classified as donors, while all the carbonyl oxygens were classified as acceptors 






Figure 7. Determination of donors and acceptors functional groups of allantoin 
The software analyses how many times the functional groups described above form hydrogen bonds in the 
structures deposited in the database (Figure 8).  
 
 
Figure 8. Hydrogen bond analysis of functional groups 
The statistical data about the probability of the allantoin’s functional groups to form hydrogen bond were used 
to evaluate the likelihood of hydrogen bond formation of allantoin. 
The software Mercury performed a regression analysis using the statistics program R. The software outcomes 
the hydrogen bond propensity calculation and reported the propensity scores table for both inter- and intra- 
molecular hydrogen bond, and coordination scores table. The first reports donor-acceptor pairs sorted by their 
propensity to form hydrogen bond. Figure 9 and Figure 10 report the intermolecular and intramolecular 
hydrogen bond propensity scores table of allantoin, respectively.  
The coordination scores table shows the individual atom likelihood to form a hydrogen bond considering the 
surrounding environment. Figure 11 reports the Hydrogen bond coordination scores table. The table shows 
calculated likelihoods for allowed coordination numbers for each donor and acceptor computed using CSD 
derived models. The coordination model evidenced which donors and acceptors of the molecule is likely to 
coordinate one or more times and which hydrogen bonds can occur simultaneously or mutually exclusive. 
Values are coloured green or red to indicate optimal or sub-optimal scores, respectively. Green highlighting 
indicates a maximum likelihood is observed. Red highlighting indicates there is a more likely alternative 
coordination number for that atom. Higher coordination value indicates increasing hydrogen bond capacity. 44 
The most probable intermolecular hydrogen bond is between the urea nitrogen N4 and the carbonyl oxygen 
O2 in the azaheterocycle with a propensity value of 0.78 corresponding to the 78% probability of formation. 
The term 'observed' indicates the hydrogen bond has been observed in the crystal structure ALATIN. The 
nitrogen N4 shows as the most probable coordination number of 2 (Figure 11), in fact it forms two hydrogen 
bonds with O2 of two different allantoin molecules. As the same way the oxygen O3 showed the most probable 
coordination number of 2 (Figure 11) and it bind both nitrogen N1 and N3. Considering the coordination scores, 
the observed hydrogen bonds of ALATIN are the most probable. Specifically, the most probable bond is N4-
O2 with 78% of propensity and coordination number of N4 of 2. These atoms are no longer available for forming 
another bond. Hence, any interactions with these atoms can be excluded despite their high propensity score. 
This explains how the bond N3-O3 with lowest propensity score of 39% is observed in ALATIN. In fact, N3 
shows lowest propensity scores, probably due to its steric density of 40.62 (Figure 9), and it cannot be 
connected with O2 and O1 already involved in other hydrogen bonds with N4 and N2. Having O3 a coordination 




It is worth noting that although higher propensity score of 69% of the intra-molecular interaction N1-O3 than 
the inter-molecular interaction (58%), the last one is observed in ALATIN. This indicates the formation of 




Figure 9. Predicted intermolecular hydrogen bond propensity scores table 
 
 
Figure 10. Predicted intramolecular hydrogen bond propensity scores table 
 
 
Figure 11. Hydrogen bond coordination scores table 
Figure 12 represents the possible hydrogen bond combinations for the system. Each data point in the graphic 
is a possible structure with unique hydrogen bonding. The horizontal axis is the average propensity for 
hydrogen bonds in the structure labelled as Mean H-Bond Propensity, while the vertical axis represents the 
average coordination probability for the atoms in the structure labelled as Mean H- Bond Coordination. The 
coordination axis is inverted to reflect that more stable structures more negative energies relative to a zero 






Figure 12. Hydrogen bond combination plot 
 
Full Interaction Maps is a tool that calculates regions around the molecule (maps) where chemical probe 
groups are likely to be found. The calculation procedure first identifies distinct functional groups in the allantoin, 
and then finds relevant interaction data in IsoStar (module of the CSD). Next it pulls together the group-based 
interaction data and takes into account the environmental effects of combinative factors and steric exclusion 
to create a full 3D picture of molecular interaction preferences. 
It represents in red those areas where there is a high probability of locating a hydrogen bond acceptor, in blue 
those where a donor is more likely to be located, and those in orange indicate hydrophobic preferences. The 
red and blue area shown in Figure 13 correspond to the presence of donors (nitrogen) and acceptors (carbonyl 
oxygen) groups of allantoin, which contribute to locate acceptors and donors of hydrogen bond, respectively.  
It worth noting that no orange area is observed, allantoin is not able to interact with hydrophobic groups. 
Coformers with hydrophobic groups are bad candidates to form cocrystal with allantoin.  
 
 





3.2.3 Co-Crystal Design 
The Co-Crystal Design was useful tool to identify possible coformers for generation of co-crystal of allantoin. 
For the analysis all the conformers of allantoin determined by CSD Conformer Generator were considered, 
labelled by the software ALATIN_00001, ALATIN_00002, ALATIN_00003, ALATIN_00004. The coformers 
molecules were selected by the library of the software. Table 2 reports the results of the elaboration reporting 
the total hit rate in percentage and the compatibility for each allantoin conformer. Hit rate of 100% indicates 
high probability for relevant coformer to generate a cocrystal with allantoin. 50 
 












(+)-camphoric_acid 0 FAIL FAIL FAIL FAIL 
(-)-camphorsulfonic_acid 0 FAIL FAIL FAIL FAIL 
1-hydroxyethylidene-1,1-
diphosphonic_acid 
100 PASS PASS PASS PASS 
2-amino-5-methylbenzoic_acid 0 FAIL FAIL FAIL FAIL 
3-methylpyridine 0 FAIL FAIL FAIL FAIL 
4-acetamidobenzoic_acid 0 FAIL FAIL FAIL FAIL 
4-aminobenzoic_acid 0 FAIL FAIL FAIL FAIL 
4-hydroxybenzoic_acid 0 FAIL FAIL FAIL FAIL 
D-alanine 100 PASS PASS PASS PASS 
D-glucuronic_acid 100 PASS PASS PASS PASS 
D-panthenol 100 PASS PASS PASS PASS 
EDTA 100 PASS PASS PASS PASS 
L-arginine 100 PASS PASS PASS PASS 
L-aspartic_acid 100 PASS PASS PASS PASS 
L-aspartic_acid_z 0 FAIL FAIL FAIL FAIL 
L-glutamic_acid 100 PASS PASS PASS PASS 
L-glutamic_acid_z 0 FAIL FAIL FAIL FAIL 
L-glutamine 100 PASS PASS PASS PASS 
L-glutathione 100 PASS PASS PASS PASS 
L-lactic_acid 75 PASS PASS FAIL PASS 
L-leucine 0 FAIL FAIL FAIL FAIL 
L-mandelic_acid 0 FAIL FAIL FAIL FAIL 
L-methionine 0 FAIL FAIL FAIL FAIL 
L-phenylalanine 0 FAIL FAIL FAIL FAIL 
L-proline 100 PASS PASS PASS PASS 
L-serine 100 PASS PASS PASS PASS 
L-tartaric_acid 100 PASS PASS PASS PASS 
L-tryptophan 0 FAIL FAIL FAIL FAIL 
L-tyrosine 0 FAIL FAIL FAIL FAIL 
N-ethylacetamide 0 FAIL FAIL FAIL FAIL 
acesulfame 75 PASS PASS FAIL PASS 
acetic_acid 100 PASS PASS PASS PASS 
acetophenone_oxime 0 FAIL FAIL FAIL FAIL 















adipic_acid 75 FAIL PASS PASS PASS 
alitame 0 FAIL FAIL FAIL FAIL 
apigenin 0 FAIL FAIL FAIL FAIL 
azelaic_acid 0 FAIL FAIL FAIL FAIL 
benzoic_acid 0 FAIL FAIL FAIL FAIL 
biotin 0 FAIL FAIL FAIL FAIL 
caprolactam 0 FAIL FAIL FAIL FAIL 
capsaicin 0 FAIL FAIL FAIL FAIL 
cholic_acid 0 FAIL FAIL FAIL FAIL 
citric_acid 100 PASS PASS PASS PASS 
ethylparaben 0 FAIL FAIL FAIL FAIL 
folic_acid 50 FAIL PASS PASS FAIL 
fumaric_acid 75 FAIL PASS PASS PASS 
gentisic_acid 100 PASS PASS PASS PASS 
glutaric_acid 100 PASS PASS PASS PASS 
glycine 100 PASS PASS PASS PASS 
glycolic_acid 100 PASS PASS PASS PASS 
hesperetin 0 FAIL FAIL FAIL FAIL 
hippuric_acid 0 FAIL FAIL FAIL FAIL 
hydrocinnamic_acid 0 FAIL FAIL FAIL FAIL 
imidazole 100 PASS PASS PASS PASS 
isonicotinamide 0 FAIL FAIL FAIL FAIL 
ketoglutaric_acid 100 PASS PASS PASS PASS 
lactobionic_acid 0 FAIL FAIL FAIL FAIL 
lactose 100 PASS PASS PASS PASS 
maleic_acid 100 PASS PASS PASS PASS 
malic_acid 100 PASS PASS PASS PASS 
malonic_acid 100 PASS PASS PASS PASS 
maltitol 100 PASS PASS PASS PASS 
mannitol 100 PASS PASS PASS PASS 
methanesulfonic_acid 0 FAIL FAIL FAIL FAIL 
methylparaben 0 FAIL FAIL FAIL FAIL 
monobutyrin 100 PASS PASS PASS PASS 
nicotinamide 0 FAIL FAIL FAIL FAIL 
oxalic_acid 100 PASS PASS PASS PASS 
pamoic_acid 0 FAIL FAIL FAIL FAIL 
phthalamide 0 FAIL FAIL FAIL FAIL 
pimelic_acid 75 FAIL PASS PASS PASS 
piperazine 0 FAIL FAIL FAIL FAIL 
propylparaben 0 FAIL FAIL FAIL FAIL 
pyrazine 0 FAIL FAIL FAIL FAIL 
riboflavin 100 PASS PASS PASS PASS 
saccharin 0 FAIL FAIL FAIL FAIL 















suberic_acid 0 FAIL FAIL FAIL FAIL 
succinic_acid 100 PASS PASS PASS PASS 
t-butylamine 0 FAIL FAIL FAIL FAIL 
t-butylhydroxyanisole 0 FAIL FAIL FAIL FAIL 
theophylline 100 PASS PASS PASS PASS 
thymidine 100 PASS PASS PASS PASS 
triphenylacetic_acid 0 FAIL FAIL FAIL FAIL 
urea 100 PASS PASS PASS PASS 
valerolactam 0 FAIL FAIL FAIL FAIL 
xanthine 75 FAIL PASS PASS PASS 
 
Successively, the Co-Crystal Design evaluation was repeated considering as coformers the molecules of 
cosmetic interest and correlated with allantoin in the patents. Table 3 evidenced that allantoin has a high 
compatibility rate with all molecules except trans-ferulic acid.  
Generally, the results evidenced the high potential of allantoin to form cocrystals with a lot of molecules, as 
observed in Table 2. Specifically, Table 3 results revealed allantoin should form co-crystals with coformers 
reported in the patents and of cosmetic interest.  
The formation of co-crystal has been experimentally evaluated through several technique extending the list of 
coformers listed in Table 3 with molecules such as DL-Panthenol, Malonic Acid, DL -Malic Acid, and Urea. 
These molecules were compatible with allantoin as reported in Table 3. Trans-ferulic acid is also considered 
in the study because of it is molecule of high cosmetic interest. 
 












D-glucuronic_acid 100 PASS PASS PASS PASS 
citric_acid 100 PASS PASS PASS PASS 
maleic_acid 100 PASS PASS PASS PASS 
L-tartaric_acid 100 PASS PASS PASS PASS 
D-Panthenol 100 PASS PASS PASS PASS 
trans-ferulic acid 0 FAIL FAIL FAIL FAIL 
L-Lysine 100 PASS PASS PASS PASS 
2,5-Dihydroxybenzoic 
Acid 
100 PASS PASS PASS PASS 
L-Ascorbic Acid 100 PASS PASS PASS PASS 






3.3 Characterization of Allantoin  
Allantoin was characterized performing X-Ray powder diffraction (XRPD) and differential scanning calorimetric 
analysis (DSC). Additionally, solubility test of allantoin was performed.  
The experimental pattern (ALL-SM) is comparable to the calculated pattern of racemic DL-allantoin (ALATIN) 
(Figure 14).  
Allantoin thermograms showed an endothermic peak at approx. 235°C relative to melting followed by 
degradation (Figure 15). 
Allantoin solubility test was carried out by weighting 50 mg of allantoin and successively adding of solvent and 
stirring the suspension after each addiction. At the concentration of 10 mg/mL, allantoin results soluble only in 
N-dimethylformamide (DMF). Hence, it is considered it is sparingly soluble in DMF. The experiments were also 
repeated in hot conditions (50° C) and showed that allantoin is soluble in hot water and in N, N-
dimethylformamide (DMF). Allantoin is sparingly soluble in hot water. It was considered not soluble in the other 
tested solvents: ethanol, methanol, acetone, acetonitrile, dichloromethane, ethyl acetate and toluene. 
 
 
Figure 14. XRPD pattern comparison between experimental pattern of allantoin (black line) and calculated 
pattern of DL-allantoin (magenta line) 
 
 





3.4 Characterization of Alphanta 
Alphanta is an Akema Chemicals product based on allantoin and panthenol.  
The XRPD pattern and the DSC thermogram of alphanta were compared with the starting material DL-
allantoin, DL-panthenol and D-panthenol. D-panthenol is a viscous and transparent liquid with amorphous 
XRPD pattern. While DL-panthenol is white and crystalline solid with melting point at 67°C (see appendix C). 
The XRPD pattern of alphanta shows all the crystalline reflection of DL-panthenol and of DL-allantoin (Figure 
16) resulting a physical mixture of the starting material DL-allantoin and DL-panthenol. This is confirmed by 
DSC analysis which shows an endothermic peak at 67° C attributable to melting of DL-Panthenol. Clearly peak 
of allantoin melting is not recognizable, but broad endothermic signal is observed in correspondence of 
allantoin melting (Figure 17). Probably allantoin is dissolved in the melted DL-Panthenol.  
 
 










3.5 Solubility and pH 
Several patent of complexes of allantoin, for instance with ascorbic acid, claim the major solubility of this 
compound compared with the solubility of the pure allantoin. It is unclear whether this better solubility of 
allantoin is due to interaction of these molecule in solution or by formation of new compound. Therefore, the 
solubility of allantoin in presence of ascorbic acid was evaluated. Ascorbic acid is a diprotic acid (pKa1 = 4.08 
and pKa2 = 10.85) but only the first dissociation will be considered in the following calculations. The initial pH 
of the aqueous solution used experimentally with ascorbic acid (55.7 mg/mL) is 2.31 (pH calculated for this 
concentration is 2.29). Two additions of 50 mg of allantoin are made to this solution; after the first addition 
(5.31 mg/mL) allantoin dissolved while after the second addition of allantoin (10.23 mg/mL) to the solution 
allantoin was not soluble. The same experiment at the same concentration of allantoin in water was performed 
in absence of ascorbic acid in the solution, allantoin has been not soluble at the concentration of 5 mg/mL, 
while it has dissolved in presence of ascorbic acid.  
This confirms that solubility of allantoin is promoted in presence of ascorbic acid, but it was not clear if it is due 
to the acid pH of the solution due to ascorbic acid or to the formation of a complex of the compounds.  
 
3.6 EvHT (evaporation at 60°C) 
High temperature evaporation experiments were performed in water because of it is the only solvent except 
DCF in which allantoin is soluble.  
50 mg of Allantoin was dissolved in 2 mL of H2O by heating. An equivalent of the coformer was then added, in 
the case of L-lysine it was added in two equivalents. Solutions were heat at temperature of 60°C until 
completely evaporation of solvent. Ferulic acid requires different preparation because of it is not soluble in 
water, but it is soluble in ethanol. Two different solutions were prepared, one with allantoin in water and the 
latter was prepared dissolving an equivalent of ferulic acid in 1 mL of ethanol. The two solutions were merged 
and evaporated at 60°C. 
The obtained precipitated were analysed by XRPD and the patterns were compared with those of the starting 
materials: allantoin (ALL-SM) and coformer. 
The diffractograms of the experiments with ascorbic and trans-ferulic acid as coformers have shown 
characteristic peaks of both allantoin and conformers, suggesting the formation of physical mixture of these 
components (see Appendix B). While the XRPD pattern of experiments with D-panthenol, galacturonic acid, 
and glucoronic acid have shown only the characteristic peaks of allantoin (see Appendix B). The absence of 
coformers’ signals suggests it has precipitated in amorphous form. It is worth noting that the product obtained 
by evaporation of allantoin and L-lysine has shown mainly amorphous XRPD pattern with some weak peaks 
not ascribable neither to allantoin nor to L-lysine hemihydrate used as reagents or toto the monohydrate form 
of L-lysine (see Figure 18). 51 These peaks could indicate a new phase, but the sample is mainly amorphous, 
and it is difficult to evaluate a real formation of new form.  
Table 4 summarizes obtained results.  
 
Table 4. Results of evaporation experiments 
 
  
EXPERIMENT RESULTS APPENDIX B 
ALL-LLYS Mainly amorphous pattern + small peaks (main peak at 9.0°2θ) Figure 28 
ALL-ASC XRPD pattern ASC+ALL  Figure 29 
ALL-DGL XRPD pattern Allantoin  Figure 30 
ALL-GAL XRPD pattern Allantoin  Figure 31 
ALL-PAN XRPD pattern Allantoin  Figure 32 






Figure 18. XRPD pattern comparison between starting materials allantoin (black line), L-lysine (blue line), EvHT 
product resulted by allantoin and L-lysine (red line) and the calculated pattern of hemihydrate L-lysine LYSDP2 
(cyan line) and monohydrate L-lysine LYSMH1 (green line). Mainly additional peaks were highlighted in yellow. 
 
3.7 Precipitation at low temperature 
50 mg of Allantoin was dissolved in 2 mL of H2O by heating at 50°C. An equivalent of the coformer was then 
added and dissolved. Ferulic acid requires different preparation because of it is not soluble in water, in this 
case two different solutions were prepared and merged, one with allantoin in water as aforementioned and the 
latter was prepared dissolving an equivalent of ferulic acid in 1 mL of ethanol. Precipitation was promoted 
placing the solutions at 5-8°C in refrigerator. 
The precipitates were filtered and analysed by X-ray diffraction. The XRPD pattern were compared with those 
of the starting compounds.  
The XRPD pattern of experiment with allantoin and D-panthenol as starting material has shown only the 
characteristic peaks of allantoin (see Appendix B), it could be due to lack of precipitation of the conformer or 
its precipitation in amorphous form. 
The diffractograms of allantoin and trans-ferulic acid has suggested the formation of a physical mixture of these 
compounds (see Appendix B).  
The products resulted by experiments performed with ascorbic acid, D-glucuronic acid, and galacturonic acid 
have shown XRPD pattern characteristic of allantoin plus some small additional peaks. In Figure 19, Figure 
20 and Figure 21 the peaks ascribable to conformer are highlighted in green, while the additional peaks not 
ascribable neither to allantoin nor conformer are highlighted in yellow. The product resulted by precipitation 
with ascorbic acid (Figure 19) showed three additional peaks at approx. 2θ =10.0, 20.1 and 20.8°.  
The product resulted by precipitation with galacturonic acid (Figure 20) showed several additional peaks at 
approx. 2θ= 6.1, 10.1, 14.4, 20.1, 28.9, 32.9, 37.7°. The peaks at 14.5 and 32.9°2θ correspond to the peak of 
galacturonic acid, while the other peaks were not ascribable to galacturonic acid.  
The product resulted by precipitation with glucuronic acid (Figure 21) showed one additional peak at approx. 
2θ= 20.1° corresponded to the main peak of glucuronic acid.  
In all the cases discussed above the new peaks showed very low intensity, and all the different XRPD patterns 
have the common peaks at 10.0 and 20.1°2θ which suggests the formation of another form probably of 
allantoin rather than formation of cocrystals. Additionally, observation of mainly allantoin pattern and lack of 
conformer’s peaks suggest the failed precipitation of coformer.  





Table 5. Results of precipitation experiments 
 
 
Figure 19. XRPD pattern comparison between starting materials allantoin (black line), ascorbic acid (blue line) 
and precipitation product resulted by allantoin and ascorbic acid (red line). Additional peaks were highlighted in 
yellow. 
 
Figure 20. XRPD pattern comparison between starting materials allantoin (black line), galacturonic acid (blue 
line) and precipitation product resulted by allantoin and galacturonic acid (red line). Additional peaks were 
highlighted in yellow, while the peaks ascribable to galacturonic acid were highlighted in green.  
 
EXPERIMENT RESULTS APPENDIX B 
ALL-DGL XRPD pattern Allantoin + some peaks Figure 34 
ALL-FER XRPD pattern FER+ALL  Figure 35 
ALL-GAL XRPD pattern Allantoin + some peaks Figure 36 
ALL-PAN XRPD pattern Allantoin  Figure 37 






Figure 21. XRPD pattern comparison between starting materials allantoin (black line), glucuronic acid (blue line) 
and precipitation product resulted by allantoin and glucuronic acid (red line). The peak ascribable to glucuronic 






50 mg of allantoin are suspended in 2 mL of solvent and coformer was added to this suspension in ratio 1:2 
between allantoin and coformer, respectively. Two set of suspensions are prepared with water and ethanol as 
a solvent. After 4 days under stirring, the suspension is taken, filtered with filter paper and the solid phase is 
analysed by X-ray diffraction. The diffractograms obtained were characteristic of the mixture of the reagents 
or of only allantoin 
This is probably because the saturation conditions of the coformer are not reached. 
The product resulted by slurry in ethanol of allantoin and L-tartaric acid (Figure 22) showed an additional peak 
at approx. 19.8°2θ not ascribable to allantoin and L-tartaric acid. Nevertheless, determination of this unique 
peak is difficult.  
Table 6 summarizes obtained results.  
 
Table 6. Results of slurry experiments 
 
 
EXPERIMENT SOLVENT RESULTS APPENDIX B 
ALL-ASC 
water XRPD pattern Allantoin Figure 39 
ethanol XRPD pattern ASC+ALL Figure 40 
ALL-CIA 
water XRPD pattern Allantoin Figure 41 
ethanol XRPD pattern Allantoin Figure 42 
ALL-DGL 
water XRPD pattern Allantoin Figure 43 
ethanol XRPD pattern DGL+ALL Figure 44 
ALL-DLPAN 
water XRPD pattern Allantoin Figure 45 
ethanol XRPD pattern Allantoin Figure 46 
ALL-FER 
water XRPD pattern FER+ALL Figure 47 
ethanol XRPD pattern Allantoin + trace of FER Figure 48 
ALL-GAL 
water XRPD pattern Allantoin Figure 49 
ethanol XRPD pattern GAL+ALL Figure 50 
ALL-LTA 
water XRPD pattern Allantoin + trace of LTA Figure 51 
ethanol XRPD pattern Allantoin + peak at 19.8°2θ Figure 52 
ALL-PAN 
water XRPD pattern Allantoin Figure 53 




Figure 22. XRPD comparison between starting materials allantoin (black line), L-tartaric acid (blue line) and 




Allantoin and coformer were placed in steel jar with two steel balls to promote the grinding. Ball milling was 
carried out at 30 Hz for 15 minutes.  
The compound obtained is recovered and analysed by X-ray diffraction and compared with the starting 
materials’ pattern. The diffractograms obtained are all characteristic of the mixture of reagents except for the 
one obtained with D-Panthenol, in which only the allantoin peaks are identified, the coformer was amorphous.  
Table 7 summarizes obtained results.  
 
Table 7. Results of grinding experiments 
 
3.10 Kneading 
Allantoin, coformer and 20 µL of H2O are placed in steel jar with two small steel balls, which promote grinding. 
Different ratios of allantoin and coformer are tested, for example 1:1 or 1:2. Grinding was carried out at 30 Hz 
for 15 or 30 minutes. 
All diffractograms were characteristic of the mixture of the starting materials except for experiments with DL-
panthenol in the ratio 1:1 in which only the allantoin was observed 
At initial assessment, the product obtained with citric acid (ratio 1:1) showed the presence of a new phase. 
Further evaluation revealed that the observed additional peaks were ascribable to citric acid monohydrate 
(CITARC) (Figure 23). 52 Increasing the amount of coformer in ratio 1:2 allantoin and citric acid it was observed 
in XRPD pattern peaks of both anhydrous and monohydrate citric acid (Figure 24). The presence of water in 
kneading promotes the conversion of anhydrous citric acid to monohydrate. 
Table 8 summarizes obtained results.  
 
Table 8. Results of kneading experiments 
 
EXPERIMENT RESULTS APPENDIX B 
ALL+DLPAN XRPD pattern DLPAN+ALL Figure 55 
ALL+PAN XRPD pattern Allantoin Figure 56 




RESULTS APPENDIX B 




Ratio 1:1 XRPD pattern monohydrate CIA+ALL Figure 59 
Ratio 1:2 
XRPD pattern monohydrate CIA+ anhydrous 
CIA+ALL 
Figure 60 
ALL+DGL Ratio 1:2 XRPD pattern DGL+ALL Figure 61 
ALL+DHB Ratio 1:2 XRPD pattern DHB+ALL Figure 62 
ALL+DLPAN 
Ratio 1:1 XRPD pattern Allantoin (broad peaks) Figure 63 
Ratio 1:2 XRPD pattern DLPAN+ALL Figure 64 
ALL+FER Ratio 1:2 XRPD pattern FER+ALL Figure 65 
ALL+GAL Ratio 1:2 XRPD pattern GAL+ALL Figure 66 
ALL+LLYS Ratio 1:2 XRPD pattern LYS+ALL Figure 67 
ALL+PAN Ratio 1:2 XRPD pattern Allantoin Figure 68 





Figure 23. XRPD comparison between starting materials allantoin (black line), citric acid (blue line), product 
resulted by kneading of allantoin and citric acid in ratio 1:1 (red line) and monohydrate citric acid (CITARC, 
green line) by CSD 
 
 
Figure 24. XRPD comparison between starting materials allantoin (black line), citric acid (blue line), product 
resulted by kneading of allantoin and citric acid in ratio 1:2 (red line) and monohydrate citric acid (CITARC, 
green line) by CSD 
 
3.11 Thermal characterization of mixtures 
The possibility to obtain cocrystal by melting was evaluated by thermal analysis of the mixtures of allantoin 
with the conformer. Compounds which soluble in liquid but insoluble in solid can from eutectic mixtures. The 
mixtures were evaluated through DSC analysis and the formation of eutectic mixture is indicated by presence 
of endothermic peak associated with the eutectic melting, at temperature lower than the melting temperature 
of starting material, immediately followed by an exothermic peak due to the crystallization that indicate the 
formation of cocrystal.  
Considering that allantoin begins to decompose subsequently after melting at around 235°C. It would be a 




Solid mixtures were prepared by mixing with mortar and pestle coformers as trans ferulic acid, L-ascorbic acid, 
and urea in molar ratio 1:1 with allantoin. The presence of eutectic mixtures is evaluated by performing DSC 
analysis with a heating rate of 10° C/min in flow of N2. 
The mixture of allantoin and ferulic acid shows an endothermic peak compatible to the melting of ferulic acid 
at 172°C and a second endothermic peak at approx. 235°C ascribable to the melting and degradation of 
allantoin (Figure 25).  
On the contrary, DSC thermogram of mixture of allantoin and ascorbic acid in the ratio 1:1 showed an 
endothermic peak at approx. 180°C and successively exothermic peak at temperature lower than the melting 
of ascorbic acid at 192°C and allantoin at approx. 235°C (Figure 26). It worth noting that the exothermic peak, 
subsequent to endothermic peak at approx. 182°C could be due to the crystallization of the co-crystal. 
In the case of the mixture of allantoin and urea in the ratio 1: 1 was observed a melting at a lower temperature 
(125°C) than the melting points of the single species, but there are no exothermic peaks that may suggest the 
formation of co-crystals (Figure 27).  
 
 
Figure 25. DSC thermogram comparison between starting materials allantoin (black line), trans-ferulic acid (blue 





Figure 26. DSC thermogram comparison between starting materials allantoin (black line), ascorbic acid (blue 
line) and their mixture 1:1 (red line) 
 
Figure 27. DSC thermogram comparison between starting materials allantoin (black line), urea (blue line) and 






Allantoin has extremely interest in cosmetic due to its wide benefits. In fact, it is used in products as such as 
skin cream, sunscreen, oral care products and healing products. It has been associated with several molecules 
to form “complexes”, such as ascorbic acid, biotin, panthenol, galacturonic acid etc. These complexes have 
been studied mainly in the 60s and 70s of the last century. Improving properties, especially solubility, of these 
complexes compared to the reagents have been claimed in some patent of 60s and 70s. 14,18–23 Additionally, 
preparation of allantoin with other compounds are commercialized, for example Alphanta sold by Akema, which 
consists of allantoin and panthenol, but the solid state of these compounds has not clearly reported.  
Dissolution of allantoin was evaluated in different conditions, in water and in an acid solution with ascorbic 
acid. The results suggest allantoin solubility dependence on the pH of the solution and it is more soluble in 
acid solution. This indicates that improving solubility of allantoin claimed in the patent may not be due to 
formation of cocrystal.  
At the first stage allantoin was studied by CSD-Materials module present within Mercury to identify its molecular 
reactive sites, to select suitable coformers and to evaluate the propensity of allantoin to form cocrystal. The 
evaluation of possible conformers of allantoin by CSD-Materials agrees with the conformations reported in the 
literature. Allantoin has four conformers in the neutral form, and in the unique known crystalline structure of 
RS-allantoin it has a conformation very similar to the trans-2 conformer and forms five inter-molecular hydrogen 
bonds. The results obtained through CSD-Materials suggest propensity of allantoin to form inter-molecular 
hydrogen bonds compared to intra-molecular interaction. The Co-crystal design application executes statistical 
analysis considering correlations of similarity, shape, and polarity of the molecules to identify possible 
coformers for generation of co-crystal of target molecule. Allantoin has shown strong compatibility with several 
molecules, particularly with all molecules of cosmetic interest selected as potential coformers, except trans-
ferulic acid.  
Experimentally, different crystallization techniques were used to obtain co-crystals, evaporation at 60°C, 
precipitation at low temperature, slurry in ethanol and water, grinding, kneading, and melting of the mixtures. 
The X-Ray diffractograms of the powders obtained do not show significantly different pattern compared to the 
reagent ones. Several tiny peaks have been detected in the powder obtained by precipitation with ascorbic 
acid, galacturonic acid and glucuronic acid. The low intensity of the signals and the absence of coformer’s 
peaks suggest the lack of precipitation of coformer. For these reasons it was excluded the presence of 
cocrystal. Probably, it is due to partial formation of new form of allantoin or possible contamination. 
Furthermore, in product obtained by evaporation with L-lysine has shown mainly amorphous pattern with some 
small peaks not ascribable neither to allantoin nor to L-lysine hemihydrate and monohydrate forms. However, 
the sample was mainly amorphous, so it is difficult to study the possible new form.  
Moreover, the DSC analysis of the mixtures evidenced the possible formation of cocrystal with ascorbic acid 
suggested by exothermic peak of crystallization after a melting endothermic peak. Further studies could be 
carried out on this system to verify the real presence of cocrystal. 
In conclusion, experimental results disagree with the statistical analysis of CSD-Materials application. 
Potentially with its numerous hydrogen bonding sites and small dimension allantoin could form cocrystal with 
several molecules. However, the unique known crystalline form of DL-allantoin has been shown extremely 
stable and not available to make interaction with other molecules. Nevertheless, the results obtained with 





5 APPENDIX A 
X-Ray Powder Diffraction (XRPD) 
Instrument type: Rigaku MiniFlex600 
Application SW:  Miniflex Guidance 
 
Measurement Details 
Measurement type: Single scan 
Sample mode: Reflection 
 
Scan 
Scan range:  3.000 – 40.000 ° (2θ) 
Step size:  0.01 ° (2θ) 
Speed: 10.0 °/min (2θ) 
Scan mode:  Continuous 
 
Used wavelength 
Intended wavelength type:  Kα1 
Kα1:  1.540598 Å 
Kα2:  1.544426 Å 
Kα2/Kα1 intensity ratio:  0.50 
Kα:  1.541874 Å 





Tube output voltage: 40 kV 
Tube output: 15 mA 
High-voltage generation method: High-frequency Cockcroft-Walton method 
Stability:  Within ±0.05% for both the tube voltage and tube current, with reference to ±10% of 
input power variation 
 
X-ray tube 
Name:  Toshiba Analix type A-26L 
Anode material:  Cu  
Maximus output:  0.60 kW 
Focus size: 1 x 10 mm 
 
Kβ Filter 
Name:  Ni-filter 
Thickness (mm):  0.015 
Material:  Ni 
 
Goniometer (Angle measuring device) 
Type: Vertical θ/2θ 
Goniometer radius: 150 mm 
Scanning axis: θ/2θ linked 
2θ scanning range: +2 ° to +140 ° 
θ/2θ axis minimum step angle: 0.005 ° (2θ) 
Position speed: 500 °/min (2θ) 
Scanning speed: 0.01 to 100 °/min 
Datum angle:  2θ = 10 ° 





DS:  1.25 ° 
IHS:  10.0 mm 
SS:  none (open) 
RS:  none (open) 
Incident side Soller slit: 2.5 ° 
Receiving side Soller slit: 2.5 ° 
 
Detector 
Name:  D/teX Ultra High-speed 1D Detector 
Detection element:  1D semiconductor element 
Window material:  Be 
Effective window size:  13 mm (H) x 20 mm (W) 




6 APPENDIX B 
6.1 EvHT results 
 
 
Figure 28. XRPD comparison between starting materials allantoin (black line), L-lysine (blue line) and EvHT 
product resulted by allantoin and L-lysine (red line) 
 
 
Figure 29. XRPD comparison between starting materials allantoin (black line), ascorbic acid (blue line) and EvHT 






Figure 30. XRPD comparison between starting materials allantoin (black line), D-glucoronic acid (blue line) and 
EvHT product resulted by allantoin and D-glucoronic acid (red line) 
 
Figure 31. XRPD comparison between starting materials allantoin (black line), galacturonic acid (blue line) and 
EvHT product resulted by allantoin and galacturonic acid (red line) 
 
Figure 32. XRPD comparison between starting materials allantoin (black line), D-panthenol (blue line) and EvHT 






Figure 33. XRPD comparison between starting materials allantoin (black line), trans-ferulic acid (blue line) and 
EvHT product resulted by allantoin and trans-ferulic acid (red line) 
 
6.2 Precipitation results 
 
Figure 34. XRPD pattern comparison between starting materials allantoin (black line), glucoronic acid (blue line) 






Figure 35. XRPD pattern comparison between starting materials allantoin (black line), trans-ferulic acid (blue 
line) and precipitation product resulted by allantoin and trans-ferulic acid (red line) 
 
Figure 36. XRPD pattern comparison between starting materials allantoin (black line), galacturonic acid (blue 
line) and precipitation product resulted by allantoin and galacturonic acid (red line) 
 
Figure 37. XRPD pattern comparison between starting materials allantoin (black line), D-panthenol (blue line) 






Figure 38. XRPD pattern comparison between starting materials allantoin (black line), ascorbic acid (blue line) 
and precipitation product resulted by allantoin and ascorbic acid (red line) 
6.3 Slurry 
 
Figure 39. XRPD comparison between starting materials allantoin (black line), ascorbic acid (blue line) and 






Figure 40. XRPD comparison between starting materials allantoin (black line), ascorbic acid (blue line) and 
slurry product resulted by allantoin and ascorbic acid in ethanol (red line) 
 
 
Figure 41. XRPD comparison between starting materials allantoin (black line), citric acid (blue line) and slurry 
product resulted by allantoin and citric acid in water (red line) 
 
Figure 42. XRPD comparison between starting materials allantoin (black line), citric acid (blue line) and slurry 






Figure 43. XRPD comparison between starting materials allantoin (black line), glucuronic acid (blue line) and 
slurry product resulted by allantoin and glucuronic acid in water (red line) 
 
Figure 44. XRPD comparison between starting materials allantoin (black line), glucuronic acid (blue line) and 
slurry product resulted by allantoin and glucuronic acid in ethanol (red line) 
 
Figure 45. XRPD comparison between starting materials allantoin (black line), DL-panthenol (blue line) and 






Figure 46. XRPD comparison between starting materials allantoin (black line), DL-panthenol (blue line) and 
slurry product resulted by allantoin and DL-panthenol in ethanol (red line) 
 
Figure 47. XRPD comparison between starting materials allantoin (black line), trans-ferulic acid (blue line) and 
slurry product resulted by allantoin and trans-ferulic acid in water (red line) 
 
Figure 48. XRPD comparison between starting materials allantoin (black line), trans-ferulic acid (blue line) and 






Figure 49. XRPD comparison between starting materials allantoin (black line), galacturonic acid (blue line) and 
slurry product resulted by allantoin and galacturonic acid in water (red line) 
 
Figure 50. XRPD comparison between starting materials allantoin (black line), galacturonic acid (blue line) and 
slurry product resulted by allantoin and galacturonic acid in ethanol (red line) 
 
Figure 51. XRPD comparison between starting materials allantoin (black line), L-tartaric acid (blue line) and 






Figure 52. XRPD comparison between starting materials allantoin (black line), L-tartaric acid (blue line) and 
slurry product resulted by allantoin and L-tartaric acid in ethanol (red line) 
 
Figure 53. XRPD comparison between starting materials allantoin (black line), D-panthenol (blue line) and slurry 
product resulted by allantoin and D-panthenol in water (red line) 
 
Figure 54. XRPD comparison between starting materials allantoin (black line), D-panthenol (blue line) and slurry 







Figure 55. XRPD comparison between starting materials allantoin (black line), DL-panthenol (blue line) and 
product resulted by grinding of allantoin and DL-panthenol (red line) 
Figure 56. 
XRPD comparison between starting materials allantoin (black line), D-panthenol (blue line) and product resulted 






Figure 57. XRPD comparison between starting materials allantoin (black line), urea (blue line) and product 







Figure 58. XRPD comparison between starting materials allantoin (black line), ascorbic acid (blue line) and 
product resulted by kneading of allantoin and ascorbic acid in ratio 1:2 (red line) 
 
 
Figure 59. XRPD comparison between starting materials allantoin (black line), citric acid (blue line) and product 






Figure 60. XRPD comparison between starting materials allantoin (black line), citric acid (blue line) and product 
resulted by kneading of allantoin and citric acid in ratio 1:2 (red line) 
 
Figure 61. XRPD comparison between starting materials allantoin (black line), glucuronic acid (blue line) and 
product resulted by kneading of allantoin and glucuronic acid in ratio 1:2 (red line) 
 
Figure 62. XRPD comparison between starting materials allantoin (black line), 2,5-dihydroxybenzoic acid (blue 






Figure 63. XRPD comparison between starting materials allantoin (black line), DL-panthenol (blue line) and 
product resulted by kneading of allantoin and DL-panthenol in ratio 1:1 (red line) 
 
Figure 64. XRPD comparison between starting materials allantoin (black line), DL-panthenol (blue line) and 
product resulted by kneading of allantoin and DL-panthenol in ratio 1:2 (red line) 
 
Figure 65. XRPD comparison between starting materials allantoin (black line), trans-ferulic acid (blue line) and 






Figure 66. XRPD comparison between starting materials allantoin (black line), galacturonic acid (blue line) and 
product resulted by kneading of allantoin and galacturonic acid in ratio 1:2 (red line) 
 
Figure 67. XRPD comparison between starting materials allantoin (black line), L-lysine (blue line) and product 
resulted by kneading of allantoin and L-lysine in ratio 1:2 (red line) 
 
Figure 68. XRPD comparison between starting materials allantoin (black line), D-panthenol (blue line) and 







Figure 69. XRPD comparison between starting materials allantoin (black line), maleic acid (blue line) and product 





7 APPENDIX C 
 
Figure 70. DSC thermogram of DL-panthenol 
 
 
Figure 71. DSC thermogram of Alphanta 
 






Figure 73. DSC thermogram of mixture 1:1 allantoin and ascorbic acid 
 
Figure 74. DSC thermogram of trans-ferulic acid 
 
 






Figure 76. DSC thermogram of urea 
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EVALUATION OF ERRORS AND ABERRATIONS AFFECTING THE ANALYSIS BY X-
RAY POWDER DIFFRACTION  
 
1 INTRODUCTION 
1.1 X-ray powder diffraction (XRPD) 
X-Ray diffraction (XRD) is the main analytical technique used to study crystalline phases of solid samples. X-
Ray diffraction results from interaction between electromagnetic radiation and matter. Each electron of sample 
is secondary diffusing center of X-Ray with the same λ of incident beam. The wavelength λ of X-Ray is in the 
range 0.1-100 Å. In crystalline samples, the diffraction of the X-Ray occurs when the interatomic distances of 
crystalline structure are comparable to the λ of the radiation. This is explained by the Bragg’s law:  
 
𝑛𝜆 = 2𝑑 sin 𝜃 
 
where n is the diffraction order, λ the wavelength of the incident radiation, d is the distance between parallel 
reticular planes, and θ is the angle between the incident rays and diffraction planes.  
The angle of Bragg θ is determined experimentally as the half of the angle between the direction of the incident 
ray and of the reflected ray. The diffraction phenomenon occurs only when the adjacent lattice planes of the 
same family hkl reflects the incident beam with constructive interference, that is when the difference between 
the optical path (AB+BC in Figure 1) is a multiple of λ 1–3.  
 
 
Figure 1. Bragg's law 
 
The X-Ray diffraction is a fundamental physical property of the crystalline phase. The experimental pattern 
obtained from the analysis show the intensities of the diffraction peaks (count or count/second) as a function 
of the angular position 2θ. The diffraction pattern is a fingerprint of each crystalline phase and it is useful for 
the unique identification of the phase and for complete interpretation of crystalline structure such as position 
of atoms and molecule in the space. Through diffraction patterns comparison, it is possible to highlight the 
different phases present in the sample (position of the peaks), their concentration (height or area of the peaks), 
the amorphous content (trend and area subtended to the background) and the size/deformation of the crystals 
(width and shape of peaks). 2 
The most common X-Ray diffractometer is in Bragg-Brentano or parafocusing reflection geometry in θ/θ mode 




θ°/min and + θ°/min. (Figure 2). This geometry, also called para-focusing, allows to use a flat sample holder, 
which is very easy to prepare. 4 
 
 
Figure 2. Bragg-Brentano geometry 
 
The diffractometer is constituted by the source of X-Ray beam, X-Ray tube mainly with a Cu anode, a series 
of optical components (Figure 2), and the detector.  
The divergence slit minimizes the equatorial divergence of the incident beam preventing the beam overflow 
phenomenon that is over-illumination of sample (Figure 3). While the anti-scatter silt limits the scatter 
contribution due to the air. Smaller divergence and anti-scatter slits reduce the irradiated sample and intensity 
of reflections accordingly. Additionally, the over-illumination of the sample is demarcated by the mask. It limits 
the width of the beam and it is chosen considering the type of sample holder. The soller slits are placed in both 
incident and diffracted beam. These optical components limit the axial divergence collimating the axial 
component of the X-ray beam. Left side of Figure 4 shows the axial divergence effect not collimated by soller 
slit, one of two rays shown illuminates center of the sample plane, while the second ray set at the same 
divergence angle hits the sample at its edge with smaller Bragg angle due to axial divergence. Right side of 
Figure 4 shows the effect of collimation of the soller slits. 1,5 
 
 
Figure 3. Beam overflow 
 
The width of the anti-scatter slit in the diffracted beam depends on the diffractometer and the type of detector. 
In single point detector usually has the same width of the anti-scatter slit in the incident beam. When linear 
detectors are present, which collect several degrees at the same time, the anti-scatter slit is chosen in 
accordance with the collection window of the detector. This slit has the task to assure just reflected beam and 
no air scatter reaches the detector. The radiation produced in the source includes higher energy X-rays such 
as Kα1, Kα2 and lower energy radiation Kβ which can be easily removed by the Beta-filter, for the Cu radiation 




The X-Ray powder diffraction (XRPD) is the mainly technique for the study of the solid state. One of the main 
advantages is its ease of use. The samples can be easily mounted and analysed with minimal operator 
intervention. Additionally, it is a non-destructive technique, since the sample can be studied without the need 
to be dissolved or destroyed. However, there are disadvantages in the use of XRPD due to its inaccuracy in 
the determination of quantities in non-homogeneous samples, in the size of crystallites, and the inability to 
detect trace phases. 6 
 
 
Figure 4. Axial divergence and collimation with soller slits 
 
1.2 XRPD errors 
It is essential to be aware of all the sources of errors to be able to minimize them and to perform good quality 
analysis. The errors on X-Ray analysis can be divided in accidental and systematic errors which can be due 
to the instrument and to sample and its preparation (Table 1). The main causes of accidental errors or 
instrumental aberrations include statistic of counting, stability of generator and of X-Ray tube and instrumental 
errors, while systematic errors include errors due to the sample, involving elemental interactions, as such as 
absorption or transparency, presence of defect and or strain, particle size, crystal size, surface, etc. The 
systematic errors due to instrumental can be controlled and avoid with suitable constructive solution and 
correct set of the instrument. 7  
 
Table 1. Type of error 
Accidental errors or 
instrumental aberrations 
• statistic of counting 
• stability of generator and of X-Ray tube 
• instrumental errors 
Systematic errors 
• nature of the sample 
• instrumental errors 
 
The accuracy of any analysis depends on both systematic and accidental errors, establish the entity of the 
individual errors is important to have control over each of them. 7 
Concerning the accidental errors, the counting time, and the power of generator impact especially in the 
intensity of the measure. Depending on the purpose of the analysis, phase identification, quantitative analysis 
or lattice parameters determination, different level of signal to noise ratio are required and consequently 
different counting time and instrument configuration are chosen. 8 The instrumental aberration due to the slits’ 
configuration will be discussed later. The systematic errors include error due to the nature of the sample and 
its preparation, and to geometry of the diffractometer and sample holder. Accidental and systematic errors 
affect the quality of the diffraction pattern, which is constituted by different element as described by the function: 
 










Where 𝑆𝑝 is the scale factor, which is a correction constitutes by flexible exponential function chosen and 
combined according to the needs of the experiment. 9 |𝐹𝑐𝑎𝑙𝑐((ℎ𝑘𝑙)𝑝)| 
2 represents the peak intensity, 
𝜙(ℎ𝑘𝑙)𝑝(2𝜃𝑖 −  2𝜃(ℎ𝑘𝑙)𝑝)  describes the peak profile, 𝐶𝑜𝑟𝑟(ℎ𝑘𝑙)𝑝(2𝜃𝑖) indicates the peak position, and 𝐵𝑘𝑔(2𝜃𝑖) 
represents the background intensity not related to the sample. Following, all the variables that impact these 
elements of the diffraction pattern and the quality of the analysis are summarized (Table 2) and examined. 
Other aspect that can impact the results of the analysis is the preparation of the sample, of course. Different 
pre-treatment of the sample, e.g., grinding of the powder, the choice of suitable sample holder and the 
preparation of the sample by operator are important aspect to consider.  
 
Table 2 Cause of error 
Sample preparation 
• Choice of suitable sample holder (sample holder scattering) 
• Sample particle size and homogeneity 
• Random orientation of crystallites in space  
• Sample surface (amount, smooth, flat, and horizontal) 
• Sample thickness 
Peak position 
• Unit cell  
• Wavelength λ 
• Misalignment of the mechanical part (zero shift) 
• Vertical displacement of the sample surface 
• Sample transparency 
Peak intensity 
• Incident radiation intensity 
• Symmetry 
• Crystalline structure  
• Preferred orientation  
• X-ray absorption 
• Lorentz-polarization factor 
• Anomalous scattering 
Peak profile 
• Slit  
• Soller (peak asymmetry) 
• Crystallites size 
• Crystallites strain 
• Reticular defects 
Background 
• Lorentz-polarization factor 
• Air scattering 
• Sample holder scattering 
• Anomalous scattering  
• Amorphous scattering 
• Sample fluorescence  
 
1.2.1 Sample preparation  
Sample preparation is extremely important for XRD analysis because several annoying effects can be 
introduced with an incorrect sample preparation that can severely affect the result. Some shrewdness can limit 
systematic errors in the analysis and improve its accuracy and reliability.  
Suitable representative sampling of the bulk is the first condition to correctly analyse sample in all the analytical 
techniques. Moreover, the sample stability should be granted during the sample preparation and analysis.  
In X-Ray powder diffraction the random orientation of the crystallites in the space is extremely important to 
avoid the preferred orientation phenomenon, which occurs when there is a strong tendency for the crystallites 
to be oriented in one direction, for instance in case of needles or plate. The preferred orientation affects the 




to run quantitative analysis. 10 Generally, in diffractometer with para-focusing geometry with flat sample, the 
sample preparation occurs using top-loading sample holder that can induce preferred orientation. This 
phenomenon can be minimize using different sample holder, as such as back-loading or side-loading. 
Otherwise, grinding of sample and reduction of the particle size promote random position of the particle during 
the sample preparation. At last, measurements in transmission mode with detector equipped with focusing 
mirror and rotating capillary, usually reduce the preferential orientation. 4 
 
To ensure optimal statistical homogeneity, another important factor is the particle size of the sample, on which 
it depends the number of particles analyzed on equal sample holder size. Considering a sample with diameter 
D = 10 mm, thickness h = 0.1 mm and ideal spherical particle with equal size and diameter = d, the number N 







It appears that to ensure optimal statistics (particles analysed > 106), particles should have a diameter d < 20 
µm. 2 Crystallites must be small and uniform. Grainy sample with presence of small number of larger crystallites 
“rocks in dust” impacts the intensity and shape of the peaks, hence it is important in that case grinding the 
sample to reduce the crystallites and to uniform it. 4 Moreover, one deduces through this formula that the 
thickness of sample is equally relevant for amount of analysed sample and even for its absorption. Generally, 
the sample is irradiated by X radiation in the first fraction of mm beyond the surface, however this depends on 
the presence of high absorption elements in the sample. The sample must be sufficiently thick to limit the loss 
of photons which are neither absorbed nor diffracted due to the transparency of the sample. 2 Furthermore, it 
is important to ensure that the primary beam irradiates the sample without exceeding its size hitting the sample 
holder and causing the phenomenon of sample holder scattering. The portion of the sample analysed depends 
on the deviation of the primary radius (Divergence slit), the goniometer radius, the Bragg angle (range of 
analysis) and the length of the sample. 2  
Eventually, for a correct preparation of the sample the surface of the powder should be perfectly smooth 
(surface porosity <10 µm), flat and horizontal, in particular with highly absorbent samples.  
 
1.2.2 Peak position 
The detection of correct peak position and intensity is fundamental. In fact, the USP chapter <941> reports 
that the qualitative method by XRPD is usually based on the visual comparison of sample XRPD pattern to the 
experimental or calculated pattern of a reference material. Another criterion for the qualitative comparison 
between reference material and an unknown sample is to list the d-spacings or 2θ-diffraction angles and their 
normalized intensities [Inorm] that represent the crystallographic fingerprint of the material. The tolerance range 
in the 2θ-diffraction angles between specimen and reference of the same crystal form is ± 0.2° 2θ, except for 
hydrates and solvates, for which the tolerance can be greater than 0.2°2θ. 8  






θm = θd(hkl) + θo + θp + θabs 
Where: 
Table 3. Peak position determination factors 
Parameter Description 
θd(hkl) d(hkl) plane 
It depends on the spacing between the parallel set of lattice planes with Miller index 
hkl. 
θo Offset error 
It is due to: 
• Misalignment of the mechanical part; 
• Specimen displacement  
θp Individual peak error 
It is different for each peak and depends on:  
• the height of the peak,  
• the standard deviation, 
• the intensity of the background, 
• the time needed to acquire the profile, 
• the total integrated signal,  
• the number of points in the peak. 
θabs Absorption error 
It depends on the nature of the atoms, especially, in organic material, which are non-
absorbing and are affected by transparency  
 
The X-ray diffraction phenomenon is resulted by an incident X-Ray beam scattered with constructive 
interference in the same direction of reflection one by crystalline lattice planes with Miller index hkl. This is 
described by Bragg’s law, reported previously.  
Therefore, the peak position θ depends on spacing between the parallel set of lattice planes with Miller index 
hkl and the λ. The λ is determined by the anode (Cu, Cr, Mo, W). Generally, the copper radiation (λ = 1.54056 
Å) is used. As reported the peak position θ depends on the lattice distance d of the crystalline, hence any 
variation occurred in the planar distance, for example due to thermal expansion, causes a shift of the peaks. 
On the other hand, the precise and accurate determination of the peak position gives insight in the cell 
parameters and structure. 
The correct determination of θd(hkl) of the reflection can be affected by several errors, reported in Table 3, 
among including offset errors due to misalignment and specimen displacement.  
Misalignment of the mechanical part can be overcome by monitoring the diffractometer performance and 
alignment of the diffractometer by the calibration check using a certificate standard as silicon powder.  
Hence, the main source of offset error (θo), is the specimen displacement that can be due to: 
• Sample preparation;  
• Sample holder. 
The sample and the mounting of the specimen in a suitable holder are critical steps in many analytical methods, 
particularly for X-Ray Powder Diffraction analysis. The sample preparation and the different sample holder can 
affect the measurement causing a shift of the peaks. The sample surface that is offset by D with focal plane 
causes systematic errors in the peak position that are very difficult to avoid entirely (Figure 5). Typically, an 
offset D = 15 µm causes a horizontal shift of the order of +0.01°2θ at low angles. The delta shift is function of 






Figure 5 Specimen displacement 
 
Moreover, the relevance of correct evaluation of the appropriate data treatment is pointed out to obtain the 
best peak profile and accurate peak positions extrapolation by function, which is usually based on Gaussian 
and Lorentzian functions and different combination of them. The use of different function can affect the θ 
position. Indeed, good description of the diffractogram is obtained when the calculated pattern fits with the 
experimental one. 
Lastly, the absorption error can be minimize the contribution of the plate using zero-background-plates 
constituted by silicon or quartz. 2  
 
1.2.3 Peak intensity 
The diffracted intensity is proportional to the incident radiation intensity, which is related to the instrumental 
parameters, as such as divergence slit and soller that determine the divergence of the incident beam and thus 
the portion of the irradiated sample.  
𝐼ℎ𝑘𝑙  ~ 𝐼0 
 
As summarized in Table 2, the peak intensity depends on several factors as described by the function: 
 
















 wherein 𝐼0 = incident radiation, 𝜆 = wavelength, 
𝑙𝑠 = width of detector’s slits, 𝑅 = radius of the goniometer 𝑟𝑒= 7.9 10
−26 cm is the radius of electron. The 𝐾𝑒 
constant expresses influence of the experimental parameters. µ is the linear absorption coefficient. 𝐾ℎ𝑘𝑙 is the 









𝐾ℎ𝑘𝑙 expresses the relation of the diffracted intensity with the volume of the unit cell (Vc), the reflection 
multiplicity factor (𝑚ℎ𝑘𝑙), that considers the number of symmetry-equivalent reflections contributing to the single 
observed peak, the structure factor (𝐹ℎ𝑘𝑙), the Lorentz-polarization (𝐿𝑝ℎ𝑘𝑙). 
2,11 Furthermore, the background 
intensity (𝐵𝑘𝑔(2𝜃𝑖)) due to air scattering, fluorescence, etc. 
8, is added to the diffracted intensity, and the 
function ca be rewrote as: 
 






) +  𝐵𝑘𝑔(2𝜃𝑖) 
 
The Lorentz-polarization factors (Lp) is known trigonometric factor, resulted by the product of the Lorentz and 




The Lorentz factor (or kinetic factor) depends on the instrument geometry and the method of recording and it 
considers the angular scanning rate ω.  
 






While the polarization factor depends only on the reciprocal lattice coordinate and it is unrelated to method of 
recording. It considers the polarization induced by a possible monochromator.  
 
𝑃𝑜𝑙𝑎𝑟𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 (𝑝) =





The structure factor 𝐹ℎ𝑘𝑙
  represents the wave diffracted by the unit cell relative to the hkl reflection. The 
structure factor formula is reported below 12,13.  
 
 
Where N represents the total number of atoms in the unit cell, fj is the atomic scattering factor of jth atom and 
uj vj wj are the fractional coordinates of the jth atom position in the unit cell. The intensity of the hkl reflection is 
proportional to the square of the structure factor. Therefore, the intensity is related to the indices hkl, and to 
the nature (fj) and the disposition (uj vj wj) of atoms in the unit cell, that means it depend on the crystalline 
structure and symmetry of the sample. 12  
Additionally, the intensity is proportional to the X-Ray absorption, already mentioned above. The X-Ray 
incident radiation I0 encounter the sample of thickness x and it is partly transmitted and partly absorbed causing 
a decrease in intensity I of an X-Ray beam proportional to distance travelled x and density (ρ) of the sample.  
  







Where µ is the linear absorption coefficient proportional to the density (ρ). µ/ρ is called Mass absorption 
coefficient (MAC), it is constant of the material and independent of physical state. Hence, crystalline or 
amorphous material with the same elemental composition and density are characterized by the same MAC.12  
The phenomenon of the preferred orientation of the crystallites, already introduced in the previous sections, 
causes a distortion of relative intensity inducing inaccuracy of quantitative data. 
Additionally, the occurrence of extra-reflections apparently attributable to the sample, can sometimes cause 
complications in the interpretation of X-ray diffractogram. These reflections may derive from the anode of the 
X-Ray tube, by detector effects and abnormal reflections by the crystalline sample. It is an uncommon effect, 
although the anomalous scattering is difficult to recognize. A way to identify the presence of abnormal 
scattering is to analyse a “blank” to exclude signals due to the anode or detector. 7  
 
1.2.4 Peak profile 
Theoretically, ideal powder diffraction pattern is characterized by narrow, symmetrical, positioned peaks. As 
already pointed out, several variables affect the diffraction pattern. Particularly, the symmetry of the peak is 
influenced by two mainly reasons: instrumental effects and real sample.  
The instruments and the experimental setup affect the peak profile. The diffraction reflections are broadened 
by several aberrations inherent in the geometry of the instrument, such as slits. 14 As demonstrated by Riello 
et al. different instruments gives different asymmetry effect. 15 Another important aberration due to experiment 
setup is the axial divergence, that causes peak asymmetry, also effects in position, and width of the reflections 
especially at angle < 40°2θ. 16 The axial divergence is due to the X-Ray beam divergence in the perpendicular 
direction along the axis of the goniometer which generates the asymmetry of the peaks, particularly evident at 




unfortunately reduce the intensity of the incident radiation, so narrower Soller slits diminish the asymmetry and 
the intensity of the peaks.14–16   
The instrumental contribution can be modelled by measuring NIST standard as Si. 
The real sample is characterized by crystal size, domain size, stress, strain all factors that contribute on the 
final peak profile. Peak broadening and asymmetry indicate crystalline smallness and micro-stress, chemical 
heterogeneity, long-range internal stress, anisotropic crystalline shape, strain, size, and shape of crystallites. 
The peak width is expressed by the full width at half maximum (FWHM). The FWHM describes the width of a 
peak at half height. For the determination of the FWHM is crucial a good description of the baseline. If the 
baseline of the peak is ambiguous, for instance due to peak overlap, is difficult to establish where exactly half 
of the height is. 17–20 
The diffraction peak profile is described using a combination of Gauss and Lorentz functions, as Voigt function, 
that is a convolution of Gauss and Lorentz function and Pseudo-Voigt function, that is a weighted sum of Gauss 
and Lorentz function. The latter is easier to handle and represent a very good approximation to Voigt functions. 
Another function for the peak profile description is the Pearson-VII function. All the mentioned functions have 
in common symmetric, and lack of defined cut-off. The variables used in the determination of the best fitting 
profile can give information on the crystal size, defects etc. 
Another difficult aspect in the description of the peak profile is the peak overlapping. Especially in organic 
compound, which are characterized by medium size cell and low symmetry, the peak overlap is elevate at high 
angle, therefore it is preferred to describe peak at low angle, although they are affected by instrumental 




As mentioned above, an accurate determination of background is essential for the subsequent accurate 
determination of all the parameters of diffraction pattern, as such as the peak height, the integrated intensity, 
the integral breadth. The background contributes to the intensity of the diffraction pattern and it is mainly 
generated by the scattering of the air and can be reduced by using monochromatic rays of a suitable 
wavelength and by removing air from the space between the sample and the detector. 21 Nevertheless, this is 
not the only source of background error and an appreciable error remains. Other contribution to the background 
can be the fluorescence scattering, Compton scattering, anomalous scattering, sample holder scattering, 
temperature diffuse scattering due to certain types of structural defects, and Lorentz-Polarization factor. Some 
of these have been previously discussed. Concerning the sample holder, the choice of suitable sample holder, 
and also experimental setup (slits) linked to the starting point is essential to avoid the sample holder scattering 
because the beam could hit it and origins to a signal not due to the sample. Other times the sample can 
contribute itself to an incorrect scattering, as in the case of fluorescence scattering. All the atoms of the crystal 
are bombarded by X-Ray radiation and themselves become a source of fluorescent radiation. If this radiation 
has enough energy to reach the detector it will have a background count increment. The magnitude of this 
background accretion depends on the diffusion power of the crystal, on the effectiveness of the detector and 
on the actuation due to the optical path distance between crystal and detector. 7 Additionally, presence of 
amorphous phase in the sample can affected the baseline of the pattern. In case of amorphous sample or 
sample containing an amorphous phase determination of the background is challenging due to the amorphous 
halo. Moreover, the determination of the background is arbitrary and subjective to operator. There are several 
ways to describe the background, as such as manually, using the peak finding of the software, using different 






The purpose is to experimentally evaluate the effects of systematic (instrumental aberration) and accidental 
error of X-Ray diffraction technique. Trust of own measure is essential. Understand the causes of which 
impacts the quality of the measure is crucial to sort the error out and improve the quality of the measure. 
Therefore, some experimental example of the effect of systematic errors and accidental errors are performed 
to point out the importance of the suitable experimental setup, sample preparation and sample holder choice.  
3 EXPERIMENTAL PROCEDURE 
For the experiments has been used PANalytical X’Pert PRO diffractometer with Bragg-Brentano geometry, 
Cu-Kα radiation (λ = 1.54 Å) and X’Celerator as detector.  
 
3.1 Instrumental aberrations 
As already noted, the most interesting characteristics in a diffraction pattern are the position of the peaks, 
determined by the size and symmetry of the unit cell, their intensity, influenced by the size of the crystals and 
by the geometry and setting of the instrument  
The components of the diffractometer that most influence the quality and shape of the reflections are 
divergence, anti-scattering, and soller slits. The divergence of the primary beam is determined by the incident 
slits, while the diffracted beam is limited by the slits placed in front of the detector. The incident slit system 
determines the surface portion of the irradiated sample and affects the intensity and shape of the peaks, while 
the diffracted slit system influences the resolution of the reflections. Furthermore, the slits placed between the 
source and the sample have the function of limiting the primary beam to optimize the surface irradiated by the 
radiation avoid the beam overflow phenomenon and the irradiation of the sample holder. 
Following are reported the results of the experimental performed changing the divergence slit (FDS) and 
correspondent incident antiscatter slit (FAS) and diffracted antiscatter slit, soller slits, and different sample 
holders.  
 
The same sample has been analysed with different sample holder: PANalytical top loading 9430 018 13321 
(a), PANalytical sample holder for non-standard sample and low angle analysis 9430 018 12001 (b), and 
PANalytical back loading sample holder 9430 018 11161 (c) (Figure 6).  
 
 
Figure 6. Sample holders: a) PANalytical top loading 9430 018 13321, b) PANalytical for non-standard sample 






Figure 7. Example of effects of sample holder: XRPD pattern comparison of sample analyzed with PANalytical 
top loading 9430 018 13321 (blue line), PANalytical sample holder for non-standard sample and low angle 
analysis 9430 018 12001 (green line) and PANalytical back loading sample holder 9430 018 11161 (red line). The 
bottom image shows the magnification at low angle (range 2-6°2θ) 
 
All the measurements have been detected with the same experimental setup: FDS 1/16°, FAS 1/8°, diffracted 
antiscatter slit 5.0 mm e soller 0.04 rad. Observing the pattern at low angle in Figure 7, the measurement 
obtained using the top loading 9430 018 13321 (blue line) shows little hump due to the irradiation of the sample 
holder. This sample holder is not suitable for analysis at low angle, while the other sample holder 9430 018 
12001 (green line) and 9430 018 11161 (red line) are appropriate for analysis starting at low angle. In fact, the 
patterns obtained using these sample holders does not showed signal ascribable to the sample holder 
scattering but just signal due to the primary beam at the beginning of the pattern. The choice of the suitable 
sample holder is fundamental in case of sample with reflection at low angle. Indeed, this signal cannot be 
detected using the wrong sample holder because the sample holder scattering could cover the sample signal.  
 
Figure 8 shows the XRPD pattern comparison of sample analysed with different experimental set up: FDS 1/4° 
- FAS 1/2° and FDS 1/16° – FAS 1/8°, the mask and the diffracted antiscatter slit was fixed at 15 mm and 5.0 
mm, respectively. FDS equal and lower 1/2° requests diffracted antiscatter slit of 5.0 mm.  
Observing the measurements at low angle (°2θ < 4), the primary beam is observed in the set up FDS 1/4° - 
FAS 1/2°. Indeed, analysis at extremely low angle needs lower slits to avoid the detection of primary beam 
and sample holder scattering. Concerning the reflections, using narrower slits (FDS 1/16° – FAS 1/8°, red line) 
the intensity is significantly reduced due to lower quantity of irradiated sample. Although, the FWHM does not 






Figure 8. Example of effects of instrument set up: XRPD pattern comparison of sample analyzed with different 
slit setup: FDS 1/4° - FAS 1/2° and FDS 1/16° – FAS 1/8° 
 
The soller slits are placed before and after the sample to limit the axial divergence of the primary and secondary 
beams. As shown in Figure 9, using Sollers with a smaller angular aperture (red line) remarkable reduction of 
intensity was obtained with gain in resolution and symmetry of peaks.  
 
 
Figure 9. Example of effects of instrument set up: XRPD pattern comparison of sample analyzed with different 
soller slit: 0.04 rad. (blue line) and 0.02 rad. (red line) 
 
The counting time is another important parameter to collect accurate diffractograms. Figure 10 reports the 
comparison between the same sample analysed with different time (seconds) per step. The sample contains 
low percentage of crystalline phase, the increasing in time per step allows the detection of the small crystalline 
peaks thanks to significant improvement in signal to noise ratio. The peaks are not detected with collection 
time of 120 and 300 sec, blue and red line, respectively. Increasing the collection time to 1000 seconds per 






Figure 10. Example of effects of time of analysis: XRPD pattern comparison of sample analyzed with different 
counting time: 120 sec (blue line), 300 sec (red line) and 1000 sec (green line) 
 
Further important parameters to consider especially during the quantitative evaluation is the stability of the 
generator and the X-Ray tube, that affected the intensity of the reflection as shown in Figure 11. The silicon 
standard has been analysed with different setup of generator power to simulate the decay of the natural lamp, 
fundamental factor to consider during quantitative method development because it significantly affects the 
intensity of the signal.  
 
 
Figure 11. Example of effects of lamp decay: XRPD pattern comparison of silicon standard analysed using 
different setup of generator power 
 
3.2 Systematic errors  
Many diffractometric systematic errors can be directly related to sample preparation. The ideal sample is 
constituted by large number of randomly oriented crystals with respect to the incident beam in a homogeneous 
powder. Therefore, to improve homogeneity, grainy samples should be ground to obtain fine powder which 
usually helps to minimize preferential orientation and avoid the presence of rocks. Additionally, the amount of 
sample placed on the sample holder and the fill of the sample holder are fundamental.  
 
Figure 12 shows the effects of grainy sample (green line) compared to the same sample after grinding (red 
line). It is impressive how the XRPD patterns are different, to the untrained eye these XRPD patterns can 
appear of different polymorphs due to the wide variations in peak intensity, shape, and profile. Compared with 




sample over XRPD pattern intensity and profile. It is worth noting that ground sample’s XRPD pattern is 
comparable to the calculated one, while the presence of grain in the not treated sample (green line) extremely 
impact the measure. The XRPD pattern of grainy sample shows altered intensity of the reflections due to 
preferred orientation phenomenon and it worth noting the presence of double signal in some peaks and the 
difference in shape and profile of the peaks, especially in the peak in position 15°2θ.  
This example evidences the grinding process can be essential to obtain solid measurement especially in case 
of grainy and orientated samples.  
Grinding process can resolved the preferred orientation effect also in case of fine powdery samples that do 
not show bigger grain. Figure 14 showed the comparison of calculated XRPD pattern (black line) and XRPD 
patterns before (blue line) and after grinding (red line) of powdery sample that presents preferred orientation. 
It is worth noting the difference of peak intensity between sample before and after grinding, ground sample 
shows relative intensity of the peaks comparable to the calculated pattern. Differently than grainy sample, this 
sample shows alteration exclusively in intensity of the peaks and not in shape and profile, in fact no double 
peaks are detected.  
Nevertheless, some sample are not stable to grinding process. In fact, as shown in Figure 15, grinding can 
promote amorphization of the sample indicated by broad and less intense peaks. Furthermore, the grinding 
process can trigger a transition process between two polymorphs.  
 
 
Figure 12. Example of effects of grainy sample: XRPD pattern comparison between grainy sample before (green 






Figure 13. Example of grainy sample: XRPD pattern comparison between grainy sample before (green line) and 
after grinding (red line) and calculated pattern of the sample (black line) 
 
 
Figure 14. Example of orientated sample: XRPD pattern comparison between orientated sample before (blue 






Figure 15. Example of amorphization due to grinding 
 
Furthermore, preferred orientation phenomenon can be minimized using different sample holder. Sample 
preparation using top loading sample holder (Figure 16 a) could promote the preferred orientation disposition 
of the crystalline, as such as needle-like shape, on the sample holder to enhance the signal of mainly expose 
crystal planes. While side and back loading (Figure 16 b and c, respectively) should promote the random 
disposition in the space of the crystalline particles and avoid this phenomenon. Figure 16 reports the XRPD 
pattern of orientated sample prepared in three different sample holder a) top loading (red line), b) side loading 
(green line) and c) back loading (blue line) to evidence the difference of relative intensity of the reflections. The 
sample was not ground to evaluate exclusively the different impact of the sample holders. Observing the 
relative intensity of three patterns it is appreciable that the XRPD pattern collected using side loading sample 
holder (green line) shows relative intensity comparable between the peaks. Both the XRPD pattern obtained 
using top (red line) and back loading (blue line) show remarkable effect of preferred orientation evidenced by 





Figure 16. Example of orientated sample prepared with a) top loading (red line), b) side loading (green line) and 





Figure 17 reports the XRPD pattern comparison between sample analysed within a capillary in transmission 
mode (cyan line) and on top loading sample holder in reflection mode (red line). The measurements are 
compared with the calculated pattern (black line) to evaluate the relative intensity. The XRPD pattern of the 
sample analysed in transmission mode shows relative intensity comparable to calculated pattern, while the 
same sample analysed in reflection mode shows slight preferred orientation phenomenon, especially evident 
in the highest reflections in the range 18-22°2θ.  
 
 
Figure 17. Example of orientated sample: XRPD comparison between sample collected in reflection mode (red 
line), transmission mode (cyan line) and calculated pattern (black line) 
 
Concerning sample preparation and the amount of analysed sample, the same sample has been analysed 
with successive addition of powder. Increasing quantities of the sample results in an increase of the intensities 
and amplitudes of reflections and not negligible shifts in the position of the peaks, due to transparency of the 






Figure 18. XRPD pattern comparison of sample with increasing amount of powder 
 
4 CONCLUSION 
The X-Ray diffraction is powerful and useful technique for the study of solid-state. It is simple not destructive 
technique that does not require elaborated sample preparation. Nevertheless, to obtain accurate measurement 
it is fundamental to not underestimate the importance of the suitable choice of experimental setup, suitable 
sample holder and appropriate sample preparation. Performing accurate analysis is extremely important for 
the study of solid-state, especially in case of quantitative analysis. In fact, the preferred orientation 
phenomenon is the most diffuse effect that alters the relative intensity of peaks compared to the corrected 
relative intensity of the calculated pattern and especially it may cause errors in the quantification analysis. 
Nevertheless, this phenomenon can be mitigated with some precautions as such as grinding of the sample, 
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UNIVARIATE QUANTITATIVE METHODS BY X-RAY POWDER DIFFRACTION 
 
1 INTRODUCTION 
The importance of the different properties of different solid forms, especially in pharmaceutical fields, is well 
established. The pharmaceutical companies spend energy and resources to identify the best API crystal form 
for the final formulation of the drug product. Metastable forms can be preferred than the thermodynamically 
stable polymorph because of their more solubility and dissolution rate. However, the possible transition to the 
thermodynamically stable form, which can be trigged by several variables such as humidity, temperature, and 
the presence of impurities, requires special attention when studying the stability of the crystalline form over 
time. In fact, the stability of the selected polymorphs must be guarantee during and after the manufacturing 
process. 1 
Frequently, the qualitatively identification of the form is not adequate alone and the quantitative determination 
is usually needed to assure that the transition is limited within the acceptable level and it does not compromise 
the product performance. The qualitative and quantitative method used to check the API crystal form in the 
bulk and in the product should be validated. The pharmaceutical companies need to develop, validate, and 
execute the qualitative and quantitative control in GMP (Good Manufacturing Practise) quality system. 
Nevertheless, there is not a guideline that reports indication and acceptance criteria for the validation of 
quantitative method for the determination of polymorphs. Frequently, the pharmaceutical companies refers to 
the ICH Q2 R(1) guideline for the validation of HPLC methods. The guideline ICH Q2 (R1) points out that the 
main purpose of validation of an analytical method is to demonstrate that the procedure is suitable for its 
intent.2 
Several techniques are suitable for development of quantitative evaluation of solid state as well as for the 
characterization of polymorphs, such as IR, Raman, NMR, and especially X-Ray Powder Diffraction (XRPD).  
USP indicates the use of X-Ray Diffraction technique for the solid state qualitative and quantitative analysis. 3 
 
1.1 Quantitative analysis in X-Ray Powder diffraction 
The XRPD is widely used for qualitative analysis of crystal form (identification) and quantitative analysis of 
mixtures of crystalline polymorphs and for determination of crystallinity degree (amorphous and crystalline 
form quantification).  
The hypothesis of a quantitative use of the technique dates back to the discovery of the technique by Max von 
Laue in 1912.4 In 1919 Hull affirmed the potential use of the technique for quantitative analysis demonstrating 
that the data obtained with a mixture is a superimposed sum of data of the pure components, in position and 
intensity of the lines quantitatively. 5 It was not until 1948 with Klug and Alexander that the first theoretical 
treatment about quantitative analysis by X-Ray Powder Diffraction has been developed 6 and from then the 
quantitative analysis has advanced. 










Where 𝐼(ℎ𝑘𝑙)𝛼 is the intensity of the hkl reflection of the component α, K is a constant which depends on the 
instrument, as such as slit size and goniometer radius, and on the sample, xα is the weight fraction of the 
component α, ρα is its density, 𝜇𝛼
∗  and 𝜇𝑀
∗  are the coefficient of mass absorption of the component α and the 
mixture, respectively. 4 
The value of the coefficient of mass absorption of the mixture 𝜇𝑀
∗  is given by the weighted mean of the value 
of coefficient of mass absorption of all the components of the mixture, and it is generally unknow. Theoretically, 
its value can be experimentally obtained because the K value can obtain by measure of the pure reference. 7 
Predominantly, the quantitative methods have the objective to determine or eliminate the contribution of 𝜇𝑀




The mass absorption coefficient of the analyte α and the mixture coincides (𝜇𝛼
∗ =  𝜇𝑀
∗ ) in mixture of polymorphs 
of the same substance. In this case, the concentration xα is directly proportional to the intensity. In case of 
𝜇𝛼
∗ ≠  𝜇𝑀
∗  the correlation between concentration and intensity deviates from the linearity. This deviation from 
linearity is severe in case of inorganic compounds, which are characterized by high and very different mass 
absorption coefficient, whereas organic compounds have relatively low and narrowed range of mass 
absorption coefficient that does not severely affect the linearity. 1,6 
The formula reveals that the quantitative phase analysis is based on the integrated intensity of a reflection of 
the phase α, although the quantitative phase analysis can be based also on the peak height or area of several 
reflections or on the full pattern. 1,3,4 
The main difficulties encountered in solid state quantitative method development are related to the sample 
preparation. The accuracy and precision of the method are affected by the characteristic of the sample, 
particularly by the homogeneity of all phases, particle size distribution in each phase, and to matrix effects. 
The inhomogeneity of the mixtures and samples is a common issue of the solid state analysis that extremely 
affect the quantitative method by XRPD and other techniques, often the problem is minimized reducing the 
particle size of the sample. 8–10 Furthermore, the reduction of particle size by grinding minimizes the preferred 
orientation phenomenon that affect the quantitative analysis, and sufficiently small particle size should make 
negligible the micro absorption effect. 6 Nevertheless, in case of organic compound the grinding of the powders 
can potentially promote the phase transition or amorphization. It is of particular concern because it irretrievably 
affects the quantitative analysis. For this reason, the quantification of organic metastable compounds and 
amorphous phase is extremely problematic because of the preparation of the standard mixtures is affected by 
the instability of the reference. 1 
Additionally, it is very important to ensure that the samples and the standards have the same particle size 
distribution. It is common that the samples are different than the standard mixtures artificially prepared with 
the products commercially available. 11 
The guidelines do not give acceptance criteria values for the development and validation of quantitative method 
in solid state. USP reports that the determination of amounts of crystalline phases as small as 10% can be 
achieved in favourable cases. 3 
Two approaches of quantitative method can be distinguished, the methods based upon on one reflection, 
namely traditional methods, or based on the whole pattern. The traditional methods are based on the highest 
single peak its area or less common the intensity of the reflection is plotted versus the concentration to 
determine the linear correlation with graphical and mathematical interpolation. 12,13 It is worth noting that the 
intensity is more sensible than the area to the nature of the sample i.e., different crystal size generates different 
intensity but not different area of the peak. 11 The traditional methods can be divided into absolute methods, 
based on the intensity of the pure phase, and relative, based on the ratio between the intensity of the pure 
phase and e.g., internal standard. 4 The absolute method is based on the ratio between intensity of α phase 
in the mixture (𝐼(ℎ𝑘𝑙)𝛼
 ) and in pure phase α (𝐼(ℎ𝑘𝑙)𝛼
0 ) analysed at the same experimental condition. 14,15 This 
method gives reproducible results in case polymorphs where 𝜇𝛼
∗ =  𝜇𝑀
∗  , otherwise the 𝜇𝑀
∗   should be 










The method with the internal standard is based on the ratio of the intensity of the analyte α and the internal 
standard (β) both in the mixture, therefore the 𝜇𝑀





= 𝐾 ∗ 𝑥𝛼/𝑥𝛽 
 
The proportional constant (K) between 
𝐼(ℎ𝑘𝑙)𝛼
𝐼(ℎ𝑘𝑙)𝛽
 versus 𝑥𝛼 can be determined analysing standard mixtures with 
known fraction of 𝑥𝛼/𝑥𝛽. Successively, the 𝑥𝛼 of the sample is quantified adding known amount of β phase.
7,16 




of the phase α. It is recommended to use compound with similar mass absorption coefficient of the phase α, 
to avoid micro absorption problem. 4,17 This approach is used by the method Reference Intensity Ratio (RIR) 
developed by Woolf and Visser, who indicates as internal standard the corundum.18 The method is based on 
the ratio of the integrated intensity of the highest peak of the phase α and the highest peak of corundum (hkl 







The RIR value of several crystalline phases are tabulated in database Powder Diffraction File (PDF) of ICCDD. 
It is worth noting that the RIR method is considered as semiquantitative. It can be improved by using RIR 
values determined with the own instrument with the target samples.4 Nevertheless, addition of internal 
standard may affect the analysis when the internal standard is not homogeneously mixed into the sample. 17 
Alternatively, method based on external standard can be used. This method avoids the inhomogeneity problem 
potentially encountered in internal standard method and the different absorption between sample and standard 
does not affected the analysis. 17 Furthermore, the external standard method has the advantages that the 
sample are not spiked and contaminated by the standard and the standard is not consumed and can be 
measured several times, and the sample and standard are measured separately avoiding the interference and 
overlapping of the peaks. 21  
The internal or external standard application is useful to normalize the signal and eliminate the variation due 
to the fluctuation of the X-Ray source that affect the intensity of the peaks.  
This method is used also in the case of amorphous and crystalline mixture because the scattered intensity by 
a compound, within the same measurement range, it is the same independently of its amorphous or crystalline 
state, because the number of electron has not changed. Chen et al. have demonstrated the application of the 
normalization of the signal of amorphous-crystalline samples with the integrated intensity of the 100% 
crystalline or amorphous reference. 22 Based on this assumption, other method normalizes the signal relating 
the integrated intensity of individual peak of the diffractogram to the total intensity of the sample’s diffractogram. 
An example will be reported in this chapter.  
Generally, the normalization of the signal contributes to minimize the variations due to the instrument 
fluctuation, although the large contribution of the measurement variation due to the inhomogeneity of the 
mixture and its sample still affects the results. Any quantitative method requires homogeneous mixing of 
calibration data set, it is extremely challenging for solid mixtures. 22 
 
The methods based on the whole pattern typically require more knowledge about the phases in the mixture 
than the traditional methods, except multivariate chemometric methods as such as Partial Least Squares 
(PLS). Through the data obtained by the single region or multiple regions of the pattern of a calibration set, 
ideally with wide source of sample variation, PLS constructs a predictive model for the determination of the 
samples based on the correlation of intensity and composition of the calibration set. 23,24 
Differently, other whole pattern methods such as Whole Powder-Pattern Decomposition (WPPD) and Rietveld 
methods require more information about the composition of the mixture and the crystalline structure of the 
individual phases. Generally, these methods are based to the achievement of best fit between the pure phases 
data and the experimental pattern and determination of the scale factor of individual phases. The intensity of 
the pattern (Y) at step i can be described by the background (B) function, the profile function (P) and the scale 
factor (S).  
 







N is the number of components in the mixture, Ijk is the integrated intensity of the jth reflection of the k phase.  
Different background and profile functions to describe the diffraction pattern are available.25 The WPPD 
method applies the least-square refinement decomposing separately the diffraction patterns of the individual 




factor of the individual component is fixed to 1 ( 𝑆𝑘
𝑠𝑖𝑛𝑔𝑙𝑒
= 1). Successively, the WPPD is executed for the 
mixture sample and the quantification is occurred determining the scale factor of the integrated intensity of the 
phase being quantified so that the sum of the scale factors of individual phases in the mixture is equal to unity. 
The ratio 𝑆𝑘/𝑆𝑘
𝑠𝑖𝑛𝑔𝑙𝑒
  is analogous to the ratio of the individual peak 𝐼(ℎ𝑘𝑙)𝛼/𝐼(ℎ𝑘𝑙)𝛼
0 . In case of mixture containing 
amorphous phase, the scale factor of the amorphous phase can be determined adding a known quantity of a 
crystalline standard (internal standard) 26  
 






The WPPD method requires knowledge of the sample composition, chemical composition and mass 
absorption coefficient of individual phases, and their unit cell parameters. The WPPD method does not require 
the structural parameters of the individual phases, differently by Rietveld method.  
The Rietveld method requires the knowledge of the composition of the multicomponent sample and the 
structural parameters of each phase involving atomic coordinates essential for the calculation of the structure 
factor. The Rietveld refinement derives the scale factor of each phase describing the experimental pattern 
minimizing the difference between the intensity of the experimental pattern and the calculated pattern of the 
individual phases through the function: 
 
𝑌𝑐𝑖 = 𝑆𝑘 ∑ 𝐿ℎ𝑘𝑙|𝐹ℎ𝑘𝑙|
ℎ𝑘𝑙
𝑃𝐵𝑟𝑎𝑔𝑔(2𝜃𝑖 − 2𝜃ℎ𝑘𝑙)𝑃𝑂ℎ𝑘𝑙𝐴 + 𝐵 
 
Where Yci is the intensity calculated at individual point i in the diffraction pattern, Lhkl involves the Lorentz, 
polarization, and multiplicity factors, Fhkl is the structure factor of the hkl Bragg reflection, PBragg is the peak 
profile function, POhkl is the preferred orientation function, A is the absorption factor, and B represents the 
background intensity. It worth noting that Rietveld method can correct the preferred orientation phenomenon, 
although in slight amount. 27 As well as the WPPD method, adding known amount of internal standard in the 
sample containing amorphous phase its quantification is possible. 28 The Rietveld method is complicated 
method that requires qualified analyst and the transfer lab-to-lab is problematic and inadvisable. 1 
Concerning the amorphous and crystalline quantification, the USP reports simple method based on the whole 
pattern that relies on the ratio between the intensity or area of the crystalline part and the total intensity or area 
of the pattern constituted by the sum of the area of the crystalline and amorphous parts net to the noise. 3,13,29 
 
1.2 Univariate analysis 
The univariate analysis is based on the assumption of linear relationship between an independent variable (x), 
e.g., concentration, and a dependent variable (y), consisting in measurable instrumental signal as peak 
intensity or area. This relationship between x and y is expressed by the equation:  
 
𝑦 = 𝑎 + 𝑏𝑥 
 
Univariate analysis involves the determination of a regression line which describes the trend between the 
instrumental signal (y) in function of the concentration of the analyte (x) and its coefficients a and b by the least 
square method.  
The equation of the regression line can be described by: 
 
𝑦 = 𝑎 + 𝑏𝑥 +  𝜀 
 
Where ε represents the experimental variability associated to each measure of y. The least square 
mathematical process determines the regression line minimizing the summation of the mean quadratic 
deviations of the ordinates (y) of the experimental data with respect to the corresponding ordinates of the 







Where yi is the experimental value corresponding to i value in x-axis and ?̂? denotes the predicted back-
calculated value of y by regression line, and v is the number of freedom grade.  
The quality of the linear correlation between y and x is statistically verifiable through the coefficient of 





Where xi is the concentration of i-th value, ?̅? and ?̅? represent the mean of the y and x values. The R value 
expresses the quality of the linear correlation, often reported as R2 which is the coefficient of determination. 
For both coefficient values can be in the range 0 < R ≤1, value of 1 denotes a perfect correlation. 30,31 
Once the analytical function of the calibration curve has been determined, it is possible to interpolate the 
analytical signal to unknown sample.  
 
The regression line method is applicable to the X-Ray Powder Diffraction (XRPD) demonstrated by the 
equation: 
 
𝐼𝑖 = 𝐾 ∗ 𝑋𝑖𝐽/𝜇𝐽 
 
Where I is the intensity of the signal (y) of the phase i, X represents the variable x i and is the weight fraction 
of the phase i in the sample j, K is a constant depending on the nature of the phase, the specific peak, the 
instrument, and the intensity of the original beam, and 𝜇𝐽 represent the average mass absorption coefficient 
of the sample determined by the sum of mass absorption coefficient of individual n phases in the sample 
multiplied by their weight fraction in the sample. 16 
To apply the regression method, it is needed adequate amount of pure analyte to prepare calibration standards 
for the construction of the calibration curve and evaluate the linear correlation between y and x within an 
interval containing x0 (unknown concentration to determine). Furthermore, another essential requirement is to 
individuate a specific signal without overlap with other signals and that depends exclusively on the 
concentration of the analyte (x) and is independent from the matrix.  
Deviation from the linearity of the analyte response due to the presence of chemical interferents, is the most 
frequently encountered problem in case of analysis of complex samples, e.g., pharmaceutical formulation 
containing several excipients and it is called matrix effect. The correction of the interferences of the matrix can 
be performed by applicating the standard addition method (SAM). This method is applicable when the 
composition of the matrix is complex, and its nature is not completely known. It is based on addition of 
increasing known amount of pure analyte to the sample assuming that the interference is the same for both 
the pure analyte and the one already presents in the sample. The concentration of the analyte CE net of spiked 
pure analyte is extrapolated by the regression line. It is possible to analyse the linear dependence and calculate 
the value of the concentration of analyte within the sample as following.  
 
𝑦 = 𝑎 + 𝑏𝐶𝐸 
 
𝐶𝐸 = (𝑦 − 𝑎)/𝑏 
 





𝐶𝐸 = 𝑎/𝑏 
 
Hence, the concentration of the analyte in the matrix can be extrapolated by the ration between the intercept 
and the slope of the regression line. 34 
The SAM is a useful calibration method especially in analysis of pharmaceutical formulation including high 
number of excipients and in which is hard to find a specific peak of analyte, not subjected to overlapping with 
other matrix’s signals. Unfortunately, it is characterized by elevated uncertainty and inaccuracy, which explain 
why the interpolation method is preferred. The deviation standard of the extrapolated concentration is 




Another drawback of SAM is the necessary to construct a calibration curve for each unknown sample spiking 
it with different amount of pure analyte. 32  
To improve accuracy and precision the univariate method are applied in combination with internal standard 
method. 16,33 
The internal standard method consists in the addition of known quantities of internal standard to the sample. 
For each standard is detected the signal specific for the analyte SA and the signal relating to the internal 
standard SIS. The response (y) is determined by the ratio between the signal of the analyte and the internal 
standard SA/SIS. In quantitative analysis by XRPD the application of internal standard is extremely useful 
because it corrects the possible instrumental error, especially the decay of the X-ray tube, that causes 
decrease of the intensity of the signal over time. The internal standard should have a simple diffraction pattern 
and with reflections that do not overlap those of the analyte of interest; be chemically stable, and have 
absorption coefficient similar to the sample Usually, the used internal standard in X-Ray powder diffraction are 
stable compounds as alumina, silicon, or zinc oxide. 1 
 
The goodness of quantification is evaluated by the statistical tools, as such as R2, standard deviation Sy/x, 
relative standard deviation (RSD%) and recovery %. Usually, R2 value should be higher than 0.99 but in solid-
state quantification values higher than 0.9 are accepted. However, excellent R2 value does not guarantee good 
prediction of the real value of concentration (x), when the standard deviation is high. The standard deviation 
value estimates the random errors in the y-direction.  
Another measure of spread is the relative standard deviation %, which is given by RSD%= 100 s/x, where s is 
the deviation and x is the mean of estimate value of the measured quantity. 34 The RSD% is an expression of 
the precision and repeatability of the assay. Accepted RSD% values in solid-state analysis are lower than 
20%. The Recovery% refers to the difference between the true value and the obtained value calculated by the 
ratio between the obtained and real values multiplicated for 100. The recovery % denotes the accuracy of the 






Several quantitative methods by X-Ray Powder Diffraction are available. Nevertheless, in pharmaceutical field 
the traditional methods are commonly used because the similarities with the quantitative analysis by HPLC, 
widely used in pharmaceutical companies. The quantitative methods peculiar to the crystallographic field as 
such as Rietveld, WPPD and RIR are less used because of their difficulties to be implemented in validation 
method, thus the traditional methods are widely used for the determination of the crystal forms and crystallinity 
degree.  
Following, some examples of quantitative methods developed and evaluated in PolyCrystalLine laboratories 
are reported. In all cases the methods are tailored on the customer requirements and the name of the 
compounds are omitted and used name of fantasy. The first is an example of limit test method, the purpose of 
the limit test method is to determine if the content of the impurity is above or below an established limit of 
content. The quantitative method evaluates the content of the analyte (polymorphic form) in the range of the 
calibration curve that can vary according to the necessity of the customer. 
The second and third examples regards the quantification of a target crystal phase in a mixture: for example, 
the unreacted starting material in the co-crystal formation or the presence of an undesired polymorphs. 
Amorphous content is of interest for pharmaceutical company due to instability of the amorphous phase, 
example of amorphous and crystalline quantification will be reported successively in following chapter. 
Acceptance criteria for solid-state quantitative method are not reported in guidelines, USP reports that the 
determination of amounts of crystalline phases as small as 10% can be achieved in favourable cases.  
In all cases, the quantification method should have the following acceptance criteria: the regression value for 
the calibration curve needs to higher than R2 > 0.9 (usually value higher than 0.99 are accepted), The relative 
standard deviation RSD% ≤ 20% and Recovery % within the range 80-120%.  
 
3 LIMIT TEST  
3.1 Aim 
The aim is to develop a limit test by X-Ray Powder Diffraction of a polymorph X in the bulk of form Y. The 
development of quantitative method or limit test is tailored to customer’s needs. Generally, limit test is adopted 
when the determination of low content of the analyte cannot be accurately determined. The manufacturing 
company is not able to product pure bulk of form Y and traces of form X are detected. The quantification of 
form X is fundamental for the company to declare its content and to demonstrate that its presence does not 
impact the quality and performance of the product. Therefore, pure form Y is not available for the construction 
of calibration curve and it is necessary applied the standard addition method (SAM) to quantify the amount of 
form X contained in the standard of form Y used for the study. 
 
3.2 Experimental procedure 
Figure 1 reports the comparison of pure forms X and Y and it is highlighted in yellow the specific peak at 
19.4°2θ of form X used for the quantification. The pure forms Y was not available in suitable amount to prepare 
a calibration set. The scale up and production of suitable amount of pure form Y without traces of form X was 






Figure 1. XRPD pattern comparison of Form X (red) and Form Y (black) 
 
The measures were performed using PANalytical X’Pert PRO diffractometer in reflection mode and Bragg-
Brentano geometry, Cu X-ray tube (λ = 1.5406) and X’Celerator detector. To minimize the effect of the lamp 
decay, the signal of the form X was normalized using external standard alumina Standard Reference Material 
1976 flat. The calibration standards were prepared by spiking the form Y containing unknown amount of form 
X with increasing amount of form X in percentage of 2.5, 5, 7.5, 10% w/w. 
Three different aliquots of each standards were analysed in the range 17-27°2θ to detect the specific peak of 
form X at 19.4°2θ. Daily, one analysis of the external standard alumina was performed to collect the peak at 
35.2°2θ used for the analysis.  
The area of the peak at 19.4°2θ of form X and the peak at 35.2°2θ of external standard alumina were 
determined using the software HighScore 4.8. The response (y) of the calibration curve is the ratio between 
the area of analyte form X and external standard alumina.  
 
𝑅𝑎𝑡𝑖𝑜 =
𝐹𝑜𝑟𝑚 𝑋 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑎𝑡 19.4°2θ  
𝐴𝑙2𝑂3 𝑎𝑟𝑒𝑎 𝑎𝑡 35.2°2θ 
 
 
Addition standard curve was constructed plotting the ratio between the peak area of form X and that of the 
alumina versus the % of form X added. 
The content of the form X in the standard of form Y was extrapolated from the standard addition curve using 
the formula:  
𝐹𝑜𝑟𝑚 𝑋% 𝑒𝑥𝑡𝑟𝑎𝑝𝑜𝑙𝑎𝑡𝑒𝑑 =
𝑖𝑛𝑡𝑒𝑐𝑒𝑝𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑎𝑑𝑑𝑖𝑡𝑖𝑜𝑛 𝑐𝑢𝑟𝑣𝑒 
𝑠𝑙𝑜𝑝𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑎𝑑𝑑𝑖𝑡𝑖𝑜𝑛 𝑐𝑢𝑟𝑣𝑒
 
 
The calibration curve was re-calculated considering the content of form X in the standard of form Y, then this 
calibration was used to quantify form X in other bulk samples of Y.  
The limit of detection was evaluated by HighScore software that automatically calculates the S/N using the 
Signal to noise Algorithm that follows the guideline ICH Q2(R1) definition and uses this simplified formula:  
 
𝑆/𝑁 = (𝑛𝑒𝑡 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦)/(3 ∗  √𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
 ) 
 
ICH Q2(R1) reports that the signal-to-noise ratio of 3 is acceptable. The measure is performed by comparing 
the signal of the standard with the baseline.  
Additionally, the robustness of the method was tested. The robustness of an analytical method is the capacity 
to remain un-effect by small, but deliberate variation in the method parameters. It provides an indication of its 
reliability during ordinary use. For XRPD, the instrumental parameter that can mainly influence the method 
performances is the lamp. Indeed, a lamp decay can influence the intensity of the signal of the analyte, 




and amperage. The routine analysis was performed with generator settings 40 mA and 45 kV. In this test the 
generator settings have been modified to simulate lamp decay. 
The aim of this assay is to define the acceptance criterion in terms of minimum area of alumina to ensure that 
the instrument can detect the form X and form Y.  
 
3.3 Results 
Figure 2 and Table 1 reports the calibration curve and results obtained with standard addition method.  
Coefficient of correlation met the acceptance criterion of 0.9. The results of SAM evidenced a content of form 
X of 2.8% with excellently low deviation standard (SE). Figure 3 reports the XRPD pattern comparison of all 
the aliquots used for the construction of the calibration curve.  
 
 
Figure 2. Standard addition calibration curve  
 
Table 1. Results of standard addition calibration curve  












Figure 3. XRPD pattern of the standard mixtures 
 
The content of form X of the standards was recalculated considering the results CE obtained with SAM (Table 
2).  
Table 2. standard re-calculation 
Standard % form X added Re-calculated % form X 
Average of Ratio  
area Form X/area Al2O3 
STD 0 0% 2.8% 0.06 
STD 1 2.5% 5.3% 0.08 
STD 2 5.0% 7.8% 0.12 
STD 3 7.5% 10.3% 0.17 
STD 4 10% 12.8% 0.22 
 
The limit of detection was evaluated to define the value for the limit test. The lamp decay of the instrument can 
affect the intensity of the signal and the limit of detection decreased over time. For this reason, the value of 
LOD obtained by HighScore cannot be used for the limit test because of it is not robustness over time, e.g., 
the LOD of 2.5% is >3 but after time it can decrease at value <3 due to the lamp decay causing an error in the 
content determination. Hence the limit test is based on the ratio between the area of form X and the alumina 
than was not affected to the lamp decay. The measurement of the alumina peak was considered a suitability 
test to determine the intensity of the X-ray beam. The aim was to determine the lowest beam intensity to detect 
form X in the range 5-10% as requested by the costumer. The limit test is evaluated by the ratio of the area of 
form X and alumina on the assumption that the decay of the lamp affects at the same way the analyte and the 




simulating the lamp decay at different generator settings: 45 kV-40 mA, 40 kV-30 mA, 35 kV-25 mA, 30 kV-10 
mA, 15 kV-5 mA. 
 
The STD 0 containing 2.8% of form X showed a LOD value of 3 at 45 kV and 40 mA, settings used for the 
analysis of measure of calibration curve The STD1 and STD 3 were measured with the different generator 
settings. Table 3 reports the minimum values of generator setting and percentage of form X when the 
characteristic peak of form X achieved the S/N >3. The ratio between area of form X and alumina was 
unchanged at different value of generator power.  
 
Detection of 5% of form X is guarantee up to area of 524 cts, whereas area ≥ 63 cts guarantee detection of 
10% of form X with suitable signal to noise.  
Successively the ratio between the area of peak of form X at 15.4°2θ and peak of alumina is calculated. If the 
ratio is ≤ 0.17 the sample contains Form X ≤ 10%, whereas ratio > 0.17 indicates content of form X > 10%. 
 
Table 3. Robustness assay 
Standard % Form X Generator Setting Area Alumina Ratio 
STD 0 2.8% 45 kV – 40 mA 1025 cts 0.06 
STD 1 5.3% 35 kV – 25 mA 524 cts 0.08 




Using the standard addition method, a 2.8% of form X was quantified in the bulk of the Y form. Using this 
value, the quantity of form X in all the standards was established. The limit of detection was evaluated in the 
different samples with different intensity of the X-ray beam. It was found that the 5% of form X was detectable 
also with the generator setting at 35 kV and 25 mA which is almost half of the intensity of the normal condition, 
and 10% of form X is the LOD with the generator setting at 20kv and 10 mA, which are the standby conditions. 
The results evidenced the robustness for Form X content of the value of the ratio between the area of form X 





4 QUANTITATIVE OF STARTING MATERIAL IN CO-CRYSTAL 
4.1 Aim 
The aim is to develop and validate quantitative method by XRPD for the determination of crystalline form X of 
molecule A in the bulk powder of the cocrystal formed by A and the conformer B.  
 
4.2 Experimental procedure 
Figure 4 reports the comparison of form X and cocrystal. The peak at 2θ =7.9° of form X was used for 
quantification.  
The form X and cocrystal have extremely similar mass absorption coefficient 5.4 and 5.5 cm2g-1, respectively.  
 
 
Figure 4. XRPD pattern comparison of Form X and cocrystal 
 
The measures were performed using PANalytical X’Pert PRO diffractometer in reflection mode and Bragg-
Brentano geometry, Cu X-ray tube (λ = 1.5406) and X’Celerator detector. To minimize the effect of the lamp 
decay, the signal of the form X was normalized using signal of the peak at 35.2°2θ of alumina Standard 
Reference Material 1976 flat.  
Seven standard mixtures were prepared with different content of form X respectively 1, 2.5, 5, 7.5, 10, 15, 20% 
w/w.  
Three different aliquots of each standards were analysed in the range 5-13°2θ to detect the specific peak of 
form X at 2θ =7.9°. Daily, one analysis of the external standard alumina was performed in the range 34-36.2°2θ 
to collect the peak at 2θ= 35.2°.  
The area (cts) the peak at 2θ= 7.9° of form X and the peak at 2θ =35.2° of external standard alumina were 
determined using the software HighScore 4.8. The response (y) of the calibration curve is the ratio between 
the area of analyte form X and external standard alumina.  
 
𝑅𝑎𝑡𝑖𝑜 =
𝐹𝑜𝑟𝑚 𝑋 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑎𝑡 7.9°2θ  
𝐴𝑙2𝑂3 𝑎𝑟𝑒𝑎 𝑎𝑡 35.2°2θ 
 
 
Calibration curve was constructed plotting the average of the ratio of the three aliquots of each standard versus 




Repeatability, intermediate precision, and accuracy were assessed on the endpoints of the calibration curve 
as reported by ICH Q2 (R1). Repeatability and accuracy were evaluated on six aliquots of the endpoints of the 
calibration and the intermediate precision was assessed in two different days.  
The limit of detection was evaluated by HighScore software that automatically calculates the S/N using the 
Signal to noise Algorithm that follows the guideline ICH Q2(R1) definition and uses this simplified formula:  
 
𝑆/𝑁 = (𝑛𝑒𝑡 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦)/(3 ∗  √𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
 ) 
 
ICH Q2(R1) reports that the signal-to-noise ratio of 3 is acceptable for LOD, whereas is 10 for the LOQ. The 
measure is performed by comparing the signal of the standard with the baseline.  
 
4.3 Results 
The calibration curve in the range 1-20% w/w form X showed good R2 of 0.98, but the recovery % of the 
standard 1% w/w was ineligible with value of 183%, indicating that the standard 1% has been overestimated 
to about the double. It is worth noting that the standard 1% w/w showed signal to noise ratio of 6 which is too 
low for LOQ as reported in the ICH Q2 (R1). The standard 2.5% showed signal to noise higher than 40. Hence, 
it is suitable for quantification. The calibration curve was recalculated in the range 2.5-20% (see Figure 5) and 
showed a good linearity with excellent R2 equal to 0.9905.  
Repeatability and accuracy were tested on six aliquots of endpoints standards 2.5% and 20% w/w of form X. 
Both standards showed excellent repeatability with RSD% of back-calculated % form X below 5% (Table 7 
and Table 8). Standard 20% w/w showed mean of recovery % of the six aliquots equal to 96% (Table 6), while 
standard 2.5% showed value within 125% (Table 7). This value can be acceptable for the lowest points of the 
curve, although it worth noting the tendency of the curve to overestimate the lowest point at 2.5% and slightly 
underestimate the second point at 5%, that showed a recovery of the three aliquots of the curve equal to 86% 
(Table 4). As ICH Q2 (R1) suggests minimum 5 points for the calibration curve, the range was narrowed down 
to 5-20% w/w (Figure 6) rising the LOQ of form X to 5% w/w. The R2 value improved and the standard 5% w/w 
achieved satisfactory repeatability and accuracy results with RSD % of back-calculated % form X of 4% and 
mean of recovery % of 94% (Table 9).  
Table 10 reports the excellent results of repeatability and accuracy of standard 20% w/w.  
The intermediate precision was assessed calculating the RSD% of six aliquots of the standards with 5 and 
20% w/w analyzed in two different days, three aliquots of day 1 and three aliquots of day 2. Both standards 
showed excellent RSD% of recovery % back-calculated % form X equal to 4% (Table 11 and Table 12).  
 
 






























Table 5. Repeatability and accuracy STD 2.5% 
Standard Ratio 
Back-Calculated 
% Form X 
Recovery% 
STD 2.5%-.M01 0.04 3.1 124% 
STD 2.5%-.M02 0.04 3.0 121% 
STD 2.5%-.M03 0.04 2.9 116% 
STD 2.5%-.M04 0.04 3.0 120% 
STD 2.5%-.M05 0.05 3.3 131% 
STD 2.5%-.M06 0.05 3.2 127% 
MEAN 3.1 123% 
SD 0.1 5% 
RSD% 5% 4% 
 
 
Table 6. Repeatability and accuracy STD 20% 
Standard Ratio 
Back-Calculated 
% Form X 
Recovery% 
STD 20%-.M01 0.62 18.5 92 
STD 20%-.M02 0.64 19.0 95 
STD 20%-.M03 0.68 20.1 101 
STD 20%-.M04 0.67 19.8 99 
STD 20%-.M05 0.65 19.3 96 
STD 20%-.M06 0.63 18.8 94 
MEAN 19.3 96% 
SD 0.6 3% 





RATIO BACK-CALCULATED % FORM X RECOVERY % 
 Mean Mean RSD% Mean 
STD 2.5% 
0.0508 

























Table 7. Repeatability and accuracy STD 2.5% 
Standard Ratio 
Back-Calculated 
% Form X 
Recovery% 
STD 2.5%-.M01 0.04 3.1 124% 
STD 2.5%-.M02 0.04 3.0 121% 
STD 2.5%-.M03 0.04 2.9 116% 
STD 2.5%-.M04 0.04 3.0 120% 
STD 2.5%-.M05 0.05 3.3 131% 
STD 2.5%-.M06 0.05 3.2 127% 
MEAN 3.1 123% 
SD 0.1 5% 
RSD% 5% 4% 
 
Table 8. Repeatability and accuracy STD 20% 
Standard Ratio 
Back-Calculated 
% Form X 
Recovery% 
STD 20%-.M01 0.62 18.5 92 
STD 20%-.M02 0.64 19.0 95 
STD 20%-.M03 0.68 20.1 101 
STD 20%-.M04 0.67 19.8 99 
STD 20%-.M05 0.65 19.3 96 
STD 20%-.M06 0.63 18.8 94 
MEAN 19.3 96% 
SD 0.6 3% 










Table 9. Repeatability and accuracy STD 5% 
Standard Ratio 
Back-Calculated 
% Form X 
Recovery% 
STD 5%-.M01 0.09 4.82 96% 
STD 5%-.M02 0.08 4.56 91% 
STD 5%-.M03 0.09 4.82 96% 
STD 5%-.M04 0.10 4.95 99% 
STD 5%-.M05 0.08 4.48 90% 
STD 5%-.M06 0.09 4.66 93% 
MEAN 4,72 94% 
SD 0,2 4% 
RSD% 4% 4% 
 
 
Table 10. Repeatability and accuracy STD 20% 
Standard Ratio 
Back-Calculated 
% Form X 
Recovery% 
STD 20%-.M01 0.62 18.3 92 
STD 20%-.M02 0.64 18.9 94 
STD 20%-.M03 0.68 19.9 99 
STD 20%-.M04 0.67 19.6 98 
STD 20%-.M05 0.65 19.1 96 
STD 20%-.M06 0.63 18.6 93 
MEAN 19.1 95% 
SD 0.6 3% 
RSD% 3% 3% 
 
Table 11. Intermediate precision of STD 5% 
Standard Ratio 
Back-Calculated 
% Form X 
Recovery% 
STD 5%-.DAY 1 0.09 4.82 96% 
STD 5%-.DAY 1 0.08 4.56 91% 
STD 5%-.DAY 1 0.09 4.82 96% 
STD 5%-.DAY 2 0.10 4.95 99% 
STD 5%-.DAY 2 0.08 4.48 90% 
STD 5%-.DAY 2 0.09 4.65 93% 
MEAN 4,71 94% 
SD 0,2 3% 
RSD% 4% 4% 
 
 
Table 12. Intermediate precision of STD 20% 
Standard Ratio 
Back-Calculated 
% Form X 
Recovery% 
STD 20%-.DAY 1 0.62 18.3 92 
STD 20%-.DAY 1 0.64 18.9 94 
STD 20%-.DAY 1 0.68 19.9 99 
STD 20%-.DAY 2 0.67 19.6 98 
STD 20%-.DAY 2 0.63 18.6 93 
STD 20%-.DAY 2 0.69 20.1 101 
MEAN 19.2 96% 
SD 0.7 4% 






The calibration curve in the range 5 to 20% showed the best R2 value and the best recovery % and it was 
chosen for the customer. The exclusion of the standard 1 and 2.5% w/w allow to obtain accurate results for 
the lowest points of the calibration curve. In fact, the recovery % of standard 5% w/w reached the value of 
94%, gaining of 8 percentage points (previous value in the range 2.5-20% of 86%). In this case quantification 






5 QUANTIFICATION OF CRYSTALLINE POLYMORPHS 
5.1 Aim 
The aim is to validate quantitative method by XRPD for the determination of polymorph X of an API within the 
bulk of the polymorph Y.  
The customer has interest to quantify extreme low percentage of the form X in form Y.   
The purpose is to evaluate the method based to the response involving the ratio between the area of the 
specific peak of the Form X and the total area of the full pattern of the mixture as required by the customer. In 
this case, the normalization of the signal is performed by the total area of the pattern in the whole range 2.5-
40°2θ. The analysis of the external standard is not necessary.  
 
5.2 Experimental procedure 
Figure 7 reports the comparison of polymorphs form X and form Y. The peak at 2θ = 17.0 °, highlighted in 




Figure 7. XRPD pattern comparison of Form X and Form Y 
The measures were performed using PANalytical X’Pert PRO diffractometer in reflection mode and Bragg-
Brentano geometry, Cu X-ray tube (λ = 1.5406) and X’Celerator detector. To minimize the effect of the lamp 
decay, the signal of the form X was normalized using signal of the whole pattern of the mixtures. 
Seven standard mixtures were prepared with different content of form X 0.5, 1, 2, 3, 5, 10, 20% w/w.  
Three different aliquots of each standard were analysed in narrow range of 16.5-17.7°2θ using slow scan rate 
to maximize the signal of the specific peak at 17.0°2θ, while the full pattern for the normalization was collected 




The area (cts) of the peak at 17.0°2θ of form X and the area of the whole pattern were determined using the 
software HighScore 4.8. The response (y) of the calibration curve is the ratio between the area of analyte form 
X and whole pattern of the mixture.  
 
𝑅𝑎𝑡𝑖𝑜 =
𝐹𝑜𝑟𝑚 𝑋 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑎𝑡 17.0°2θ  
𝐴𝑟𝑒𝑎 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑝𝑎𝑡𝑡𝑒𝑟𝑛
 
 
Calibration curve was constructed plotting the average of the ratio of the three aliquots of each standard versus 
the % of form X in the standards. 
 
5.3 Results 
Seven standard mixtures were prepared and analysed in three different aliquots.  
Figure 8 displays the calibration curve with excellent R2. Nevertheless, the standard 5% w/w showed high 
variability probably due to the inhomogeneity of the mixture and the samplings evidenced by the wide values 
of RSD% but good mean values and excellent recovery %. Considering the excellent mean value and recovery 
the 5% was not excluded from the calibration curve, its back-calculated value perfectly fit the calibration curve 
as showed by the recovery % value. For this reason, this exclusion does not significantly improve the 
calibration as showed in Figure 10.  
Nevertheless, the excellent R2 the calibration curve was not precise and accurate especially for the lowest 
point of the calibration curve (0.5%). The back-calculated and recovery% of the standards of the calibration 
curve were used to the assessment of the precision and accuracy of the calibration (Cross-validation). The 
RSD% of ratio and of back-calculated % of the standards 0.5, and 5% w/w form X showed wide values higher 
than 20%. Additionally, the recovery of standard 2% w/w form X was lower than 80% (Table 13).  
The technique is not able to quantify accurately percentage of 0.5% w/w, thus this data was excluded and the 
calibration curve was evaluated in the range 1-20% w/w (Figure 9).  
The results reported in Table 14 indicate that the method is accurate for all the standards and precise, except 
for the standard 5% w/w form X due to its inhomogeneity.  
The results, especially of standard 5%, evidenced the importance of effective mixing of the standard to obtain 
good value of precision.  
 
 






Table 13. Cross-validation range 0.5-20% w/w form X 
 
 
Figure 9. Calibration curve standard range 1-20% w/w form X 
 
STANDARD 
RATIO BACK-CALCULATED % FORM X RECOVERY % 
 Mean RSD% Mean RSD% Mean 
STD 0.5% 
0,0019 






























Figure 10. Calibration curve standard range 1-20% w/w form X without standard 5% 
 




The range of this method is extremely challenging with respect to the limits of quantification of the technique, 
trying to quantify a percentage of 0.5% w/w. In fact, the recovery % results for this standard revealed that the 
X-Ray Powder Diffraction cannot accurately quantify content of 0.5% w/w. Nevertheless, the method showed 
accurate determination of the standard at 1 and 2%, widely lower than the suggested limit of 10% of the 
technique reported by the USP.  
The data of the standard 5% showed the influence of the inhomogeneity of the mixture. The deviation standard 
values are huge due to the variability of the signal cause by the sampling of inhomogeneous mixture. In this 
case, the plotted mean value fit the calibration curve not affecting the results, evidenced by the excellent value 
of R2, and mean of back calculated % and recovery % of the standard 5%.  
  
STANDARD 
RATIO BACK-CALCULATED % FORM X RECOVERY % 
 Mean RSD% Mean RSD% Mean 
STD 1% 
0,0058 
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QUANTIFICATION BY STANDARD ADDITION METHOD IN X-RAY 
DIFFRACTOMETRY: A COMPARISON OF UNIVARIATE AND MULTIVARIATE 
ANALYSES 
 
1 INTRODUCTION  
1.1 Multivariate analysis 
Multivariate analysis is a statistical powerful method capable to analyse wide number of data. In univariate 
analysis exclusively are involved two variables, independent x and dependent y, directly correlated. The 
determination of the concentration x involving a single variable y. Differently to univariate analysis, multivariate 
analysis involves wide number of experimental data consist of numerous variables y. For example, the 
univariate analysis determines the concentration using a single wavelength, while multivariate analysis 
considers several wavelengths often improving the estimation thanks to the average effect. 1. In various 
experimental situations the number of variables can be extremely high and even higher than the number of 
samples, moreover these variables are often highly correlated. Nevertheless, in a multicomponent sample the 
multivariate method can determine the concentration of all the components basing on several variables. As for 
univariate method, multivariate analysis requires a calibration curve based on a training set of mixtures of 
compounds of known concentration.  
The multivariate linear regression model is expressed by the equation: 
 




+ ⋯ + 𝛽𝑛𝑥𝑖
𝑛  
 
Where Yi is the estimation of the i-th component of the dependent variable y, n is the number of the independent 
variables, xi indicates the i-th component of the n-th variable, and β represents the coefficients. 2 
 
Several multivariate methods have been developed, of particular importance are the Principal Component 
Regression (PCR) and Partial Least Square Regression (PLS) models. 
The PCR used the PCA (principal component analysis), that is the most popular multivariate statistical 
technique. It has the scope to reduce the wide number of variables of interest using independent auxiliary 
variables created by a linear combination of the original ones. The construction of these latent variables has 
the scope to maximize the information contained in the data and to reduce the number of variables, preserving 
the accuracy of the data. In this way, reduction of typical noise of real cases, e.g., due to instrumental 
oscillations, is obtained avoiding possible data interpretation problems. These latent variables are the principal 
components. The principal components that efficiently highlight and summarize the information from the 
original huge variables, are used to construct the regression line which is based on the equation 2,3 
 
 
𝑌 = 𝑋 ∗ 𝐵 + 𝐸 
 
Where Y is n*q matrix, X is n*p matrix, B is p*q matrix, and E represents the residuals. The n represent the 
observations on q responses y and p are the independent or explanatory variables. 4,5 
Both PCR and PLS methods decomposed X into orthogonal scores T and loadings P to overcome the excess 
of variables (columns) compared to the rows represent the number of objects (samples).  
 
𝑋 = 𝑇𝑃 
 
The differences between PCR and PLS methods is that PCR includes information from the vector X, whereas 
PLS includes information on both X and Y. 4,6 The PLS differs from the PCR because it uses the data set of X 




P are selected to reach a better description of the covariance between X and Y, while PCR is focus on the 
variance of X. In this way, for PLS the choice of the main components to be used for the regression is more 
targeted and effective. 6 
The model constructs a new set of variables, the principal components (PCs) on which to perform a multivariate 
analysis. These variables are a linear combination of the original ones and identify in the space of the 
explanatory variable directions of maximum variance between them, also taking into account the correlations 
with the response variables. 3 PLS organizes the data in number A of latent variables (vectors) tj and uj linked 
together by the least squares regressive model: 
 
𝑢𝑖 =  𝑏𝑗𝑡𝑗 +  𝑒𝑗    𝑗 = 1, … … , 𝐴 
 




𝑇𝑢𝑗, while the latent variables are computed through unit vector wj and qj obtained maximizing 
the covariance between scores tj and uj. 6,7 
 
𝑡𝑗 =  𝑋𝑗𝑤𝑗   𝑢𝑗 =  𝑌𝑗𝑞𝑗 
 
The matrices X and Y are described  
 
𝑋 =  ∑ 𝑡𝑗
𝐴
𝑗=1 𝑝𝑗
𝑇 + 𝐸   𝑌 =  ∑ ?̂?𝑗
𝐴
𝑗=1 𝑞𝑗
𝑇 + 𝐹 
 
E and F represents the residuals of X and Y. The procedure stops when there are no more pairs of components 
in X and Y significantly correlated with each other or when there is no longer any useful information obtainable 
for the prediction. The number A of optimal PCs is determined by validation, maximizing the coefficient of 
determination in cross validation (R2) and minimizing the mean square error in prediction (RMSEP). 
The vectors tj, pj, for j = 1, ..., A, respectively constitute the j columns of the matrices of the scores (T), of the 
loadings (P) of X, wj and qj are the weight vectors of X and Y, respectively. The first matrix has as elements 
the coordinates of the objects with respect to the PCs in the space of the explanatory variables, the second 
represents the relevance of these variables with respect to the PCs and the last two report the coefficients of 
the combinations of the matrix X and of the matrix Y, from which the components tj and uj are generated, 
respectively. 6–8 
 
After the application of the multivariate analysis the information is used to extract from the analytical signals 
the information about the analyte of interest. For this purpose, various methods have been proposed, such as 
Net Analyte Signal (NAS) introduced by Lorber et al. and developed by Ferré et al. and Hemmateenejad et al. 
9–11 NAS is based on search for that part of the analytical signal orthogonal (independent), respect to other 
species in the sample. In statistical processing it can be assumed that the NAS signal increases linearly as the 
concentration of the analyte under study increases. The NAS technique, combined with the standard addition 
method (SAM), allows quantification even in the case of not known matrix containing the analyte and different 
species of interferences. 12 
The calibration matrix Y is constituted by the rows si of the experimental measures, for i = 1, n, while the matrix 
X reports the vector of the added concentrations c. The matrix Y is decomposed in:  
 
𝑌𝑟𝑖𝑝 = 𝑇 𝑃
𝑇 
 
Subsequently, the signal related to all the species in the sample is determined after the subtraction of the 
contribution of the k-th analyte under study through: 
 
𝑌 −𝑘 =  𝑌𝑟𝑖𝑝 − 𝛼𝑐𝑘𝑠
𝑇 
 
where 𝑐𝑘 is the prediction of the vector c in the A-dimensional subspace of the PCs and the vector s is obtained 
based on the signal of the pure analyte. Respectively, 𝑐𝑘 and s are a linear combination of the columns and 





𝑐𝑘 =  𝑌𝑟𝑖𝑝𝑌𝑟𝑖𝑝
+ 𝑐   𝛼 = 1/𝑠𝑇𝑌𝑟𝑖𝑝
𝑇 𝑐𝑘 
 
To determine the signal relative to the analyte of interest, the orthogonal component of the original signal is 
compared to the space identified by the interferences present in the sample. For this purpose, the prediction 
matrix is considered.  
 
𝑂 = 𝐼 − 𝑌−𝑘𝑌−𝑘
+  
 
Where I is the matrix of identity of order mm. The Net Analyte Signal vector si* is calculated as: 
 
𝑠𝑖
∗ = 𝑂𝑠𝑖 
 
Bro and Andresen propose a modification to the calculation procedure directly considering the results of the 
PLS analysis and assuming the following as projection matrix: 
 
𝑂 = 𝑏(𝑏𝑇𝑏)−1𝑏𝑇 
 
where b is the vector of the regression coefficients of the component PCs. 13 The Net Analyte Signal vector si* 
is again calculated with the above equation.  
The NAS vector is the part of the spectrum used to make the prediction alone, therefore no information is lost 
by transforming this vector into its Euclidean norm (e.g., length) ║si*║, which constitutes the scalar NAS, often 
identified in literature simply as NAS. At this point, a pseudo-univariate regressive model of the NAS can be 
constructed based on the added concentrations: 
 
‖𝑠∗‖ = 𝑏𝑐 + 𝑎 
 
Hence, the concentration of the analyte of interest in the original sample and the relative standard error can 












𝑁𝐴𝑆̅̅ ̅̅ ̅̅ 2
𝑏2 ∑ (𝑐𝑖 − 𝑐̅)
2𝑛
𝑖=1
                          
 
Being 𝑠𝑦 𝑥⁄  the root of the mean square error (RMSE), 𝑁𝐴𝑆̅̅ ̅̅ ̅̅
  and 𝑐̅ are the means of the NAS norm and of the 
concentration, respectively.  
Deep analysis for the calculation of the analyte concentration can be carried out by subsequently adding 
components in the model, starting from the first PC, performing linear regressions of the NAS on the 
concentrations each time and, through determining different values of cE. Eventually, the number of PCs in the 
model that optimizes both RMSE and coefficient of determination R2 is then selected and the corresponding 






This study deals with the solid-state quantitative analysis by X-Ray Powder Diffraction (XRPD) applying the 
standard addition method and comparing univariate and multivariate analysis in two different scenarios. The 
first scenario is the quantification of paracetamol form II in tachifludec formulation containing various excipients 
and paracetamol form I as API. The second scenario consists in amorphous-crystalline quantification of α-
lactose.  
The multivariate analysis is performed in collaboration with Laboratory of "Analytical Methodologies" of the 
"Giacomo Ciamician" Department of Chemistry of the University of Bologna.  
In pharmaceutical field the control of the crystal form of the API at any stage of the process, as well as in the 
final product, is essential. Nevertheless, it is common to obtain drug substance and product containing trace 
of another form. Frequently, it does not cause a rejection of the drug substance or product because the 
presence of this “contaminant” does not affect the quality and efficacy of the products. However, the regulatory 
agencies could require a limit test or quantification of the “contaminant” in the product. In case of impossibility 
to obtain polymorphic pure drug substance the application of the standard addition method is the solution. In 
this case, it is necessary the availability of the pure contaminant to spike the sample. Additionally, in case of 
analysis of formulation containing several excipients, the matrix effect can be overcome.  
Here after, The SAM was evaluated applying univariate and multivariate methods, combining the SAM with 
the NAS in NASSAM multivariate model (NAS + SAM) to quantify the presence of paracetamol form II in the 
formulation of tachifludec. 
The amorphous phase is typically unstable, and it is common to obtain sample mainly amorphous with some 
trace of crystalline phase. Due to the different properties between amorphous and crystalline phases, such as 
solubility, the presence of partial crystallization of the API can impact the efficacy of the product. For this 
reason, the crystalline-amorphous quantification is an important issue. Here after the amorphous-crystalline α-
lactose quantification is evaluated by spiking the crystalline phase and the univariate and multivariate method 
are compared. 
The crystalline-amorphous quantification is extremely troublesome for the instability of amorphous, transition 
can occur during the mixture preparation. In some cases, to overcome the amorphous instability, instead of 
the amorphous API, the standard mixtures can be prepared with a “surrogate” amorphous which is a stable 
organic amorphous phase i.e., hydroxyl propyl methylcellulose (HPMC).  
To evaluate the correctness of this procedure the quantification of crystalline α-lactose monohydrate was 
determined in two set of standards, one containing amorphous lactose and the second containing hydroxyl 
propyl methylcellulose (HPMC) as amorphous surrogate. The univariate analysis is tested evaluating the 
response of different peaks of α-lactose monohydrate to observing the different response with the differ type 
of amorphous content. Additionally, the signal of the α-lactose monohydrate was evaluated with and without 





3 QUANTIFICATION METHODS OF PARACETAMOL FORM II IN TACHIFLUDEC 
3.1 Paracetamol polymorphism 
Paracetamol, also known as acetaminophen, is a drug substance included in class of non-steroidal anti-
inflammatory drugs. It has central and peripheral analgesic and antipyretic action due to inhibition of enzyme 
cyclo-oxygenase (COX) that yield the prostaglandins. Preventing the production of these important mediator 
of inflammation, paracetamol is effective for treatment of headaches, fever, and pain even post-operative. 14–
17 Paracetamol is included in several pharmaceutical products of pharmaceutical company Angelini (Ancona, 
Italy), e.g., tachipirina, tachifludec, etc. Its chemical structure is shown in Figure 1. 
 
Figure 1. Chemical structure of paracetamol 
Paracetamol exists in three different polymorphs, form I and form II and the elusive form III. Form I is the stable 
polymorph at RT and it is marketed form, although it is not suitable for compression and making tablets. Haisa 
et al. obtained form I and form II from aqueous solution and slow evaporation from ethanol solution, 
respectively. They resolve the structures of both forms I and II, reported in CSD as HXACAN01 and HXACAN, 
respectively. 18,19 Form I and form II share the same hydrogen bond network. Both the structures showed two 
hydrogen bonds involving the phenolic OH that acts as donor and acceptor respectively with carbonyl group 
(acceptor) and amide NH (donor). Although, the two forms showed very different structures. Form I crystallizes 
as monoclinic unit cell with group of symmetry of P21/a. The structure is characterized by fish bone packing 
with sheet stacked along b axis, causing no sliding surfaces which affect the compressibility of the structure 
(Figure 2). 20 
 
 
Figure 2. Form I structure along axis c 
 
Form II crystallizes in orthorhombic crystal system and Pcab space group. It showed sheet-like packing with 
sheets stacked along the c axis (Figure 3, left side). 18 Form II has well developed sliding surfaces and 
undergoes plastic deformation, this makes it very suitable for producing tablets. 21 Form I and form II differ also 
for habit, form I showed hexagonal blocks while form II rectangular ones. 20 
 
Form I is thermodynamically stable at room temperature and atmospheric pressure, while form II is metastable 
under environmental conditions. In fact, Form II and form III are metastable polymorph, labelled elusive forms 
over the years. 22,23 The method of preparation of form II by Haisa et al. was revealed to be not reproducible. 
Di Martino et al. provided method for production of form II and form III by melting of form I. 24 Form I melts at 
approx. 168° C - 169° C, slowly cooling the molten form I until room temperature it gets a glassy phase, which 
heating at about 60°C it converts into form II, that melts at approx. 157/158° C. The crystallization of the glassy 




The existence of metastable form III was reported for the first time by Burger about 40 years ago, but it was 
only in 2002 that Peterson et al. have collected XRPD pattern of paracetamol form III. 25,26 First Perrin et al. 
have resolved the structure of form III, successively improved by Reiss et al. the structures are deposited in 
CSD labelled as HXACAN29 and HXACAN40, respectively. 20,27 Reiss et al. confirm the orthorhombic unit cell 
and Pca21 space group of form III (Figure 3, right side). 20 Form III showed analogies with form II structure, 
both forms equivalent two-dimensional layers of hydrogen bonded molecules. The two forms differ in hydrogen 
bonding plane and in the tilt angles between the benzene rings. Moreover, as shown in Figure 3 surprisingly 
the cell axis of the forms are correlated in perfect ratios, namely a (III) = b (II), c (II) = 2b (III), and c (III) = 2a 
(II). 27 
Figure 4 reports the comparison of XRPD pattern of paracetamol form I, II, and III.  
 
 
Figure 3. Unit cell and structure of Form II and Form III along axis a 
 
 
Figure 4. XRPD pattern of paracetamol form I (red line), form II (blue line), and form III (green line) 
 
During their study, Reiss et al. have discovered and solved the structure of another monoclinic polymorph of 
paracetamol, labelled form III m, obtained by cooling of form III to 100 K (- 173°C). The reversible transition 
from form III-o to form III-m occurred in the range 170-220 K. 20 
Furthermore, Parkin et al. and McGregor et al. report the existence of monohydrate and trihydrate form of 
paracetamol, respectively. 28,29 The monohydrate form of paracetamol was characterized at the low 
temperature of 150 K (-123° C) because it is unstable in ambient condition, the quick loss of water in five 
minutes induces the conversion in stable form I. 28 The trihydrate form of paracetamol has been prepared by 
McGregor et al. through slow cooling at 0°C in 12 hours of aqueous solution of paracetamol. McGregor et al. 
have succeeded in characterizing the trihydrate form despite its instability because of it rapidly dehydrates in 
more stable form. Table 1 reports the crystal data of the known paracetamol forms. Nevertheless, the forms 





Table 1. Crystal data of paracetamol forms 







HXACAN0119 HXACAN18 HXACAN4020 HXACAN3920 HUMJEE28 XOMWOL29 
T (K) 295 295 293 100 150 150 
Space 
Group 
P21/a Pcab Pca21 Pc11 P21/n Pbca 
Unit Cell Monoclinic Orthorhombic Orthorhombic Monoclinic Monoclinic Orthorhombic 
a (Å) 12.93(4) 11.805(5) 11.8376(3) 111.7546(3) 4.5039(6) 7.3324(16) 
b (Å) 9.40(1) 17.164(2) 8.5688(3) 8.5720(3) 10.5391(14) 12.590(3) 
c (Å) 7.10(2) 7.393(2) 14.81837(16) 14.5155(5) 17.048(2) 22.636(6) 
α 90° 90° 90° 84.160(14)° 90° 90° 
β 115.9(2)° 90° 90° 90° 96.399(3)° 90° 
γ 90° 90° 90° 90° 90° 90° 
Z (Z’) 4 8 8 8 4 8 
Volume 
(Å3) 
776.272 1497.98 1503.09 (7) 1454.99 (9) 804.18 (19) 20897 (9) 
 
 
3.2 Experimental procedure 
3.2.1 Characterization of Paracetamol form I 
Form I paracetamol was characterized by XRPD and DSC.  
Figure 5 shows the comparison between experimental (red line) and calculated (HXACAN01 1178859, black 
line) XRPD pattern of paracetamol form I. XRPD pattern of paracetamol form I is comparable to the calculated 
pattern.  
The stability of paracetamol form I was evaluated after grinding for 30 minutes at 30 Hz. Figure 6 reports XRPD 
pattern comparison between paracetamol for I before and after extremely stressful condition of grinding. 
Ground paracetamol form I XRPD pattern is superimposable to XRPD pattern of Paracetamol form I before 
grinding. Paracetamol form I is stable to grinding process. 
DSC analysis of paracetamol form I was performed at rate of 5K/min in different step. The first heating cycle 
was performed in the range 25-180°C, after the sample was cooled up to 25°C and successively heating until 
180°C. 
In the first heating (orange background in Figure 7) the endothermic peak at approx. 169°C with enthalpy of 
about 183 J/g corresponds to the melting of paracetamol form I. During the cooling cycle (light blue 
background) no event is observed. In the second heating cycle (second segment with orange background in 
Figure 7) the exothermic peaks at about 72°C with enthalpy of about -129 J/g is related to crystallization (cold 








Figure 5. XRPD pattern comparison between experimental (red line) and calculated pattern (HXACAN01 1178859, 
black line) of paracetamol form I 
 
 
Figure 6. XRPD pattern comparison between paracetamol form I before (red line) and after (green line) grinding 






Figure 7. DSC analysis of paracetamol form I: heating cycles (orange background) and cooling cycle (light blue 
background) 
 
3.2.2 Crystallization and characterization of paracetamol form II  
Di Martino et al. provide the method for crystallization of paracetamol form II via melting and slow cooling of 
form I. 24 2 g of form I in closed glass vial was placed in the oven at temperature of 180°C for 30 minutes to 
completely melt the form I. Then the oven was turned off and the sample was kept inside the oven for 24 hours 
to slowly cool at room temperature and to promote the crystallization.  
The obtained sample was characterized by XRPD which confirmed the formation of form II  
(see Figure 8) and no peaks of form I are detected.  
 
 
Figure 8. XRPD pattern comparison between experimental (blue line) and calculated pattern (HXACAN 1178858, 
purple line) of paracetamol form II 
 
Stability of the form II was evaluated by grinding for 30 minutes at 30 Hz. The sample showed some tiny peaks 
of paracetamol form I (highlighted in yellow in Figure 9) which suggest avoiding stressful condition during the 






Figure 9. XRPD pattern comparison between paracetamol form II before (blue line) and after (cyan line) grinding 
for 30 minutes at 30 Hz and calculated pattern of paracetamol form I (black line) 
 
3.2.3 Specificity assay 
Tachifludec is a multicomponent formulation consistent of paracetamol form I and several excipients. 
Generally, univariate method requires a specific peak of the analyte, which should not overlap with other peaks 
in the mixture and it should be well separated from the nearby reflections. Furthermore, the peak should have 
a good relative intensity and not be subject to preferential orientation. Nevertheless, the method of the 
additional standard is useful in case of matrix effect and a specific peak is not available. Exclusively, the peak 
at approx. 15.0°2θ of paracetamol form II has all these features and it is used for the construction of the 
calibration curve. Although, it has not a remarkable intensity, which can affect the limit of detection. The highest 
peak of paracetamol form II at 24°2θ is not specific but it can be used for construction of calibration curve with 
the method of addition standard. Figure 10 reports the comparison between tachifludec (black line) and 
paracetamol form II (blue line), the peak at 15.0°2θ is highlighted in yellow, while the peak at 24.0°2θ is 






Figure 10. Specificity: XRPD pattern comparison between tachifludec (black line) and paracetamol form II (blue 
line) 
3.2.4 Standard mixtures preparation 
Tachifludec is a granulated product, hence it was ground using an agata mortar to obtain a fine powder.  
Successively, six standard mixtures were prepared containing tachifludec and increasing amount of form II. 
Additionally, the same quantity of silicon equal to about 10% of the total mass was introduced into each mixture 
(Table 2). The use of silicon as internal standard allows to minimize errors due to sample preparation and 
instrumental variables, especially in univariate method in which the signal of the analyte was normalized out 
the signal of the internal standard. Moreover, the presence of silicon, which is a black powder allows a visually 
evaluation of the efficiency of the mixing of the samples.  
The mixing of the standard was performed via the geometric dilution method in a ceramic mortar.  
 
 
Table 2. Standard preparation with additional standard method 
 STD 0 STD 1 STD 2 STD 3 STD 4 STD 5 
TACHIFLUDEC 434.66 427.42 397.54 377.06 340.82 319.94 
FORM II 10.99 25.11 49.87 74.79 100.04 124.38 
SILICON 49.47 50.27 49.75 50.15 49.08 49.41 






3.2.5 Data analysis 
PANalytical X’Pert Pro X-Ray Diffractometer in reflection mode and Bragg-Brentano geometry with Cu source 
(λ = 1.5406) and XCelerator detector was used for the collection. Each standard mixture has been analyzed 
in three different aliquots. The mixtures were analyzed in the range 3-40°2θ collecting the whole pattern for 
the evaluation with the chemometric method. For the construction of the calibration curve via univariate method 
the mixtures were analysis with two different programs of analysis, one in the range 14-16°2θ for the collection 
of the signal of paracetamol form II and the latter in the range 55-57°2θ for the collection of the reflection of 
silicon. The program settings were summarized in Table 3. 
  
Table 3. Experimental settings  
EXPERIMENTAL SETTING 
Incident beam path 
Soller slit (rad) 0.04 
Divergence slit  ¼ 
Mask 15 
Antiscatter slit ½ 
Filter  None 
Diffracted beam path 
Soller slit 0.04 
Antiscatter slit 5.0 
Measurement Settings 
Full range  
Multivariate analysis 
Form II signal  
Univariate analysis  
Silicon signal  
Univariate analysis 
Generator settings 40 kV-40mA 40 kV-40mA 40 kV-40mA 
Scan Range (°2θ) 3-40 14.4-16 55-57 
Step size (°θ) 0.017 0.017 0.017 
Time per step (s) 20 300 300 
Spinner revolution time (rps) 1 1 1 
 
3.3 Data evaluation and results 
3.3.1 Univariate analysis  
Univariate analysis is based on the linear relationship between the signal y and the concentration of analyte x 
graphically displayed in a calibration curve.  
In this case the response value y was the ratio between the area of the paracetamol form II peak at 2θ = 15.0° 
and the area of the internal standard silicon at 2θ = 56.1°.  
The area was determined using the software PANalytical HighScore 4.8. The integration of peak at 15.0°2θ of 
paracetamol form II was evaluated in the range 14.6-15.2°2θ.  
The background and the peak position of paracetamol form II and silicon peaks were determined using the 
dedicated function of the software. The profile, width, and shape of the peaks were fitted using the Pseudo 





Table 4 Integration method 
 Analyte Internal standard 
Clip range 14.6-15.2°2θ - 
Background 
Bending = 2 
Granularity = 100 
No smoothed data 
Bending = 2 
Granularity = 100 
No smoothed data 
Search peak 
Minimum significance = 1 
Minimum tip width = 0,01 
Maximum tip width = 1 
Peak base width = 2 
Method = Minimum 2nd derivative 
Minimum significance = 5 
Minimum tip width = 0,01 
Maximum tip width = 1 
Peak base width = 2 
Method = Minimum 2nd derivative 
Fitting 
FWHM function = Individual FWHM 
Profile function = Pseudo Voigt 
Asymmetry type = Split width and shape 
No shape function 
FWHM function = Individual FWHM 
Profile function = Pseudo Voigt 
Asymmetry type = Split width and shape 
Shape function 
 
The ratio between obtained values of area of peak of paracetamol form II at 15.0°2θ and the peak of silicon at 
56.1°2θ was calculated and plotted versus the percentage of paracetamol form II in the mixture. Figure 11 
shows peak at 15.0°2θ of the standards.  
For each standard was calculated the average, standard deviation (SD) and the residual standard deviation 
(RSD%).  
The slope, intercept, coefficient of determination R2, deviation of the linear regression (Sy/x), and limit of 
detection (LOD) were calculated.  
 
 
Figure 11. XRPD comparison of signal of peak at 15°2θ of the standards: STD 0 (cyan line), STD 1 (magenta 
lines), STD 2 (black lines) STD 3 (red lines), STD 4 (green line), and STD 5 (blue line) 
 
Figure 12 and Table 5 report the results for the univariate analysis using the signal of peak at 15.0°2θ. The 
signal of peak at 15.0°2θ in the standard STD 0 (2% w/w Form II) was not detected, hence it was not used for 













Area Silicon Ratio Average Ratio SD RSD% 
STD 1 5% 
M01 27.89 634.04 0.04 
0.04 0.02 47% M02 21.18 957.65 0.02 
M03 51.85 838.72 0.06 
STD 2 10% 
M01 66.54 783.69 0.08 
0.09 0.01 6% M02 58.80 624.36 0.09 
M03 70.49 839.65 0.08 
STD 3 15% 
M01 78.68 1048.06 0.08 
0.08 0.02 24% M02 87.80 881.76 0.10 
M03 63.97 1035.63 0.06 
STD 4 20% 
M01 137.03 929.43 0.15 
0.16 0.01 6% M02 139.83 854.60 0.16 
M03 149.74 906.55 0.17 
STD 5 25% 
M01 192.99 900.08 0.21 
0.20 0.01 7% M02 192.63 1036.98 0.19 








Figure 12. Calibration curve via univariate analysis using peak at 15.0°2θ 
 
The calibration curve showed unsatisfactory coefficient of determination lower than the minimum acceptance 
value of 0.90. Additionally, the limit of detection, calculated with the formula below, was quite high 
approximately 9%, higher than the first point in the calibration curve (5%).  
 







STD 1 (5%) and 3 (15%) are the samples with high RSD %   clearly visible in the calibration curve in Figure 
12. Moreover, data and calibration curve revealed the inability of the regression to distinguish between the 
standard STD 2 (10%) and STD 3 (15%) probable because of underestimation of the signal of STD 3.  
 
The results evidenced that the peak at 15.0°2θ is not suitable for the quantification because of its low intensity. 
In fact, no signal was detected in the STD 0 (2%), and also STD 1 (5%) is below the value of the limit of 
detection of 9%. 
Additionally, some standard such as STD 3 (15%) showed highly variable results probable due to 
inhomogeneity of the mixture maybe due to partial conversion of form II. Although, energic mixing was avoided. 
In conclusion, it is not possible to quantify small quantities of Form II in tachifludec using the univariate method 
by XRPD.   
 
3.3.2 Standard addition method (SAM) 
In standard addition method it is not necessary to identify a specific peak of the analyte, therefore the highest 
peak of form II at 2θ= 24.0° was used for the univariate method, while for the multivariate method was based 
on the NAS approach.  
The STD 0 containing the 2% of form II was considered the unknow sample. Consequently, the other standards 
were considered as spiked with form II.  
 
3.3.2.1 Univariate analysis 
The calibration curve was constructed using as response value y the ratio between the area of the paracetamol 
form II peak at 24.0°2θ and the area of the internal standard silicon at 56.1°2θ.  
The area the silicon’s peak was determined as reported in right column of Table 4. While the area of the peak 
at 24.0°2θ of form II was determined using the software PANalytical HighScore 4.8 as reported Table 6.  
 
Table 6 Integration method of peak at 24.0°2θ of form II 
 Analyte 
Background 
Bending = 0 
Granularity = 100 
No smoothed data 
Search peak 
Minimum significance = 1 
Minimum tip width = 0,01 
Maximum tip width = 1 
Peak base width = 2 
Method = Minimum 2nd derivative 
Fitting 
FWHM function = Individual FWHM 
Profile function = Pseudo Voigt 
Asymmetry type = Split width and shape 
Shape function 
 
The ratio between area of peak of paracetamol form II at 24.0°2θ and of the peak of silicon at 56.1°2θ was 
calculated and plotted versus the percentage of paracetamol form II in the mixture.  
For each standard was calculated the average, standard deviation (SD) and the residual standard deviation 
(RSD%).  
The slope, intercept, coefficient of determination R2, and deviation of the linear regression (Sy/x) were 
calculated.  






Figure 13. XRPD comparison of signal of peak at 24°2θ of the standards: STD 0 (cyan line), STD 1 (magenta 
lines), STD 2 (black lines) STD 3 (red lines), STD 4 (green line), and STD 5 (blue line) 
 
Figure 14 and Table 7 report the results for the univariate analysis using the signal of peak at 24.0°2θ and the 
additional standard method. In this case the STD 0 considered with unknow sample and therefore added from 
II equal to 0% was considered in the construction of calibration curve.  
 
The results evidenced the high value of RSD% for all the standard mixtures, especially for STD 0 an STD 1. 
Compared to the RSD% obtained in the analysis based on peak at 15.0°2θ, the data of peak at 24.0°2θ showed 
highly variable results. Observing the average values of the ratio and the calibration curve in Figure 14 it is 
noticeable the underestimation of the STD 3 and the consequent inability of the regression to distinguish 
between the standard STD 2 (8%w/w form II) and STD 3 (13% w/w form II). This drastically affected quality of 
the regression and of coefficient of determination, which value was lower than the acceptance criterion of 0.90.  
The extrapolated concentration of the unknown sample STD 0 was calculated using the ratio between the 
intercept and slope of the calibration curve obtaining the value of 1.7%, but the deviation standard (Se) of this 













Area Silicon Ratio Average Ratio SD RSD% 
STD 0 0% 
M01 864.81 903.22 0.96 
1.00 0.40 40% M02 519.14 834.50 0.62 
M03 1132.26 799.50 1.42 
STD 1 3% 
M01 451.34 634.04 0.71 
1.37 0.59 43% M02 1485.62 957.65 1.55 
M03 1556.02 838.72 1.86 
STD 2 8% 
M01 2657.70 783.69 3.39 
3.48 0.55 16% M02 2535.08 624.36 4.06 
M03 2497.09 839.65 2.97 
STD 3 13% 
M01 3140.07 1048.06 3.00 
3.12 0.46 15% M02 3195.22 881.76 3.62 
M03 2824.70 1035.63 2.73 
STD 4 18% 
M01 5651.29 929.43 6.08 
6.04 0.82 14% M02 5843.11 854.60 6.84 
M03 4717.49 906.55 5.20 
STD 5 23% 
M01 9370.94 900.08 10.41 
8.54 1.70 20% M02 8411.51 1036.98 8.11 









Figure 14. Calibration curve of additional standard method via univariate analysis using peak at 24.0°2θ: six 
points 
Because the underestimation of the STD 3 significantly affects the regression, the calibration curve was re-
calculated excluding the STD 3.  The new calibration curve presents improved R2 and deviation Sy/x values 
(see Figure 15 and Table 8). The R2 reaches and exceed the value of 0.9, the extrapolated concentration (CE) 




Despite the good results of CE, the standard mixtures showed significant variability between the three aliquots 
evidenced by the high RSD% values, probably due to the inhomogeneity of the mixtures.  
Inhomogeneity of the standard mixtures extremely affect the quality of the regression and it is the main issue 
of the solid-state quantification.  
 










Figure 15. Calibration curve of additional standard method via univariate analysis using peak at 24.0°2θ: five 
points 
3.3.2.2 Multivariate analysis 
The addition standard method combined with the multivariate NAS technique allows the quantification of 
unknown sample bypassing the matrix effect using the signal of the pure analyte and using all the signals of 
the analyte instead of only one peak giving reliable results based on more data 
The NAS technique was applied to the standards of tachifludec and form II. The concentration of STD 0 
(2%w/w Form II) was extrapolated by the application of NAS technique using the statistical software R. The 
descriptive system based on five main components PC was chosen based on the values of R2 and RMSE.  
The value obtained for the coefficient of determination R2 indicates excellent fit of the linear NAS model to the 
data.  
The analysis with NAS technique reached excellent value of standard deviation of the extrapolated 
concentration compared to the high values obtained using the univariate analysis. Thus, the NAS results were 
more precise than the univariate method, however the CE is not accurate. Nevertheless, it is worth taking in 
mind that the matrix effect and the potential shift of the pattern, common in the XRPD technique, could have 
undermined the reliability of the data. The results in Table 9 and the curve in Figure 16 suggest that multivariate 
analysis overcomes the problem of the inhomogeneity of mixtures, especially of the STD3 mixture, observing 




















4 QUANTIFICATION METHODS OF CRYSTALLINE AND AMORPHOUS LACTOSE 
4.1 α-lactose polymorphism 
Lactose is a natural disaccharide derived from the condensation of galactose and glucose, which form by a β-
1,4 glycosidic bond. The α-lactose and β-lactose refer to the anomeric form of the glucopyranose ring which 
can be in either α-pyranose form or the β-pyranose form, whereas the galactose can only have the β-pyranose 
form. Lactose is extensively used as pharmaceutical excipients especially in tablet and inhalation dosing 
products. Lactose exists in five different forms, one amorphous form and four crystalline forms. The α-lactose 
monohydrate (LαH2O) is the commercially leading form and largely used as excipient. Additionally, α-lactose 
exists in two anhydrous forms which differ for the stability and hygroscopicity, stable form is labelled Lαs while 
unstable LαH. Whereas β-lactose is just known in one anhydrous form (Lβ). 30 
 
 
Figure 17. Chemical structure of lactose 
Several studies have been conducted on the stability of the lactose polymorphs because it can affect the 
quality of the pharmaceutical products, especially solubility and compressibility.  
The leading form α-lactose monohydrate is extremely stable and poorly hygroscopic, at 75% RH and 25°C it 
absorbs just <1%. 31 It is not deliquescent behaviour until 99% RH and it does not undergone to dehydration 
after 2 hours at 0% RH and 50°C. 32 Dehydration occurs at temperature higher than 140°C, giving a mixture 
of Lαs and LαH depending on the temperature. 33 Generally, the other forms of lactose tend to convert in more 
stable LαH2O. LαH is extremely hygroscopic, it absorb water and crystallize in LαH2O already at 10%RH, by 
heating in the range 120-170°C it converts in more stable anhydrous Lαs. 33,34 Whereas, compared to LαH, Lαs 
and Lβ irreversibly crystallize in LαH2O at higher relative humidity, about 64% and 77% respectively.34 
Amorphous is extremely hygroscopic, it starts to gain water at 30% RH until it crystallizes in LαH2O at 50-60% 
RH. DSC analysis reveals it crystallizes at about 174°C. 35,36 However, because it is widely used as excipient 
several studies on its stability and quantifications are reported. 36–41  
The crystal data of the polymorphs of lactose are reported in Table 10. 
 
Table 10. Crystal data of lactose forms 
 LαH2O Lαs LαH Lβ 
CSD Refcode LACTOS0142 EYOCUQ0143 EYOCUQ44 BLACTO0234 
Space Group P21 P1 P21 P21 
Unit Cell Monoclinic Triclinic Monoclinic Monoclinic 
a (Å) 7.815 7.6521(17) 7.7795(2) 4.9325(4) 
b (Å) 21.567 19.8637(5) 19.6931(6) 13.2700(11) 
c (Å) 4.844 4.98773(13) 4.90643(11) 10.7792(9) 
α 90° 92.0279(10)° 90° 90° 
β 106.2° 106.2610(7)° 103.6909(15)° 91.554(4)° 
γ 90° 97.1529(8)° 90° 90° 
Z (Z’) 2 2 2 2 




4.2 Experimental procedure 
4.2.1 Characterization of crystalline α-lactose monohydrate 
The crystalline α-lactose monohydrate was ground to tested to stability and to detect eventual transition of the 
form during the mixing of the standard samples. The starting materials were analysed by X-Ray diffraction with 
Bragg-Brentano geometry diffractometer PANalytical X’Pert PRO in the range 3-40°2θ with step size of 0.017° 
and time per step of 20 s.  
The crystalline α-lactose monohydrate was analyzed after grinding in agata mortar and in more stressful 
condition in grinder Retsch MM 200 for 10 minutes at 30 Hz. Figure 18 reports the comparison between the α-
lactose monohydrate before and after grinding, the XRPD patterns were superimposable indicating that α-
lactose monohydrate is stable to grinding process.  
Figure 19 shows the comparison of experimental XRPD pattern of α-lactose monohydrate (red line) and the 
calculated pattern LACTOS03 (black line). It is worth noting that the relative intensities the experimental pattern 
are not comparable the calculated pattern revealing the presence of preferred orientation phenomenon. In fact, 
the relative intensities of the experimental pattern are comparable to the ones of the calculated pattern 
considering the plane 011 preferred orientated (green line).  
 
 
Figure 18. XRPD pattern comparison between α-lactose monohydrate starting material (red line) and after 






Figure 19. XRPD pattern comparison between α-lactose monohydrate (red line), calculated pattern LACTOS03 
(black line), and the calculated pattern considering plane 011 orientated (green line) 
 
4.2.2 Synthesis and stability of amorphous lactose 
The amorphous lactose was produced by Spray drying. Solution 7 mg/L of monohydrate α-lactose in HPLC 
water was processed using Bϋchi Spray Dryer B-290 at following condition: inlet temperature 170°C, aspiration 
100%, Nitrogen flow 357 L/min. The solution inlet rate was 5 mL/min and the outlet temperature was 93°C. 
The obtained lactose was verified by X-Ray powder Diffraction. Amorphous lactose is extremely unstable 
because it is highly hygroscopic. It tends to absorb water and to convert in monohydrate α-lactose. Therefore, 
amorphous lactose was placed in P2O5 to avoid its crystallization in the monohydrate form.  
The stability of amorphous lactose was evaluated after manually grinding in agata mortar, the results are 
reported in Figure 20 and revealed the stability of amorphous lactose to grinding.  
 
 
Figure 20. XRPD pattern comparison between amorphous lactose starting material (blue line) and after grinding 





4.2.3 Standard preparation 
The starting sample, labelled STD 0 was prepared as a binary mixture of amorphous and crystalline lactose in 
percentage of 10% w/w.  
The bulk STD 0 was spiked with increasing percentage of crystalline α-lactose monohydrate. Additionally, 
silicon powder was introduced as internal standard in the mixtures in amount equal to 10% of the total weight. 
α-lactose monohydrate and silicon were purchase by Sigma-Aldrich (Saint Louis, MO, USA). 
The presence of silicon minimizes errors due to sample preparation and instrumental variables. Moreover, 
given its black colour, it allows the evaluation of the mixing efficiency of the components to obtain the maximum 
homogeneity of the mixtures. Table 11 reports the preparation of the standard mixtures.  
 
Table 11. Standard mixture preparation of amorphous and crystalline α-lactose 
 STD 0 STD 1 STD 2 STD 3 STD 4 
BULK (MG) 300.32 282.49 267.28 239.80 224.95 
ADDED CRY LACTOSE (MG) 0.00 15.77 29.57 60.96 75.57 
SILICON (MG) 30.73 30.37 30.96 30.26 30.20 
ADDED CRY LACTOSE (%) 0% 5% 10% 20% 25% 
 
Effective mixing was achieved through the method of geometric dilutions performed by mildly mixing the 
components in a ceramic mortar with gradual additions. This step is extremely sensitive because the mutual 
presence of crystalline and amorphous α-lactose can promote the crystallization of the amorphous triggered 
by the seeding of crystalline part. Furthermore, to avoid the transition of the amorphous phase the preparation 
of the standard was performed in humidity condition below to 40%RH to avoid the absorption of water. 
Transition of amorphous was observed in previously prepared standard set in which the amorphous lactose 
converted in monohydrate α-lactose probably promoted by excessively energetic mixing and not controlled 
ambient condition. The transition of amorphous in crystalline form was evidenced by the not gradual intensity 
of the peaks but the intensity was visually comparable between the mixtures (Figure 21).  
 
 





4.2.4 Data analysis 
Each standard was analysed in three different aliquots (labelled M01, M02, M03) by XRPD in the range 3-
40°2θ with step size equal to 0.02°, a time per step of 100 s, and generator settings of 40 kV and 40 mA.  
The XRPD diffraction patterns of crystalline form constituted of well-defined peaks, while amorphous does not 
show the phenomenon of diffraction and its pattern results in the diffusion measurements as hump. The 
quantification of the amorphous content was carried out indirectly, determining the percentage of crystalline. 
The specificity for the lactose’s peaks was not evaluated because no crystalline interferents were presented 
in the mixture except for silicon that showed the first peak at 28.4°2θ.  
The internal standard must be evaluated in a range where the analyte has not signal. For this reason, the 
standard’s aliquots were also analysed in the range 55-57°2θ to collect the peak at 56.1°2θ of silicon. Table 
12 summarized the experimental setting used for the collection of analyte and internal standard signal.  
 
Table 12. Experimental settings  
EXPERIMENTAL SETTING 
Incident beam path 
Soller slit (rad) 0.04 
Divergence slit  ¼ 
Mask 15 
Antiscatter slit ½ 
Filter  None 
Diffracted beam path 
Soller slit 0.04 
Antiscatter slit 5.0 
Measurement Settings Analyte signal Internal standardsignal  
Generator settings 40 kV-40mA 40 kV-40mA 
Scan Range (°2θ) 3-40 55-57 
Step size (°θ) 0.017 0.017 
Time per step (s) 100 100 






4.3 Data evaluation and results 
4.3.1 Univariate analysis 
For the univariate linear model, instead of unique peak the area of five peaks at approx. 12.5, 19.1, 19.6, 20.0, 
and 21.3°2θ of α-lactose monohydrate were used for the construction of the calibration curves. Figure 22 
shows the XRPD pattern of the aliquot M01 of the standard mixtures and the peaks chosen for the calibration 
were highlighted in yellow.  
 
 
Figure 22. XRPD pattern of standard mixtures with peaks using for the construction of calibration curves 
highlighted in yellow 
Table 13 Integration method 
 Analyte Internal standard 
Strip Kα2 - Ratio 0.5 
Background 
Bending = 2 
Granularity = 13 
No smoothed data 
Bending = 0 
Granularity = 92 
Smoothed data 
Search peak 
Minimum significance = 1 
Minimum tip width = 0,01 
Maximum tip width = 1 
Peak base width = 2 
Method = Minimum 2nd derivative 
Minimum significance = 5 
Minimum tip width = 0,01 
Maximum tip width = 1 
Peak base width = 2 
Method = Minimum 2nd derivative 
Fitting 
FWHM function = Individual FWHM 
Profile function = Pseudo Voigt 
Asymmetry type = Split width and shape 
Shape function 
FWHM function = Individual FWHM 
Profile function = Pseudo Voigt 
Asymmetry type = Split width and shape 
No shape function 
 
The α-lactose monohydrate peaks’ area and the area of the silicon’s peak at 56.1°2θ were determined using 
the HighScore 4.8 software as summarized in Table 13.  
For each peak two different calibration curves were plotted One considering as response the area of the α-
lactose monohydrate ( Table 14), while in the latter the response was constituted by the ratio between the area 
of α-lactose monohydrate’s peak and area of silicon 
 
The calibration curves based only on the peak shows unsatisfactory value of R2 for the peaks at 19.1 and 20.0° 




higher than acceptance criterion of 0.9, especially the calibration with 12.5°2θ peak. Furthermore, it showed 
excellent value of Sy/x. It is worth mentioning that the Sy/x value is related to the value of the response of the 
calibration. CE values were excellent, especially for the calibration based on 12.5°2θ peak (real value 10%). In 
conclusion, the calibration based on 12.5°2θ peak showed the best results in term of R2, Sy/x, CE and related 
SE. 
 
Table 14. Data of calibration curves from area [cts] of α-lactose monohydrate’s peaks 
STANDARD % w/w cry 
Area [cts] 
at 12.5°2Θ 
Area [cts]  
at 19.1°2Θ 
Area [cts]  
at 19.6°2Θ 
Area [cts]  
at 20.0°2Θ 
Area [cts]  
at 21.3°2Θ 
STD 0 M01 0% 255.20 525.33 664.79 2119.22 447.08 
STD 0 M02 0% 260.67 884.51 693.26 2099.61 375.39 
STD 0 M03 0% 326.51 558.01 641.42 2013.99 394.02 
STD 1 M01 5% 403.87 579.89 847.51 2519.34 521.50 
STD 1 M02 5% 355.81 701.06 834.95 2709.98 489.56 
STD 1 M03 5% 431.04 845.18 744.85 2714.31 519.56 
STD 2 M01 10% 500.72 1130.06 1136.17 3900.12 822.26 
STD 2 M02 10% 484.75 1065.52 1221.74 3680.85 838.87 
STD 2 M03 10% 500.13 1017.32 954.06 4043.26 704.11 
STD 3 M01 20% 747.68 2595.72 1683.37 7850.63 1220.81 
STD 3 M02 20% 840.71 1671.28 1628.36 6291.94 1262.82 
STD 3 M03 20% 783.60 1357.69 1544.76 4480.49 1091.87 
STD 4 M01 25% 946.76 1976.69 1803.84 5984.15 1163.97 
STD 4 M02 25% 915.00 1812.35 1599.90 5627.67 1197.73 
STD 4 M03 25% 946.36 2281.49 1870.03 6821.83 1160.17 
R2 0.9828 0.7984 0.9582 0.8387 0.9368 
SLOPE 26.41 61.23 46.36 182.15 34.38 
INTERCEPT 263.02 532.00 634.97 2004.69 401.46 
SY/X 3.48E+01 3.07E+02 9.65E+01 7.96E+02 8.90E+01 
CE 10% 9% 14% 11% 12% 
SE 8.76E-01 3.16E+00 1.58E+00 3.02E+00 1.83E+00 
 
The calibration curves constructed based on the ratio between the area of α-lactose and silicon are 
summarized in Table 15 The regression obtained with peak at 19.1 and 20.0° showed unsatisfactory value of 
R2. While the R2 of calibration with peaks 12.5, 19.6 and 21.3°2θ has good values of R2, higher than 
acceptance criterion of 0.9.  
 
The calibration based on 19.6°2θ peak showed the best results in term of CE and related SE and good results 
of R2 and Sy/x. 
 
For each peak, the difference between the calibration curves based on area of peaks of α-lactose monohydrate 
(orange) and on ratio between α-lactose monohydrate and silicon signal (blue) as response are graphically 
displayed in Figure 23.  
Both calibration curves, area and ratio, constructed based on peaks 12.5 and 19.6°2θ showed comparable 
trend. It is worth noting that aliquots of STD 3 (20% w/w crystalline) showed high variability in both area and 
ratio calibration curve of peaks at 19.1 and 20.0°2θ. Although, the variability decreased using the ratio of α-
lactose monohydrate area and silicon area as response. The RSD% of the three aliquots of STD 3 improved 
from 34% to 23% for peak 19.1°2θ respectively in area and ratio curves, and from 27% to 15% for the curves 





The curves based on the peak at 2θ = 21.3° showed comparable area and ratio values for STD 3 and STD 4, 
respectively 20 and 25%w/w crystalline. Hence, these curves cannot accurately discriminate between standard 
at 20 and 25%w/w crystalline.  
The high variability of the peak’s area in the standards and the similar values of STD 3 and 4 affected the 
linear correlation of curves constructed in particular the curves based on peaks at 19.1, 20.0 and 21.3°2θ of 
α-lactose monohydrate. Contrary, the signal of peaks at 12.5 and 19.6°2θ of α-lactose monohydrate reached 
good value of R2 and extrapolated concentration.  
Nevertheless, it worth pointing out that the RSD% of standards were better for the area curves compared to 
the ratio curves of peaks 12.5 and 19.6°2θ (Table 16). The normalization with internal or external standard in 
X-Ray diffraction quantitative analysis is appropriate to adjust the signal change over time due to the lamp 
decay. Additionally, the presence of internal standard is beneficial to minimize errors due to sample 
preparation. In our case the normalization with silicon, did not improve the situation, and the calibration curves 
based on peak 12.5, 19.6 and 21.3°2θ, showed a better linearity without normalization. 
Generally, the comparison between the deviation standard of the regression through Test F demonstrated that 
the method without normalization with silicon is more precise. The test was conducted computing the back 
calculating of the standard to compare the entity of the deviation standard.  
In this case, it would be more favourable the use of daily single measure of external standard, e.g., silicon or 
alumina.  
It is worth noting that the peaks at 19.1° and 20.0° are those which are more affected by the preferential 
orientation and this could explain the great variability on the peak area 
 
Table 15. Data of calibration curves from ratio between area of α-lactose monohydrate and silicon 
STANDARD % w/w cry 
Area [cts] 
of silicon at 
Ratio area lactose/silicon at 
56.1°2θ 12.5°2θ 19.1°2θ 19.6°2θ 20°2θ 21.3°2θ 
STD 0 M01 0% 1148.47 0.22 0.46 0.58 1.85 0.39 
STD 0 M02 0% 1135.94 0.23 0.78 0.61 1.85 0.33 
STD 0 M03 0% 1146.58 0.28 0.49 0.56 1.76 0.34 
STD 1 M01 5% 813.92 0.50 0.71 1.04 3.10 0.64 
STD 1 M02 5% 1032.32 0.34 0.68 0.81 2.63 0.47 
STD 1 M03 5% 927.23 0.46 0.91 0.80 2.93 0.56 
STD 2 M01 10% 1247.80 0.40 0.91 0.91 3.13 0.66 
STD 2 M02 10% 936.64 0.52 1.14 1.30 3.93 0.90 
STD 2 M03 10% 976.75 0.51 1.04 0.98 4.14 0.72 
STD 3 M01 20% 983.38 0.76 2.64 1.71 7.98 1.24 
STD 3 M02 20% 893.18 0.94 1.87 1.82 7.04 1.41 
STD 3 M03 20% 766.85 1.02 1.77 2.01 5.84 1.42 
STD 4 M01 25% 999.19 0.95 1.98 1.81 5.99 1.16 
STD 4 M02 25% 851.77 1.07 2.13 1.88 6.61 1.41 
STD 4 M03 25% 828.77 1.14 2.75 2.26 8.23 1.40 
R2 0.9283 0.8653 0.9245 0.8908 0.9206 
SLOPE 0.03 0.07 0.06 0.22 0.04 
INTERCEPT 0.23 0.45 0.57 1.77 0.36 
SY/X 9.03E-02 2.94E-01 1.67E-01 7.83E-01 1.25E-01 
CE 7% 6% 10% 8% 8% 





Figure 23. Comparison of the calibration curves obtained with area of peaks of α-lactose monohydrate (orange) 
and with ratio between α-lactose monohydrate and silicon (blue) as response 
 
Table 16. Comparison between RSD% of standards for area and ratio curves obtained with peaks 12.5°2θ and 
19.6°2θ 
Peak Curve STD 0 STD 1 STD 2 STD 3 STD 4 
12.5°2θ 
Area 14% 10% 2% 6% 2% 
Ratio 14% 18% 14% 15% 9% 
19.6°2θ 
Area 4% 7% 12% 4% 8% 






4.3.2 Multivariate analysis 
The addition standard method combined with the multivariate NAS technique allows the quantification of 
content of crystalline α-lactose monohydrate in the bulk based on all the diffractometric data and not only 
relying on the signal of individual peak.  
The NAS technique was applied to determine the concentration of STD 0 (10%w/w crystalline α-lactose) 
extrapolated using the statistical software R. The descriptive system based on nine main components PC was 
chosen based on the R2 and RMSE values.  
 
The results of the analysis are shown in Figure 24 and Table 17. The value obtained for the coefficient of 
determination R2 indicates a very good fit of the linear NAS model to the data. The extrapolated concentration 
value of 12% is very close to that introduced in the preparation of the initial bulk equal to 10%. Additionally, 
the deviation of extrapolated concentration SE is remarkable low, the method is extremely accurate and 
precise. 
 
Both univariate and multivariate analysis gave back satisfactory value of concentration of bulk sample, but the 
multivariate analysis showed excellent R2value and especially highly better SE value compared to univariate 
analysis. The possibility to average the analyte signal on the whole pattern allowed to minimize the variability 
and error due to the preferred orientation. 
 
Figure 24. Amorphous-crystalline α-lactose curve of additional standard method via NAS technique 












5 QUANTIFICATION METHOD OF CRYSTALLINE LACTOSE AND HPMC 
Generally, amorphous phase is unstable form and in presence of crystalline form, the crystallization can be 
easily trigged. That is way is fundamental that the amorphous is stable during all the processes of standard 
preparation, mixing, and analysis, to guarantee a correct quantification.  
Indeed, a set of standards containing crystalline and amorphous α-lactose monohydrate showed transition of 
the amorphous phase probably occurred during the standard preparation and observable from the similar 
intensity of the peaks of theoretically different crystalline concentration standards.  
To overcome the crystallization of the amorphous, the quantification of crystallinity of α-lactose was carried out 
in standard which contains stable amorphous component to prevent errors in quantification.  Hydroxypropyl 
methyl cellulose (HPMC) was used as amorphous surrogate. HPMC is a semi-synthetic, inert, and viscoelastic 
polymer used as excipient in several commercial products. The choice of this polymer was motivated by 
analogous characteristics to real amorphous particularly its MAC (Mass Absorption Coefficient) of 6.49, very 
similar to those of α-lactose (7.46). The MAC coefficient is related to the intensity transmitted by a material 
when interacting with X-rays, its density, and its thickness. Nevertheless, XRPD pattern of HPMC and 
amorphous α-lactose looked slightly different, especially at low angles (Figure 25).  
 
 
Figure 25. XRPD pattern comparison between HPMC (red line) and amorphous α-lactose (blue line) 
 
5.1 Experimental procedure 
5.1.1 Standard preparation  
The preparation of the mixtures containing HPMC was carried out using the same procedure for amorphous 
α-lactose mixtures.  
A bulk, labelled STD 0, constitutes the binary mixture of HPMC and crystalline α-lactose in percentage of 10% 
w/w then the samplewas spiked with increasing percentage of crystalline α-lactose monohydrate. HPMC was 
provided by Acros Organics (Geel, Belgium). 
Furthermore, silicon powder was introduced as internal standard in the mixtures in amount equal to 10% of 
the total weight. Table 18 reports the preparation of the standard mixtures.  






Table 18. Standard mixture preparation of amorphous and crystalline α-lactose 
 STD 0 STD 1 STD 2 STD 3 STD 4 
BULK (MG) 399.50 380.10 359.75 319.49 299.39 
ADDED CRY LACTOSE (MG) 0.00 20.25 40.4 80.73 100.71 
SILICON (MG) 39.84 40.06 40.03 40.00 40.00 
ADDED CRY LACTOSE (%) 0% 5% 10% 20% 25% 
 
5.1.2 Data analysis 
The analysis of the standard mixtures containing HPMC was carried out using the same procedure for 
amorphous α-lactose mixtures.  
Each standard was analysed in three aliquots by XRPD in the range 3-40°2θ with step size equal to 0.02°, a 
time per step of 100 s, and generator settings of 40 kV and 40 mA.  
Table 12 summarized the experimental setting used for the collection of analyte and internal standard signal.  
 
Table 19. Experimental settings  
EXPERIMENTAL SETTING 
Incident beam path 
Soller slit (rad) 0.04 
Divergence slit  ¼ 
Mask 15 
Antiscatter slit ½ 
Filter  None 
Diffracted beam path 
Soller slit 0.04 
Antiscatter slit 5.0 
Measurement Settings Analyte signal Internal standard signal  
Generator settings 40 kV-40mA 40 kV-40mA 
Scan Range (°2θ) 3-40 55-57 
Step size (°θ) 0.017 0.017 
Time per step (s) 100 100 






5.2 Data evaluation and results 
5.2.1 Univariate analysis 
The area of peaks at approx. 12.5, 19.1, 19.6, 20.0, and 21.3°2θ of α-lactose monohydrate were used for the 
construction of the calibration curves in the univariate model 
 
Table 20 Integration method 
 Analyte Internal standard 
Strip Kα2 - Ratio 0.4 
Background 
Bending = 2 
Granularity = 10 
No smoothed data 
Bending = 0 
Granularity = 92 
Smoothed data 
Search peak 
Minimum significance = 1 
Minimum tip width = 0,01 
Maximum tip width = 1 
Peak base width = 2 
Method = Minimum 2nd derivative 
Minimum significance = 10 
Minimum tip width = 0,01 
Maximum tip width = 1 
Peak base width = 2 
Method = Minimum 2nd derivative 
Fitting 
FWHM function = Individual FWHM 
Profile function = Pseudo Voigt 
Asymmetry type = Split width and shape 
No shape function 
FWHM function = Individual FWHM 
Profile function = Pseudo Voigt 
Asymmetry type = Split width and shape 
No shape function 
 
The α-lactose monohydrate peaks’ area and the area of the silicon’s peak at 56.1°2θ were determined using 
the HighScore 4.8 software as summarized in Table 20.  
For each peak two different calibration curves were plotted. One considering as response the area of the α-
lactose monohydrate (Table 21) while in the latter the response was constituted by the ratio between the area 
of α-lactose monohydrate’s peak and area of silicon( Table 22)  
 
The results in Table 21 show that all the regression showed satisfactory value of R2, higher than acceptance 
criterion of 0.9, except the regression obtained with the area of the peak at 19.1°2θ. CE values were generally 
excellent (real value 10%). The best SE, R2, and Sy/x was observed for the calibration curve based on peak 






Table 21. Data of calibration curves from area [cts] of α-lactose monohydrate’s peaks 











STD 0 M01 0% 289.19 453.46 444.13 1836.53 503.59 
STD 0 M02 0% 238.56 574.69 485.39 1598.84 555.77 
STD 0 M03 0% 247.17 409.56 692.18 1477.26 430.66 
STD 1 M01 5% 468.57 804.89 941.25 2551.66 609.20 
STD 1 M02 5% 396.39 672.26 788.66 3126.11 606.18 
STD 1 M03 5% 473.69 646.27 689.08 2280.25 597.36 
STD 2 M01 10% 563.98 838.02 847.39 3703.76 721.38 
STD 2 M02 10% 493.82 909.85 970.85 3562.44 780.81 
STD 2 M03 10% 500.92 1084.89 977.69 4831.52 809.24 
STD 3 M01 20% 870.54 1106.24 1456.88 5627.89 1155.80 
STD 3 M02 20% 1024.13 1493.13 1593.58 6274.77 1110.47 
STD 3 M03 20% 801.31 1734.08 1697.08 5564.81 1216.75 
STD 4 M01 25% 916.71 1551.47 1531.62 6996.14 1374.12 
STD 4 M02 25% 987.86 1581.65 2067.81 6509.41 1478.26 
STD 4 M03 25% 996.01 1950.59 1731.03 6720.61 1367.56 
R2 0.9513 0.8947 0.9185 0.9622 0.9738 
SLOPE 29.06 48.82 50.61 204.52 36.85 
INTERCEPT 269.19 468.27 520.28 1723.26 445.66 
SY/X 6.55E+01 1.67E+02 1.50E+02 4.04E+02 6.02E+01 
CE 9% 10% 10% 8% 12% 
SE 1.45E+00 2.24E+00 1.99E+00 1.23E+00 1.17E+00 
 
 
Table 22 reports the results related to the calibration curves constructed based on the ratio between the area 
of α-lactose and silicon. Again, the regression obtained with peak at 19.1 showed unsatisfactory value of R2. 
While the R2 of the calibration with the other peaks showed good values higher than acceptance criterion of 
0.9. Nevertheless, they were worse than the values in Table 21, also in term of Sy/x values.  
Also, the obtained CE were less accurate as highlighted by the higher the SE values.   
 
, In Figure 26 the difference between the calibration curves based on area of peaks of α-lactose monohydrate 
(red) and on ratio between α-lactose monohydrate and silicon signal (green) as response are graphically 
displayed. 
Both calibration curves, area and ratio, constructed based on peaks 12.5 and 21.3°2θ showed comparable 
trend.  
It is worth noting that all the curves showed comparable response (y value) for STD 3 and STD 4, respectively 
20 and 25%w/w crystalline. Hence, accurate discrimination between standard at 20 and 25%w/w crystalline 
was not possible, except for both calibration curves of peak 21.3°2θ.  
Even for the α-lactose-HPMC quantification, the results obtained using the ratio between area of α-lactose and 
silicon were lesser satisfactory, as well as for the quantification amorphous-crystalline α-lactose. Test F carried 
out on the deviation standard of the back-calculated regressions revealed all the regression based on the area 
were more precise than the regression with normalization with silicon.  
Concerning the response of the different peaks in the two type of quantification, the calibration curve based 
on the peak at 19.1°2θ gave the worst results in both the quantifications while the peak at 12.5°2θ had good 
correlation and results in both the calibration. In the quantification HPMC-crystalline α-lactose the best results 
were obtained using the peak at 21.3°2θ.  
Generally, the determination of crystallinity degree of α-lactose monohydrate using HPMC as amorphous was 





Table 22. Data of calibration curves from ratio between area of α-lactose monohydrate and silicon 
STANDARD % w/w cry 
Area [cts] 
of silicon at 
Ratio area lactose/silicon at 
56.1°2θ 12.5°2θ 19.1°2θ 19.6°2θ 20°2θ 21.3°2θ 
STD 0 M01 0% 1120.54 0.26 0.40 0.40 1.64 0.45 
STD 0 M02 0% 1314.16 0.18 0.44 0.37 1.22 0.42 
STD 0 M03 0% 1052.14 0.23 0.39 0.66 1.40 0.41 
STD 1 M01 5% 1189.08 0.39 0.68 0.79 2.15 0.51 
STD 1 M02 5% 1092.16 0.36 0.62 0.72 2.86 0.56 
STD 1 M03 5% 1218.79 0.39 0.53 0.57 1.87 0.49 
STD 2 M01 10% 1178.77 0.48 0.71 0.72 3.14 0.61 
STD 2 M02 10% 1320.23 0.37 0.69 0.74 2.70 0.59 
STD 2 M03 10% 1303.55 0.38 0.83 0.75 3.71 0.62 
STD 3 M01 20% 1109.61 0.78 1.00 1.31 5.07 1.04 
STD 3 M02 20% 1141.72 0.90 1.31 1.40 5.50 0.97 
STD 3 M03 20% 1056.42 0.76 1.64 1.61 5.27 1.15 
STD 4 M01 25% 1031.61 0.89 1.50 1.48 6.78 1.33 
STD 4 M02 25% 1249.95 0.79 1.27 1.65 5.21 1.18 
STD 4 M03 25% 1255.37 0.79 1.55 1.38 5.35 1.09 
R2 0.9273 0.8854 0.9012 0.9341 0.9406 
SLOPE 0.03 0.04 0.04 0.18 0.03 
INTERCEPT 0.22 0.38 0.44 1.42 0.37 
SY/X 7.15E-02 1.55E-01 1.46E-01 4.79E-01 8.20E-02 
CE 9% 9% 10% 8% 11% 







Figure 26. Comparison of the calibration curves obtained with area of peaks of α-lactose monohydrate (red) and 
with ratio between α-lactose monohydrate and silicon (green) as response 
 
To evaluate the possible use of HPMC for the construction of calibration curve in case of unstable amorphous, 
the calibration curve based on the integrated area of the peak at 21.3° was used to quantify the crystalline 
phase of STD3 (20%) made of α-lactose crystalline and amorphous. The interpolated values are reported in 
Table 23. Satisfactory results were obtained with an average of recovery nearby the 100% and RSD% of the 
three aliquots less than 20%.  
 
Table 23. Interpolation of STD 3 (20%) 











5.2.2 Multivariate analysis 
The addition standard method combined with the multivariate NAS technique was evaluated for the 
quantification of content of crystalline α-lactose monohydrate in the binary mixtures containing α-lactose 
monohydrate and HPMC.  
The NAS technique was applied to determine the concentration of STD 0 (10%w/w crystalline α-lactose) 
extrapolated using the statistical software R. The descriptive system based on nine main components PC was 
chosen based on the R2 and RMSE values.  
 
The results of the analysis are shown in Figure 27 and Table 24. The value obtained for the coefficient of 
determination R2 indicates a very good fit of the linear NAS model to the data. The extrapolated concentration 
value of 9% is very close to that introduced in the preparation of the initial bulk equal to 10%. Additionally, the 
deviation of extrapolated concentration SE is remarkable low, the method is extremely accurate and precise. 
 
Both univariate and multivariate analysis gave back satisfactory value of concentration of bulk sample. 
Nevertheless, multivariate analysis showed excellent R2 value and especially highly better SE value compared 
to univariate analysis for both system amorphous-crystalline α-lactose and HPMC-crystalline α-lactose. The 
analyses carried out using both the real amorphous and the surrogate one (HPMC) showed a substantial 
agreement in the results, particularly by multivariate method. 
 
 
Figure 27. HPMC-crystalline α-lactose curve of additional standard method via NAS technique 
 












6 CONCLUSION  
The work aimed to evaluate the potential application of the standard addition method (SAM) in solid-state 
quantification in two different cases, formulation, and amorphous-crystalline samples. Additionally, the 
comparison between univariate and multivariate statistical methods was carried out.  
In case of analysis of paracetamol form II in tachifludec formulation, the selection of suitably intense specific 
peak of paracetamol form II was difficult. In fact, the only specific peak, which does not overlap the peaks of 
the matrix was not enough intense to obtain a satisfactory calibration curve. Hence, the SAM method was 
applied with univariate analysis based on the most intense peak at 24.0°2θ of paracetamol form II, which gave 
accurate quantification, but with a high standard deviation. 
. The multivariate analysis gave better results than the univariate analysis, especially in term of R2 and deviation 
standard of the extrapolated concentration. Probably, the multivariate analysis based on whole pattern can 
overcome the problem of the variability of the aliquots of the same standard mixtures, that affect the solid-state 
analysis, especially the univariate analysis based exclusively on one peak.  
The determination of the crystalline fraction in the amorphous-crystalline samples was quite challenging. α -
lactose monohydrate is affected by preferential orientation and in the mixtures the relative intensities are not 
preserved which decrease the precision and accuracy of the quantification.   
Even in the case of amorphous-crystalline quantification the multivariate analysis evidenced the best results.  
Concerning the comparison between real amorphous and HPMC standard sets, slightly different results were 
observed for the five α-lactose monohydrate peaks tested. Although, for both the standard set the calibration 
curves based on peaks 12.5 and 21.3°2θ showed satisfactory results with R2 values within the acceptance 
criterion of 0.9. It was possible to quantify the crystalline in STD3 of the sample containing amorphous lactose 
and 20% of α-lactose monohydrate on the curve of 21.3°2θ peak constructed with HPMC. The obtained back-
loading and recovery % are accurate. Hence, the HPMC may be used as surrogate amorphous in construction 
of calibration curve in case of unstable real amorphous.  
Surprisingly, both the curves with real amorphous and HPMC showed worst results normalizing the area of 
the α-lactose monohydrate with the internal standard silicon. Increase in deviation standard and decrease of 
the R2 was observed with the application of internal standard. Nevertheless, the use of internal standard is 
useful in X-Ray Powder Diffraction because of the decay of the lamp. The results of samples analysed with 
calibration curve constructed with normalization are more trustworthy than calibration without normalization 
because the changes in intensity due to the decay of the lamp over time are considered. Therefore, the minor 
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DIRECT DERIVATION OF THE CRYSTALLINE FRACTION OF HIGHLY POTENT 
ACTIVE PHARMACEUTICAL INGREDIENTS BY X-RAY POWDER DIFFRACTION 
 
1 INTRODUCTION 
Solid drugs are commonly delivered in crystalline forms, including polymorphs, solvates, salts, and cocrystals. 
However, amorphous forms are attracting considerable interest because of their superior physicochemical and 
absorption properties. 1,2 The main disadvantage associated with the amorphous form is its tendency to convert 
into crystalline form because of environmental conditions such as humidity, temperature, or presence of 
impurities. 3–7 
Determining the crystalline fraction in drugs and formulations is extremely important to pharmaceutical 
companies because the behavior of an active pharmaceutical ingredient is affected by its form (amorphous or 
crystalline). 8–10 The quantification of crystalline and amorphous content is an important and difficult task that 
has been tackled using various techniques. 11–13 The Unites States Pharmacopeia (USP) reports a method for 
estimating the amorphous and crystalline fractions of a compound via X-ray powder diffraction (XRPD) in 
chapter <941>; this is the main method for qualitative and quantitative analyses in case of phase 
investigation.14 
The difficulties associated with the usage of XRPD for amorphous quantification can be attributed to 
the different response of crystalline and amorphous compounds observed in the diffractogram. The crystalline 
solids can diffract the X-ray beam and generate sharp peaks, whereas the amorphous solids can only scatter 
the X-ray beam, generating a broad halo in the diffractogram. Thus, the amorphous part is mainly detected 
from the XRPD pattern via an indirect method. Madsen et al. comprehensively surveyed methods for 
quantifying amorphous materials via XRPD. They identified the following three main approaches: 1) single-
peak intensity analysis, 2) whole-powder-pattern fitting (WPPF), and 3) crystallinity degree estimation. 15 The 
single-peak intensity analysis method is extensively used because it can be easily performed and requires no 
particular knowledge of crystallography. This method requires the construction of a calibration curve based on 
the intensity of a peak or group of peaks, but it can be easily subject to systematic alteration due to, for 
example, the presence of preferential orientation phenomenon. 16,17 This method is frequently used with an 
internal or external standard or normalization to eliminate the sample variation and X-ray tube fluctuations. 18 
The whole-powder-pattern fitting method includes the crystal modeling method (Rietveld modeling) 
and the pattern summation method. Rietveld modeling is an indirect approach based on which the absolute 
concentration of the crystalline phases can be determined using an internal standard and the amorphous 
content can be estimated on the basis of the difference between the total and crystalline contents. 19 However, 
Rietveld modeling requires the crystal structure parameters of all the crystalline phases so it will be useless 
when the crystal structure of an individual phase will be partially or completely unknown (which is frequently 
observed). An alternative solution called PONKCS (denoting “partial or no crystal structures”) provides an 
empirical derivation of the structural information of ZMV (where ZM represents the mass of the contents of the 
unit cell and V is the unit-cell volume) based on a mixture of phases and a known standard. 20 
The pattern summation method is a direct approach based on which the concentration of the 
amorphous phase can be estimated from its contribution to the pattern. 15 The degree of crystallinity method 
reported in USP <941> is based on the ratio of the crystalline intensity to the sum of the crystalline and 
amorphous intensities minus the constant background. 21,22 However, this method is limited to compounds with 
the same elemental composition and does not consider the microabsorption problem. Recently, a more 
sophisticated degree of crystallinity method was developed by Toraya. 23 This new quantification technique, 
called direct derivation (DD), relies on whole pattern fitting and uses a simple intensity–composition (IC) 






Where 𝑎𝑘 is the total scattering intensity per chemical formula weight and 𝑆𝑘 is the sum of the observed powder 
diffraction intensities of each component. For the calculation of 𝑎𝑘 and 𝑆𝑘 and to obtain the weight fraction using 
the IC equation only the chemical formulas of all the phases in the mixture of known components are required 
as external input. 23 Similar to the degree of crystallinity method and Rietveld modeling, the DD method is a 
single-measurement technique; however, it does not require spiking with an internal standard or the crystal 
structure parameters as Rietveld method. Moreover, it is applicable to multicomponent mixtures because it 
accounts for mass absorption. Toraya and Omote successfully applied the DD method to the quantitative 
phase analysis of the mixtures containing an amorphous phase claiming that the total scattering power per 
molecular formula weight (𝑎𝑘), which depends on the chemical formula and not on the crystallinity, plays a 
fundamental role with respect to the IC equation.24 They applied WPPF to the diffraction patterns of the 
mixtures containing amorphous phase and directly fitted the amorphous halo extracted from the experimental 
pattern along the crystalline phase model. Toraya and Omote indicated the importance of determining the 
background of an amorphous component because it was difficult to identify the edge between the background 
and amorphous halo. 24 
This study evaluates the DD method with respect to the quantification of the crystallinity degree of 
crystalline–amorphous mixtures of organic compounds, wherein the crystalline part does not exceed 20%. The 
considered scenarios are observed in real cases. The active pharmaceutical ingredient (API) is a 
nonstoichiometric hydrated, highly potent compound dispensed in batches of 20 mg. The crystal structure of 
the API is known, and it refers to the highest degree of water molecule. The crystalline part of the formulation 
shows a different degree of hydration respect to the known structure, as a result, the position of the peaks in 
the powder diffractogram do not perfectly match the calculated values. 25  
In case of highly potent API, it must be handled and analyzed under safe conditions within a suitable 
containment system, hence, prior to the XRPD measurements, highly potent APIs are commonly covered with 
Kapton® film on the top of the sample holder. Although the Kapton® film is amorphous and transparent to X-
ray, it considerably contributes to the background signal. 
Therefore, we prepared different mixtures of hydroxypropyl methylcellulose (HPMC) and α-lactose 
monohydrate as amorphous and crystalline phases, respectively. The different natures of the amorphous and 
crystalline parts prevent spontaneous crystallization of the amorphous; further, the slightly different mass 
absorption coefficients of the two compounds (MAC = 7.58 and 6.49 for α-lactose monohydrate and HPMC, 
respectively, under copper radiation) can be corrected by the DD method. 
The quantification method was evaluated in three scenarios: a) the unit cell parameters of the target API 
are available, b) the unit cell parameters are not known but the pure crystalline and pure amorphous reference 
materials are available and c) only the mixture of amorphous and crystalline material with unknown weight 
composition is available. Finally, to simulate the measurement of a high potent compound the measurements 
were collected with the use of the Kapton® film as the containment system and the crystallinity was determined 





2 MATERIAL AND METHODS 
2.1 Materials 
α-lactose monohydrate (C12H24O12) and hydroxypropyl methylcellulose (HPMC) were selected as standards 
because they are stable organic compounds regularly used as excipients in the pharmaceutical industry. α-
lactose monohydrate (purity ≥ 99%) was purchased from Sigma-Aldrich (Saint Louis, MO, USA). HPMC, an 
amorphous polymer with the chemical formula C56H108O30 was purchased from Acros Organics (Geel, 
Belgium). It is worth noting that in the DD method requires only the chemical formula. 26 
 
2.2 Sample preparation and data collection  
The mixing process is affected by the different densities, particle sizes, and morphologies of the powder 
constituents. The preparation of large quantities of bulk mixtures and sampling for analysis are primary sources 
of error in solid-state quantification. For this reason, the mixtures were prepared in small amounts and analyzed 
in their entirety to avoid inaccuracy because of the inhomogeneity of the mixture and its sampling. 
Both the standard materials were sifted through a 100-µm sieve to improve the particle statistics and powder 
homogenization before preparing the mixture. Prior to sieving, the particle size of HPMC was vigorously 
reduced by grinding with an agata mortar and pestle. Samples were prepared with 5% w/w (SM1) and 15% 
w/w (SM2) crystalline α-lactose monohydrate, respectively. Three different samples of 50 mg each were 
prepared for each percentage (see Table 1). The samples were prepared by accurately weighting the powders 
on a microanalytical balance that records values of up to six decimal figures (Mettler Toledo XPE26DR). The 
weighted compounds were manually mixed in an agata mortar using the geometric dilution method. The main 
difficulty associated with solid-state quantification is obtaining homogeneous mixtures.  
The mixtures were loaded into a top-loading zero-background silicon sample holder with a recess having a 
diameter and depth of 15 and 0.2 mm, respectively. All the mixtures and pure compounds were analyzed with 
a PANalytical X'Pert PRO diffractometer in Bragg–Brentano geometry with Cu Kα radiation (40 kV, 40 mA) 
and an X'Celerator detector. The operating parameters were a divergence fixed slit of 1/4, a mask of 15 mm, 
an antiscatter slit of 1/2, a diffracted antiscatter slit of 5.0 mm, and a soller slit of 0.04 rad (for both incident and 
diffracted radiation). During the measurement, the sample spun at 1 rps to analyze whole sample surface. All 
the data were collected when 2θ = 3.5°–80° with a step size of 0.0167° and a scanning speed of 0.02°/s.  
Measurements in containment were performed using the Kapton® film. Kapton® is a polyimide film 
commonly used to isolate highly potent API from the ambient environment. However, its signal is a source of 
error in quantitative phase analysis. All the standard mixtures were analyzed with and without the Kapton® 
film to inspect the contribution of Kapton® signal to the measurement. Blank analysis of the empty sample 
holders with the Kapton® film was performed.  
 





% w/w crystalline  
α-lactose monohydrate 
SM11 2.59 (4) 47.51 (2) 5.2 
SM12 2.55 (6) 47.49 (6) 5.1 
SM13 2.51 (6) 47.49 (8) 5.0 
SM21 7.51 (4) 42.70 (2) 15.0 
SM22 7.59 (6) 42.44 (6) 15.2 






2.3 Data analysis 
The XRPD patterns were characterized by a broad halo introduced by the scattering of the amorphous material 
and well-defined peaks generated by the crystalline part. In this study, we applied the DD method presented 
by Toraya and Omote.24 They proved that the commonly used IC equation, which can be used to obtain the 
weight fractions of the individual phases in a mixture from the sum of their intensities measured over a wide 
2θ range with respect to the chemical composition data, can be extended to quantify amorphous materials with 
nonperiodic structures. 
The DD method is based on the WPPF procedure. The fitting function is a linear combination of 
subfunctions with different profile models to describe the powder diffraction patterns of the individual phases. 
Based on the information and knowledge of the single components, three subfunctions were proposed in this 
study. These subfunctions are necessary to extract the intensities of the different compounds, apply the IC 
equation, and derive the weight fraction. 27 
The reference material patterns were obtained using three methods. In method a, wherein the unit cell 
parameters of crystalline reference were known, the Pawley method can be applied and the integrated 
intensities were considered to be adjustable parameters. In method b, wherein no structural information was 
available, the peak positions and intensities can be determined from the X-ray powder patterns of the pure 
standard reference materials.20 The pattern can be fitted directly by adjusting the scale parameter, as reported 
in case of the full-pattern-fitting method by Smith et al.28 In method c (the worst-case scenario), only the mixture 
of amorphous and crystalline references with unknow weight composition was available and no structural 
information and pure standard references were available; therefore, the peaks were detected directly based 
on the mixture. 29 
The organic crystalline compounds are usually characterized by their low symmetry and large cells. 
Therefore, their peaks often overlap, and their determination is a nontrivial task, especially when the peaks 
are both weak and overlapped at 2θ exceeds 30°. The method a based on the Pawley method should reduce 
this problem because the peak positions are determined based on the unit cell parameters.  
We applied the DD method to the α-lactose monohydrate analyzed by methods a, b, and c and 
compared the results to evaluate the importance of detecting the maximum number of peaks. All the data in 
this study were elaborated using the Malvern PANalytical HighScore Plus 4.8 software. 
 
2.3.1 Common observations in all the methods 
In accordance with the proposal of Toraya and Omote, all the samples were analyzed over a wide range (2θ 
= 3.5°–80°).24 Although no α-lactose monohydrate signals were observed beyond 60°, extending the range to 
high angles improved the background determination. In quantification analysis by X-Ray diffraction, the 
background treatment is the most challenging step, especially in case of crystalline-amorphous quantification. 
In crystalline pattern, the background is determined due to the presence of the peaks, while it is difficult to 
divide the halo of the amorphous phase from the background generated by air scattering, fluorescence, and 
equipment. Toraya and Omote suggested that the materials of the same composition analyzed under identical 
experimental conditions resulted in the same background intensity which can be determined at high angle 
where the signal is dominated by the instrument contribution.24 In the USP crystallinity degree quantification 
method, the background noise is considered constant and described as a flat line.14,21 The same approach 
was applied in our study, and the background line was set flat with costant value determined at high angles. 
Aware of the roughness of the approximation, we were surprised of the goodness of the results, while more 
elaborated description of the background, which are at the same time more user dependent, gave results less 
accurate and reproduceable. 
The halo of the amorphous reference material was described by four manually added peaks and was 
individually refined with a pseudo-Voigt function. After inputting the peaks, the background was set as a flat 
function with a constant value equal to the counts of the experimental pattern at high angles (see SI for details). 
This model of the amorphous halo was used in methods a and b. 
The % w/w of crystalline α-lactose monohydrate (Wc%), the relative error percentage (Er%), the weighted 
profile residual error (Rwp), and the chi-square (χ2) were reported for each mixture. The relative error 




and it is an indication of the accuracy of the method (the lower, the better). The absolute error is the difference 
between the crystalline fraction determinate in the quantification (Wc%) and the known value (true value %w/w 
in table 1). In solid-state quantification an Er% lower than 20% is considered acceptable. The weighted profile 
residual error (Rwp), and the chi-square (χ2), also called Goodness of fit indicate the fitting quality between the 
experimental pattern and the calculated one. The Rwp is calculated using a point-by-point weighting factor 
directly from the square root of the quantity minimized. The χ2 is equal to (Rwp /Rexp)2, while Rexp is the expected 
R factor and it is the best possible Rwp.30 Generally, Rwp value < 10% is considered satisfactory, while for χ2 
values in the range 1-2 are good, but they do not guarantee the accuracy of the model and a careful inspection 
of the difference plot is recommended.31  
3 RESULTS 
3.1 Method a 
In method a, the diffraction pattern of the pure crystalline α-lactose monohydrate reference was refined using 
a Pawley function. The peak positions were refined with the unit cell information of the crystalline α-lactose 
monohydrate LACTOS03 of CCDC and the pseudo-Voigt function for the peak profile. 32 The background was 
described using a polynomial function. The refinement reached weighted profile R-value Rwp = 8.04 (see SI for 
details).  
The refined crystalline and amorphous references were used as the initial pattern to describe the 
diffraction patterns of the mixtures. The refined background was considered to be flat in all the diffraction 
patterns to eliminate the instrumental offset. During the first step, the specimen displacement was refined and 
the scale parameters of the references and quantification approached their actual values in all the SM1 
mixtures. However, the difference plot showed several problems in crystalline peak assignment (Figure 1), 
especially in the SM2 mixture with high crystalline content. The agreement between the calculated and 
experimental profiles was improved after Pawley refinement of the crystalline reference, which refined the 
lattice parameters and the peak profile. Further, each peak shape of the amorphous reference was individually 
refined. Figure 1 compares the refinements and difference plots after the first and final steps in method a; 
based on the difference plot, the y-axis entity was observed to considerably decrease in method a (right side, 
red line) because of the considerably improved peak profile and intensity description. The difference plots were 
almost flat, and the quantification as well as Rwp are reported in Table 2 (Figure 2). 
 
Table 2. Results of the SM1 and SM2 mixtures in Method a, showing the %w/w of the crystalline α-lactose 
monohydrate (Wc, %), relative errors Er (%), and reliability indices Rwp 






SM11 5.7 10 1.97 1.23 9 b) 
SM12 4.8 6 2.64 1.68 8 b) 
SM13 3.8 24 2.38 1.51 7 b) 
SM21 13.1 13 3.37 2.15 6 b) 
SM22 13.2 13 2.92 1.86 5 b) 






Figure 1. Comparison of the refinement results of the diffraction pattern of SM21 in Method a. Left panels show 
the signals after refinement and scaling of the SRM patterns (Step 1). Right panels show the signals after Pawley 
refinement (method a). The bottom panel compares the difference plots in the range 2θ = 10°–30°in Step 1 (blue 
line) and method a (red line).  
 
 
Figure 2. Refinement results for the diffraction pattern of SM11 in Method a. Red and blue patterns are the 
experimental and calculated patterns, respectively and the gray lines correspond to the peaks used to describe 
the amorphous signal of HPMC and the green line to the α-lactose reference. The bottom plot shows the 





3.2 Method b  
In method b, the peak positions, profiles, and intensities were determined from the diffraction pattern of the 
pure crystalline α-lactose monohydrate reference. The peaks were determined by applying the peak-finding 
function of the Malvern PANalytical HighScore Plus 4.8 software. The peak positions, profiles, and intensities 
were refined as a group. The profiles were fitted by a pseudo-Voigt function, and the full-width-at-half-maximum 
(FWHM) and asymmetry function were determined using the Caglioti formula. The refinement reached Rwp = 
9.74 (see SI for details). The listed peaks and parameters of the crystalline reference were assumed to 
constitute the initial pattern to fit the whole pattern of the mixtures (SMxy), and the background was described 
by a flat function. The first step with the SMxy included refining the profile of the crystalline and amorphous 
references based on the scale parameter (Figure 3). However, the difference plots were very noisy and the 
Rwp values were quite high, especially in the SM2 mixtures. Therefore, a second refinement was performed. 
Here, the peak set of the crystalline reference was described as a group using the Caglioti formula, but the 
FWHMs of the amorphous reference were individually refined for each peak. Figure 3 compares the diffraction 
patterns of the first step and those obtained after final refinement in method b. The bottom panel compares 
the difference plots of step 1 and the final step of method b. The crystalline α-lactose monohydrate and 
amorphous references’ description clearly improved after refinement, as evidenced in the flat difference plot, 
improved quantification, and low Rwp values (Table 3 and Figure 4).  
 
Table 3. Results of the SM1 and SM2 mixtures in Method b, showing the %w/w of crystalline α-lactose 
monohydrate (Wc, %), relative errors Er (%), and reliability indices Rwp 






SM11 5.0 4 2.17 1.29 16 b) 
SM12 4.8 6 2.30 1.39 15 b) 
SM13 5.0 0 2.23 1.35 14 b) 
SM21 13.2 12 2.69 1.63 13 b) 
SM22 13.8 9 2.63 1.60 12 b) 








Figure 3. Comparison of the refinement results of the diffraction pattern of SM21 in Method b. Left panels report 
the signals after refinement and scaling of the patterns (step 1). Right panels report the signals after refinement 
with the Caglioti function (method b). The bottom panel compares the difference plots in the range 2θ = 10°–30° 
in step 1 (blue line) and at the end of method b (red line).  
 
Figure 4. Refinement results for the diffraction pattern of SM11 in method b. Red and blue patterns are the 
experimental and calculated patterns, respectively and the gray lines correspond to the peaks used to describe 
the amorphous signal of HPMC and the green line to the α-lactose reference. The bottom plot shows the 





3.3 Method c  
We also evaluated the DD method in the absence of pure crystalline and amorphous materials which can be 
used as references. Although this approach is discouraged in text books, the crystal parameters of the 
reference materials are often unknown in reality and not always the references are available. The DD method 
was applied directly to the diffraction patterns of the mixtures. Because the background description critically 
affected the quantification, initially, the peak set of the α-lactose monohydrate was determined by the peak-
finding function of the software and refined as a group using the Caglioti formula. In this case, the crystalline 
area is represented only by the peaks with significant signal-to-noise ratios, which can be detected by the 
peak-finding function. Subsequently, the amorphous hump was described by inserting four peaks and 
modeling them manually against a flat background. The crystalline and amorphous peaks were scaled and 
refined with a profile-fitting function (the pseudo-Voigt function) and an asymmetry function (Figure 5). The 
refinement and quantification values are presented in Table 4. 
 
Table 4. Results of the SM1 and SM2 mixtures in Method c, showing the %w/w of the crystalline α-lactose 
monohydrate (Wc, %), relative errors Er (%), and reliability indices Rwp 






SM11 3.3 37 2.29 1.35 23 
SM12 3.1 39 2.11 1.27 22 
SM13 3.0 40 2.39 1.43 21 
SM21 12.2 19 3.26 1.98 20 
SM22 11.7 23 3.47 2.11 19 
SM23 10.6 30 3.13 1.85 18 
 
 
Figure 5. Diffraction patterns of SM11 refined with a peak-finding function (method c). Red and blue patterns are 
the experimental and calculated patterns, respectively and the gray lines correspond to the peaks used to 
describe the amorphous signal of HPMC and the green line to the α-lactose reference. The bottom plot shows 





3.4 Kapton film 
An increasing number of pharmaceutical compounds are highly potent APIs. Such materials must be handled 
safely to prevent their release into the environment and avoid the exposure of the operators. Therefore, they 
are covered with the Kapton® film during the XRPD analysis. This protective material, which is amorphous, 
contributes to the background signal and should be removed from the measurements before quantification. As 
a blank control, an empty sample holder wrapped in Kapton® film was measured under the same experimental 
conditions, and the blank Kapton® intensities were subtracted from the observed measurements of the 
mixtures by assuming that the intensities of the Kapton® were identical in all the standard mixtures. Figure 6 
shows the diffraction patterns obtained after the subtraction of the Kapton® signals. After this subtraction, the 
diffraction patterns were elaborated as described for method b (subsection 3.2). 
The Kapton® film pattern made a large contribution at low angles, necessitating an additional peak in 
the description of the first hump of the amorphous reference. The added peak improved the agreement 
between the calculated and observed patterns (Figure 7). The refinement and quantification values are 
presented in Figure 7 and Table 5.  
 
Table 5. Results of the SM1 and SM2 mixtures covered with the Kapton® film and analyzed by method b, showing 
the %w/w of the crystalline α-lactose monohydrate (Wc,), relative errors Er (%), and reliability indices Rwp  






SM11 5.4 4 5.22 2.16 30 
SM12 5.1 0 4.59 1.97 29 
SM13 5.9 18 4.63 2.01 28 
SM21 12.9 14 5.88 2.59 27 
SM22 13.3 13 4.78 2.18 26 






Figure 6. Example of the effect of subtracting the Kapton® signal from the signals of the SM11 mixture. The 
black line and blue line are the patterns collected of the sample SM11 and of the empty sample holder with 
Kapton® film respectively. The red pattern is obtained by subtracting the blue pattern from the black one.   
 
 
Figure 7. Refinement results of the diffraction pattern of the SM11 mixture with the Kapton® film (method b). The 
red and blue patterns are the experimental and calculated patterns, respectively and the gray lines correspond 
to the peaks used to describe the amorphous signal of HPMC and the green line to the α-lactose reference. The 
bottom plot shows the difference between the experimental and calculated intensities. The short lines indicate 
the peak positions.  
4 DISCUSSION 
Here, we discuss the quantitative and refinement results of method a when unit cell parameters of crystalline 
reference are available and the refinement is based on Pawley function; method b when no structural 
information is known but crystalline and amorphous references are available and can be used to describe the 
pattern profiles; and method c, when no structural information or pure standard references are available. The 




refinement are reported. Methods a and b obtained comparable Wc and Er, except in case of SM13, where 
method a resulted in a considerably high relative error (out of trend with the remaining SM1 mixtures). Both the 
methods achieved excellent Wc and Er values of lower than 20%. When converted into absolute errors, these 
percentage errors were around one unit in SM1 and approximately two percentage points in SM2. As expected, 
the results obtained using method c showed large errors, with significant underestimation of the crystalline 
percentages and extremely large relative errors (up to 40%). However, the reliability indices Rwp and the χ2 
values were similar and achieved satisfactory values in all the refinements. The exceptionally low values of 
the reliability indices were affected by the large amount of amorphous material, and the Rwp values increases 
with the increasing of the crystalline percentage. The χ2 were always lower than 3 in all the method, except for 
the method b which showed excellent χ2 values lower than 2. As indicated by Toby, the goodness of fitting can 
be optimally assessed by observing the experimental and calculated difference plots, which were almost flat 
in our study, taking into account the scale of the y-axis of the difference plot, and its relation with the intensity 
of the diffraction pattern.31 
Figure 2, Figure 4, and Figure 5 show the diffraction patterns and difference plots of the SM11 mixture 
obtained using methods a, b, and c, respectively. The main differences between these methods are the 
descriptions of the final peaks of the amorphous reference (method c versus methods a and b) and the number 
of crystalline peaks, which considerably decreased from methods a to c. The number of crystalline peaks was 
determined based on the unit cell parameters obtained via method a, the peaks detected in the pure crystalline 
α-lactose monohydrate reference via method b, and the peaks detected in the mixtures via method c. In the 
final case, the crystalline peaks obtained using the peak-finding function were dominated by the limit of 
detection (LOD) and several peaks were missed. Although the peaks at high angles could be barely detected, 
they significantly contributed to the quantification. When the SM11 pattern refined by method a was clipped to 
the range of 2θ = 3.5°–40° (Figure 8), to eliminate the contribution of high angles peaks, the crystalline 
percentage decreased from 5.7% to 3.3%, equal to that obtained using method c.  
Collecting the powder patterns obtained up to 2θ = 80° is important not only for defining the 
background contribution, which severely affected the quantification, but also for considering the crystalline 
contribution at high angles when the reference crystalline material was known. The spinning of the sample 
guarantees the irradiation of the all sample also at high angle, consequently the representativity of the sample. 
The error percentages of the samples wrapped in the Kapton® film (Table 5) were similar to those 
obtained in case of the same samples using method b but were more variable. In case of SM1, the percentage 








Figure 8. Refinement results of the diffraction pattern in the range 2θ = 3.5°–40° of SM11 in method a. The red and 
blue patterns are the experimental and calculated patterns, respectively and the gray lines correspond to the 
peaks used to describe the amorphous signal of HPMC and the green line to the α-lactose reference. The bottom 







The IC formula is a powerful equation based on which the weight fraction of the individual phases in a mixture 
can be determined using only the chemical formulas of the mixture’s constituents. The formula requires two 
input parameters: the sum Sk of the observed powder diffraction intensities of each component measured over 
a wide 2θ range and the parameter 𝑎𝑘 representing the total scattering power per chemical formula weight. 
Toraya and Omote indicated that the IC formula can be used to quantify the amorphous materials in mixtures 
because the scattering power obtained from unit composition is dependent on the number of electrons in its 
atoms, regardless of whether the atom assemblage is ordered.24,33  
The DD method for crystalline degree determination is extremely advantageous respect to other common 
quantification method. It does not require the use of internal standard, which is compulsory for Rietveld and 
univariate methods. The addition of internal standard is challenging in case of small amount of material and 
the errors due to the weighting, mixing procedures can deeply affect the results. In case of high potent 
compounds, the difficulties of these operations are enhanced due to the safety protocols. Additionally, the DD 
method avoids construction of calibration curve, impossible in case of lack of reference materials.  
 
In this study, the DD method was applied to the quantification of an amorphous–crystalline binary 
mixture of organic materials. The quantification of crystalline materials in amorphous matrices is gaining 
interest and is always difficult.34 The difficulties are exacerbated by the lack of information, such as crystal 
structures or standard reference materials, low amount of materials, or the presence of high potent API, which 
have to be handled and analyzed under safe conditions within a suitable containment system. 
We evaluated the DD method in mixtures containing low percentages of crystalline α-lactose 
monohydrate (5 and 15% w/w) in amorphous HPMC under different scenarios. Three refinement methods 
were tested: method a (unit cell parameters available), method b (unit cell parameters are not available but 
the pure crystalline and pure amorphous references are available), and method c (no structural information 
and references available). Method b was also applied to mixtures contained within the Kapton® film. 
Based on the results of these different procedures, the importance of determining the crystalline 
reflections can be understood. The limited number of peaks in the mixtures observed using method c resulted 
in the low area of the crystalline reference and considerable underestimation of the crystalline weight fraction. 
As expected, the usage of standard reference materials improved the accuracy of the results. No large 
differences were observed between the results of methods a and b, although describing the peaks based on 
the cell parameters offers distinct advantages. For instance, the task of adding the peaks becomes easier, and 
Pawley refinement can reveal crystalline impurities. Further, the differences of the crystalline profile from that 
of the standard reference can be tracked in nonstoichiometrically hydrated mixtures.  
The powder pattern must be collected up to a high angle to properly describe the background. The 
background was described by a flat line in agreement with the degree of crystallinity method of USP. 21 
The DD method was also applied to the mixtures contained within the Kapton® film. The film signal was 
eliminated by subtracting the blank measure of the film from the measured diffractogram. The obtained 
diffractograms were studied using method b. Despite the difficulty in describing the diffractograms at low 
angles, accurate crystalline weight percentage results were obtained. The subtraction of the Kapton® film 
signal to remove the matrix effect is an outstandingly effective approach for evaluating potent compounds that 
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7 SUPPLEMENTARY DATA 




𝐼𝑗𝑘= integrated intensity of j 
th reflection of K th component in a K-component mixture 
𝐺𝑗𝑘 = 2𝑠𝑖𝑛𝜃𝑗𝑘 𝑠𝑖𝑛2𝜃𝑗𝑘/(1 + 𝑐𝑜𝑠
22𝜃𝑗𝑘) 
𝑀𝑘= molecular weight 
𝑁𝑘
𝐴 = number of atoms in the chemical formula unit 
𝑛𝑖𝑘 = number of electrons belonging to i 
th atom of the chemical formula  
 
Toraya, H., 2016. A new method for quantitative phase analysis using X-ray powder diffraction: Direct derivation of weight fractions from observed integrated 
intensities and chemical compositions of individual phases. J. Appl. Cryst. 49, 1508–1516. https://doi.org/10.1107/S1600576716010451 
 
7.2 Instrument and measure settings  
Instrumental Settings 




Sample holder Top loading Silicon Zero background plate 
Incident beam path 
Soller slit (rad) 0.04 
Divergence slit Fixed 1/4° 
Mask Fixed 15mm 
Antiscatter slit Fixed 1/2° 
Filter None 
Diffracted beam path 
Soller slit 0.04 
Antiscatter slit 5.0mm 
Filter Nickel 
Measurement Settings 
Scan axis Gonio 
Scan properties Continuous 
Generator settings 40 kV, 40 mA 
Scan Range (°θ) 3,5 - 80 
Step size (°θ) 0.0167 
Time per step (s) 100 






7.3 Integration methods 
 
 Method a Method b Method c 
Crystalline 
reference 
• Pawley function Refinement (LACTOS03): 
o FWHMs function: Caglioti 
o Profile function: Pseudo Voigt 
o Asymmetry function: Split width and shape 
• Peak finding function 
• Profile fit refinement: 
o FWHMs function: Caglioti 
o Profile function: Pseudo Voigt 




• Manually add four peaks 
• Profile fit refinement: 
o FWHMs function: Individual FWHMs 
o Profile function: Pseudo Voigt 
o Asymmetry function: No asymmetry 
Function 
• Manually add four peaks 
• Profile fit refinement: 
o FWHMs function: Individual FWHMs 
o Profile function: Pseudo Voigt 
o Asymmetry function: No asymmetry 
Function 
Not available 
Mixtures Crystalline reference Amorphous reference Crystalline reference Amorphous reference Crystalline reference Amorphous reference 
Step 1 
• Scale parameters 
• Specimen 
displacement 
• Scale parameters • Scale parameters • Scale parameters 
• Peak finding 
function 
• Profile fit 
refinement 




• Pawley function 
refinement: 
o FWHMs function: 
Caglioti 
o Profile function: 
Pseudo Voigt 
o Asymmetry function: 
Split width and shape 
• Profile fit refinement: 
o FWHMs function: 
Individual FWHMs 
o Profile function: 
Pseudo Voigt 
o Asymmetry function: 
No asymmetry 
Function 
o Shape function 
• Profile fit 
refinement: 
o FWHMs function: 
Caglioti 
o Profile function: 
Pseudo Voigt 
o Asymmetry function: 
Split width and 
shape 
• Profile fit refinement: 
o FWHMs function: 
Individual FWHMs 
o Profile function: 
Pseudo Voigt 
o Asymmetry function: 
No asymmetry 
Function 
o Shape function 
• Profile fit 
refinement: 
o FWHMs function: 
Caglioti 
o Profile function: 
Pseudo Voigt 
o Asymmetry 
function: Split width 
and shape 
• Profile fit 
refinement: 
o FWHMs function: 
Individual FWHMs 
o Profile function: 
Pseudo Voigt 
o Asymmetry function: 
No asymmetry 
Function 




7.4 Standard reference material 
 
Figure 1. Refinement results for the diffraction pattern of HPMC. Red and blue patterns are the experimental and 
calculated patterns, respectively. The bottom plot shows their difference. The grey lines indicate the peak 
positions and area of HPMC. The chi-square is 0.91.  
 
Figure 2. Refinement results for the diffraction pattern of α-lactose monohydrate in Method a. Red and blue 
patterns are the experimental and calculated patterns, respectively. The bottom plot shows their difference. The 
green lines indicate the peak positions area of α-lactose monohydrate. The chi-square is 1.78. 
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Figure 3. Refinement results for the diffraction pattern of α-lactose monohydrate in Method b. Red and blue 
patterns are the experimental and calculated patterns, respectively. The bottom plot shows their difference. The 
green lines indicate the peak positions and area of α-lactose monohydrate. The chi-square is 2.12. 
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7.5 Method a 




Figure 4. Refinement results for the diffraction pattern of SM23 in Method a: picture a) shows the signals after 
refinement and scaling of the SRM patterns (Step 1) and picture b) shows the results after final Pawley 
refinement. The chi-square is 2.72 and 2.12, respectively. Red and blue patterns are the experimental and 
calculated patterns. The bottom plot shows their difference. The grey and green lines indicate the peak 
positions and area of HPMC and α-lactose monohydrate, respectively.  
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Figure 5. Refinement results for the diffraction pattern of SM22 in Method a: picture a) shows the signals after 
refinement and scaling of the SRM patterns (Step 1) and picture b) shows the results after final Pawley 
refinement. The chi-square is 2.38 and 1.86, respectively. Red and blue patterns are the experimental and 
calculated patterns. The bottom plot shows their difference. The grey and green lines indicate the peak 
positions and area of HPMC and α-lactose monohydrate, respectively.  
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Figure 6. Refinement results for the diffraction pattern of SM21 in Method a: picture a) shows the signals after 
refinement and scaling of the SRM patterns (Step 1) and picture b) shows the results after final Pawley 
refinement. The chi-square is 2.87 and 2.15, respectively. Red and blue patterns are the experimental and 
calculated patterns. The bottom plot shows their difference. The grey and green lines indicate the peak 
positions and area of HPMC and α-lactose monohydrate, respectively.  
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Figure 7. Refinement results for the diffraction pattern of SM13 in Method a: picture a) shows the signals after 
refinement and scaling of the SRM patterns (Step 1) and picture b) shows the results after final Pawley 
refinement. The chi-square is 1.51 and 1.51, respectively. Red and blue patterns are the experimental and 
calculated patterns. The bottom plot shows their difference. The grey and green lines indicate the peak 
positions and area of HPMC and α-lactose monohydrate, respectively.  
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Figure 8. Refinement results for the diffraction pattern of SM12 in Method a: picture a) shows the signals after 
refinement and scaling of the SRM patterns (Step 1) and picture b) shows the results after final Pawley 
refinement. The chi-square is 1.91 and 1.68, respectively. Red and blue patterns are the experimental and 
calculated patterns. The bottom plot shows their difference. The grey and green lines indicate the peak 
positions and area of HPMC and α-lactose monohydrate, respectively.  
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Figure 9. Refinement results for the diffraction pattern of SM11 in Method a: picture a) shows the signals after 
refinement and scaling of the SRM patterns (Step 1) and picture b) shows the results after final Pawley 
refinement. The chi-square is 1.43 and 1.23, respectively. Red and blue patterns are the experimental and 
calculated patterns. The bottom plot shows their difference. The grey and green lines indicate the peak 
positions and area of HPMC and α-lactose monohydrate, respectively.  
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• Mixture SM11 clipped at 40°2θ Method a  
 
Figure 10. Refinement results for the diffraction pattern of SM11 clipped at 40°2θ in Method a. Red and blue 
patterns are the experimental and calculated patterns, respectively. The bottom plot shows their difference. The 
grey and green lines indicate the peak positions and area of HPMC and α-lactose monohydrate, respectively. 
The chi-square is 1.23.  



















7.6 Method b 





Figure 11. Refinement results for the diffraction pattern of SM23 in Method a: picture a) shows the signals after 
scaling of the SRM patterns (Step 1) and picture b) shows the results after final refinement. The chi-square is 
3.18 and 1.61, respectively. Red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
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Figure 12. Refinement results for the diffraction pattern of SM22 in Method a: picture a) shows the signals after 
scaling of the SRM patterns (Step 1) and picture b) shows the results after final refinement. The chi-square is 
2.66 and 1.60, respectively. Red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
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Figure 13. Refinement results for the diffraction pattern of SM21 in Method a: picture a) shows the signals after 
scaling of the SRM patterns (Step 1) and picture b) shows the results after final refinement. The chi-square is 
3.88 and 1.63, respectively. Red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
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Figure 14. Refinement results for the diffraction pattern of SM13 in Method a: picture a) shows the signals after 
scaling of the SRM patterns (Step 1) and picture b) shows the results after final refinement. The chi-square is 
1.25 and 1.35, respectively. Red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
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Figure 15. Refinement results for the diffraction pattern of SM12 in Method a: picture a) shows the signals after 
scaling of the SRM patterns (Step 1) and picture b) shows the results after final refinement. The chi-square is 
2.01 and 1.39, respectively. Red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
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Figure 16. Refinement results for the diffraction pattern of SM11 in Method a: picture a) shows the signals after 
scaling of the SRM patterns (Step 1) and picture b) shows the results after final refinement. The chi-square is 
1.60 and 1.29, respectively. Red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
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• Mixture SM11 clipped at 40°2θ Method b 
 
Figure 17. Refinement results for the diffraction pattern of SM11 clipped at 40°2θ in Method b. Red and blue 
patterns are the experimental and calculated patterns, respectively. The bottom plot shows their difference. The 
grey and green lines indicate the peak positions and area of HPMC and α-lactose monohydrate, respectively. 
The chi-square is 1.29.  





















7.7 Method c 
• Mixture SM23 Method c  
 
Figure 18. Refinement results for the diffraction pattern of SM23 in Method c. The chi-square is 1.85. The red and 
blue patterns are the experimental and calculated patterns. The bottom plot shows their difference. The grey and 
green lines indicate the peak positions and area of HPMC and α-lactose monohydrate, respectively. 
 
• Mixture SM22 Method c 
 
Figure 19. Refinement results for the diffraction pattern of SM22 in Method c. The chi-square is 2.11. The red and 
blue patterns are the experimental and calculated patterns. The bottom plot shows their difference. The grey and 
green lines indicate the peak positions and area of HPMC and α-lactose monohydrate, respectively. 
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• Mixture SM21 Method c 
 
Figure 20. Refinement results for the diffraction pattern of SM21 in Method c. The chi-square is 1.98. The red and 
blue patterns are the experimental and calculated patterns. The bottom plot shows their difference. The grey and 
green lines indicate the peak positions and area of HPMC and α-lactose monohydrate, respectively. 
 
• Mixture SM13 Method c 
 
Figure 21. Refinement results for the diffraction pattern of SM13 in Method c. The chi-square is 1.43. The red and 
blue patterns are the experimental and calculated patterns. The bottom plot shows their difference. The grey and 
green lines indicate the peak positions and area of HPMC and α-lactose monohydrate, respectively. 
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• Mixture SM12 Method c 
 
Figure 22. Refinement results for the diffraction pattern of SM12 in Method c. The chi-square is 1.27. The red and 
blue patterns are the experimental and calculated patterns. The bottom plot shows their difference. The grey and 
green lines indicate the peak positions and area of HPMC and α-lactose monohydrate, respectively. 
• Mixture SM11 Method c 
 
Figure 23. Refinement results for the diffraction pattern of SM11 in Method c. The chi-square is 1.35. The red and 
blue patterns are the experimental and calculated patterns. The bottom plot shows their difference. The grey and 
green lines indicate the peak positions and area of HPMC and α-lactose monohydrate, respectively. 
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• Mixture SM11 clipped at 40°2θ Method c 
 
Figure 24. Refinement results for the diffraction pattern of SM11 clipped at 40°2θ in Method c. The chi-square is 
1.63. The red and blue patterns are the experimental and calculated patterns. The bottom plot shows their 
difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose monohydrate, 
respectively.  





















7.8 Method b - Kapton 
• Mixture SM23 Kapton Method b 
 
Figure 25. Refinement results of the diffraction pattern of the SM23 mixture with the Kapton® film (method b). 
The chi-square is 2.17. The red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
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• Mixture SM22 Kapton Method b 
 
Figure 26. Refinement results of the diffraction pattern of the SM22 mixture with the Kapton® film (method b). 
The chi-square is 2.18. The red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
• Mixture SM21 Kapton Method b 
 
Figure 27. Refinement results of the diffraction pattern of the SM21 mixture with the Kapton® film (method b). 
The chi-square is 2.59. The red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
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• Mixture SM13 Kapton Method b 
 
Figure 28. Refinement results of the diffraction pattern of the SM13 mixture with the Kapton® film (method b). 
The chi-square is 2.01. The red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
• Mixture SM12 Kapton Method b 
 
Figure 29. Refinement results of the diffraction pattern of the SM12 mixture with the Kapton® film (method b). 
The chi-square is 1.97. The red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
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• Mixture SM11 Kapton Method b 
 
Figure 30. Refinement results of the diffraction pattern of the SM11 mixture with the Kapton® film (method b). 
The chi-square is 2.16. The red and blue patterns are the experimental and calculated patterns. The bottom plot 
shows their difference. The grey and green lines indicate the peak positions and area of HPMC and α-lactose 
monohydrate, respectively.  
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DIRECT DERIVATION OF THE CRYSTALLINE FRACTION OF FORMULATION 
DEPOSITED ONTO DRUG COATED BALLOON BY X-RAY POWDER DIFFRACTION 
 
1 INTRODUCTION 
1.1 Drug-coated balloon catheter 
Cardiovascular diseases are the first cause of death globally. In 2016, 17.9 million people died from 
cardiovascular diseases, equivalent to 31% of all global deaths, a number that is expected to grow to more 
than 23.6 million by 2030.1 Cardiovascular diseases include several disorders of the heart and blood vessels 
as such as coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart 
disease, congenital heart disease and deep vein thrombosis and pulmonary embolism.1  
Peripheral arterial disease (PAD) is noncoronary arterial syndromes affecting the arterial beds causing 
alteration of structure and function of the arteries, it can process in stenosis and aneurysm of the noncoronary 
arterial circulation and develop in coronary artery disease and cerebrovascular disease with the risk of 
cardiovascular ischemic events. PAD may arise in any blood vessel, commonly it appears in legs.1,2 Worldwide 
PAD affects 35.54% of adult population. 
Coronary artery disease (CAD), also called Coronary heart disease (CHD) or ischemic heart disease, is caused 
by atherosclerosis which partially or, in the most severe cases, totally blocks coronary artery caused by plaque 
of cholesterol and other substances in the wall’s arteries that supply blood to heart.3 American Heart 
Association acknowledges that heart diseases (including Coronary Heart Disease, hypertension, and stroke) 
are the first cause of death in the USA. From 2006 to 2016 the annual death rate attributable to coronary heart 
disease declined 31.8%, however risk factors remain alarmingly high.1 Risk factors of PAD and CAD are 
smoking, physical inactivity, nutrition, obesity, cholesterol diabetes and high blood pressure. The reduction of 
incidence of heart diseases is to be awarded to the prevention of risk factors and treatments as such as 
percutaneous transluminal angioplasty (PTA) and percutaneous coronary interventions (PCI).1 
In the years, several studies and technological progresses have been done in the treatment of PAD and CAD 
through PCI. Coronary angioplasty was introduced by Grüntzig in 1977, who is considered the father of the 
percutaneous transluminal coronary angioplasty (PTCA). PTCA is a nonsurgical method for arterial 
revascularization based on dilatation of stenotic artery by inflation of balloon catheter system introduced by 
systematic artery under local anaesthesia.4,5 PTCA had showed some shortcomings abrupt vessel occlusion, 
dissection and restenosis.6 Restenosis is inflammation response to injury that causes elastic recoil, mural 
thrombosis formation, neointimal proliferation and chronic arterial changes.7 In 1986 the first patients affected 
by restenosis after PTCA were treated by implantation of bare metal stents (BMS), hollow cylinders metal 
stretched opened by inflating of balloon catheter. Comparing to the PTCA, BMS had showed better long-term 
success (85-90%). Although the most common cause of failure of treatment with BMS is local inflammation 
and successively restenosis (20-25%). Additionally, other drawbacks of BMS were the difficulties to place it at 
correct side in tortuous vessel and possible mechanical stent deformity and strut fractures. In 2001 the BMS 
evolves into drug eluting stent (DES), it was developed to overcome the problem of restenosis encountered 
with BMS.8 DES is metal scaffolding device coated with single or multiple bioactive ingredients. The localized 
and controlled release of drug has numerous advantages as such as the delivery in the precise site of the 
lesion, achievement of high local tissue concentration of active agents and minimal systematic concentration 
with constrained systematic side effects and toxicity.9 DES improved the long-term success below 90% and 
decreased the insurgence of in-stent restenosis at 7-15%.10 Different therapeutic drug mechanism of action 
against restenosis process has been picked out: immunosuppressive, antiproliferative, anti-inflammatory and 
antithrombotic. The drugs deposited onto DES should have the specific characteristics: wide therapeutic 
window, both local and systematic safe profile and it should reach the therapeutic concentration. Literature 
reports several active pharmaceutical ingredients that can be used in DES: rapamycin (sirolimus), paclitaxel, 




actinomycin D, estrogen, cyclosporin, angiopeptin, C-myc antisense and nitric oxide.7,9 The adhesion onto 
metallic stent surface was an obstacle for most drugs, which needed a biocompatible polymeric coating as 
carrier. Nevertheless, the permanent device implantation and the polymeric coating can induce foreign body 
reaction, inflammation and thrombosis.10–12 Furthermore the rigid structure of the stent did not allowed the 
implantation in particularly location as such as small vessel and vessel bifurcations and sometimes in the 
margins of the device it was observed an incomplete suppression of neointimal hyperplasia.13,14 Stent 
increases rigidness of the vessel affecting its compliance and it is not suitable for small vessel because it has 
reduced already narrowed lumen with its physical footprint. Moreover, the presence of stent may be 
problematic in case of necessity of subsequent surgeries.15 These drawbacks have been overcome by the 
latest developed technique: the drug coated balloon (DCB). Drug coated balloon combines two therapeutic 
effects: mechanic action, due to the dilation of the balloon, and pharmacological bioactivity due to the release 
of drugs triggered by the inflation of the balloon. The first multicenter clinical trial of this new technology dates 
back to 2003 of PACCOCATH-ISR, which has taken out the several advantages of DCB.16 In fact, the DCB 
does not require the implantation of stent eliminating the inflammatory response due to the permanent foreign 
scaffold in the vessel and DCB is placeable in location not reachable by DES, for instance in small and tortuous 
vessel and vessel bifurcation. Nowadays, DCB is the treatment of choice of in-stent restenosis, in de novo 
coronary diseases in challenging side for DES.10,17 Moreover, DCB is indicated for the treatment of peripheral 
artery disease, even de novo femoropopliteal and below to knee disease and it can be a valid alternative for 
the treatment of de novo coronary diseases.13,18–21 DCB releases therapeutic dose of active agents directly in 
the target with brief time of exposure and high drug surface area present to wall vessel.16,22 Indeed, the 
recommended time of inflection is not higher than 60 seconds. Even with this short time of contact between 
vascular muscle cells and lipophilic agents, DCB achieves inhibition of proliferation of such cells for long period 
thank to the drug retention by tissue for prolonged time.6,23 Among the many advantages of DCB there is also 
the short-term of dual antiplatelet therapy of few months following DCB treatment, while after DES implantation 
dual antiplatelet therapy is recommended for 6 to 12 months.18,24,25 The first line drug for DCB has been the 
anti-proliferative taxane paclitaxel, though DCB coated with other drugs have been emerging, as such as 
zotarolimus, sirolimus, everolimus, biolimus A9, dexamethasone, tranilast and nuclear factor-kappa B 
oligodeoxynucleotides.26–30 In DCB the release of the drug is not controlled, but the transfer of the active agent 
in the tissue is influenced by the coating characteristic. Hence the active ingredient, the excipients and the 
manufacturing process is extremely important and impactful for the drug release and the success of the 
therapy22. The excipients must be compatible with the active ingredients, able to generate a homogeneous 
coating, enhance the adherence of the drug during the handling and the release of the drug to the vessel upon 
balloon dilatation.23 Scheller et al. estimate paclitaxel DCB loses 6% of the dose during the transit and about 
80% of the drug is released during inflation.14 Additionally, Afari & Granada pointed the impact of coating 
crystallinity out.22 For paclitaxel DCB, they observed that amorphous coating has better uniformity and less 
particulate formulation but steeper decrease of tissue levels and lower long term tissue retention than 
crystalline coatings which, instead, reach higher tissue level and biological efficacy.22 These studies highlight 
the importance of the study of the polymorphism and crystallinity degree of the formulation to achieve efficacy 
product, consequently it requests a control of the manufacturing process.  
 
1.2 Drug polymorphism 
As pointed out by Afari & Granada the polymorphism and the crystallinity degree of the drug coated onto the 
balloon catheter impact the tissue transfer and consequently affect the efficacy of the therapy.22 Hence, the 
control of the manufacturing process from which depends the final characteristic of the formulation, is 
extremely important.  
Polymorphism refers to the ability of a certain compound to exist in different crystallographic structures, 
resulting from different packing arrangements of its molecules in the crystal structure. While the term 
polymorphism is restricted to compound with have the same chemical formula in pharmaceutical industries the 
attention is focused also in the presence of hydrates and solvates which are regulated in the same way.31–33 
Crystal forms are of particular importance in the pharmaceutical industry, as many APIs receive regulatory 
approval only for a single crystal form or polymorph. Furthermore, polymorphism in drugs can affect such 




In this study we evaluated the crystal forms and crystallinity degree of the formulation coated onto a balloon 
catheter. This work was conducted in collaboration with the manufacturing company of the device. For 
business and conflict of interest the manufacturing company, the device commercial name, the active 
ingredient and the formulation ingredients cannot be revealed. For this reason, the references consulted will 
not be cited.  
The API is a huge molecule with molecular mass higher than 800 u.m.a.. Studies associate the formation of 
particular crystallinity grade of API with the polarity of the solvent used in the evaporation process. Especially, 
higher polarity index and lower viscosity of organic solvents achieve API with higher crystallinity degree, 
whereas amorphous API is obtained using non-polar solvents with polarity index lower than 4.00.  
The Cambridge Structure Database (CSD) reports six structures of the API, of which five are solvates and one 
is anhydrous. Table 1 and Figure 1 report the structure information and the XRPD patterns comparison. The 
structure coordinates and the calculated XRPD pattern of Form 6 are not available.  
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Hydrate and the anhydrous forms show very similar XRPD patterns, in fact the crystalline structure of the forms 
is resembling. The core of the molecule maintains basic conformation in all the hydrated and anhydrous forms 
and the packing is almost unchanged between the forms. Nevertheless, hydrated and anhydrous forms show 
some difference in intermolecular hydrogen bonding network, which is affected by the presence of water in the 
system. In the anhydrous form the two API molecules in the asymmetric unit are connected by one hydrogen 
bond. While the hydrated forms showed the same hydrogen bonding network with two more intermolecular 
bonds between the API molecules, the water molecules are not directly involved in the hydrogen bonds. This 
different interaction between the molecules affect the physical properties, especially the solubility. In fact, the 






Figure 1 XRPD comparison of the calculated patterns of API by the CSD 
 
Figure 2 shows the crystal structures of the hydrated forms and anhydrous form. The blue spots represent the 
water molecule in the structure. Hemihydrate Form 4 and dihydrate Form 3 share the position of one water 
molecule. The yellow spots in anhydrous Form 5 represent the void in the structure, which amounts to 1.5% 
of unit cell. In conclusion the API structures are characterized by cavities between the drug molecules which 
are filled up by solvent without substantial changing in packing arrangement. This behaviour is typical of non-
stoichiometric hydrates, whose structure can allocate a variable number of water molecules with only small 
structural change. The absolute determination of the amount of solvent can be challenging also in the single 
crystal structure because usually their position is highly disordered into the cavities between the API molecules. 
Figure 3 reports the structure representation of N-methyl-2-pyrrolidone acetonitrile solvate trihydrate (Form 1) 
dimethylformamide solvate monohydrate (Form 2), dihydrate form (Form 3) and hemihydrate form (Form 4). 
The structures are isostructural: the molecules are almost in the same positions. Moreover, the cell parameters 
of all the structures are very similar as reported in Table 1, it suggests the capability of the API to incorporate 
different solvent molecules in the structures without significant structure changes. Additionally, the literature 
points out the similarity between the unit cell parameters of dihydrate Form 3 and dioxane hydrate Form 6 
(structure coordinates not available).  
Solvate solids are common in pharmaceutical compounds, especially hydrates, it is estimated one third of 
pharmaceutical active ingredients can arranging in hydrated crystalline. Based on their structure, hydrates can 
be classified in three different classes. Class 1 is constituted by isolated hydrates in which water molecules 
interact exclusively with drug molecule without interaction between other molecule of water. Contrarily, in class 
2 category water molecules are contiguous into channels through crystalline structure. Hydrates included in 
class 3 contain metal ion coordinated with water molecules. Class 2 hydrates can be differentiated in 
stoichiometric and non-stochiometric.33 Stochiometric hydrates have peculiar crystal structure clearly distinct 
from other phases and they have a definite content of water at defined relative humidity. Contrarily, non-
stoichiometric solvates has not a well-defined content of solvent but they have continuously variable 
composition and their crystal structure is stable in a wide range of solvent content.35,36 Especially non-
stoichiometric behaviour is observed in large and rugged shaped molecules that cannot pack closely and 
present voids and channels in the structure in which the solvent molecules can locate. In literature is commonly 
reported example of non-stochiometric hydrates, e.g. rifaximin37,38, moreover the structure can host not 
exclusively water molecules but also different solvents. The amount of solvent’s molecules in the structure 
depends on several factors as such as the partial pressure of the solvent in the environment, the temperature, 
and relative humidity. 39 The peculiarity of non-stoichiometric compounds is the absence of significant changes 
in the crystal structure in response to variation in solvent content, except for some anisotropic distortion due 
to accommodation or loss of solvent molecules. Hence, the structure is retained with different solvent content, 




position of the diffraction peaks. Non-stoichiometric compounds with different solvent content usually show 
some small difference in X-Ray diffraction patterns, as such as variation of intensity of specific peaks and shifts 
in the peak position.37 Additionally, the presence of water and solvent molecules within the lattice impacts 
solubility, dissolution rate, stability, and bioavailability of pharmaceutical compounds due to the packing 
arrangement and the intermolecular interactions in a crystal structure.40 In the crystal structure of stoichiometric 
solvates, the solvent has stabilizing role of the crystal packing. When no clear hydrogen bonding is present in 
the crystal, the molecules are weakly bound and appear to be disordered, as such the compound shows a 
non-stoichiometric behaviour. In non-stoichiometric solvates the free water can interact with other components, 
compromising the stability and performance of formulated products.36 Additionally, the loss of solvent lets voids 
in crystal structure that can reduce chemical or physical stability, besides the original solvent to minimize the 
void space the compound can take up other solvents.41  
 
Figure 2 Structure of anhydrous form (Form 5), dihydrate form (Form 3) and hemihydrate form (Form 4) 
 
Figure 3 Structure of N-methyl-2-pyrrolidone acetonitrile solvate trihydrate (Form 1) dimethylformamide solvate 






The aim of this work is the quantification of the crystallinity degree by X-Ray powder Diffraction of formulation 
coated on Drug Coated Balloon. For business and conflict of interest the active ingredient and excipients of 
the formulation cannot be revealed. The manufacturing company is concerned to determine the crystallinity 
degree of its formulation since studies have revealed more bioactivity and efficacy than the competitor’s 
products attributed to differences in grade of crystallinity of the various formulations.  
DCB is a complex sample that present several difficulties. First, it is a formulation including excipients that 
contribute to sample signal. DCB devices are very expensive, each DCB carries tiny amount of powder, 
therefore available quantity of sample is exiguous for the collection. Hence, the use of internal standard is not 
possible because weight and mixture errors in such small amount of powder can remarkably affect the 
quantification. Moreover, suitable amounts of crystalline and amorphous API references are not available 
wherefore the preparation of set of standard mixtures and construction of calibration curve is not feasible. 
Additionally, it is important to point out the difference between the mixtures of standard references and the real 
formulation which undergoes a production process. Indeed, the manufacturing process impacts on several 
features as such as morphology, particle size, content of solvent and crystallinity degree, important elements 
in solid-state quantitative analysis which make the standard mixtures not representative of the DCB formulation 
samples. Furthermore, the API is classified as highly potent due to its activity and its side effects. Hence, it is 
necessary to enclosure the powder for environment and operator safety with system as Kapton® film or sealed 
glass capillary. Both Kapton® and glass capillary give amorphous contribution, which is necessary to consider 
in the quantitative analysis and elaboration of the data.  
Thereby the impossibility to use an internal standard, the low amount of sample and the lack of reference 
standards exclude the quantification by many of common amorphous-crystalline quantitative methods, as such 
as univariate and multivariate methods, RIR and Rietveld. Three methods were pinpointed as suitable for the 
quantification of this project: Direct Derivation Quant Method (DDQM), US Pharmacopeia (USP) method and 
Autoscale.  
Autoscale method is very simple method that scale the patterns of references with the sample. It is evaluated 
for its simplicity and execution speed, despite the pattern of DCB sample and references are not perfectly 
superimposable.  
USP method is semi-quantitative and comparative method reported in the Unit State Pharmacopeia. USP 
recommends this method for crystallinity degree quantification of compound with the same elementary 
composition. Nevertheless, USP method is evaluated for DCB formulation because API and excipient have 
similar mass absorption coefficient (MAC).  
DDQM is a new quantitative method, it is similar but more sophisticated than USP method. It is based on the 
Intensity-composition (IC) equation which takes in consideration the chemical formula and consequently the 
electronic density and mass absorption coefficient of the phases in the mixture. Additionally, the references’ 
patterns can be described by the cell parameters. 
Accuracy and precision of quantitative method could not be evaluated due to impossibility of construction of 
calibration curve with DCB samples. Therefore, the three described methods are applied on standard mixtures 
of α-lactose monohydrate (crystalline part) and HPMC (amorphous part). The standards are prepared to 
simulate the DBC in crystallinity fraction and measurement conditions (i.e., small amount of material and 
amorphous signal due to the sample holder), which allowed us to define the best way to describe the 
background signal (capillary or Kapton®) for each method and finally to choose the more appropriate method 





3 EXPERIMENTAL PROCEDURE 
3.1 Lactose – HPMC 
3.1.1 Material 
α-lactose monohydrate (C12H24O12) and hydroxypropyl methylcellulose (HPMC) were chosen as respectively 
crystalline and amorphous standards because they are stable organic compounds regularly used as excipients 
in the pharmaceutical industry.  
α-lactose monohydrate (purity ≥99%) was from Sigma-Aldrich (Saint Louis, MO, USA). Hydroxypropyl 
methylcellulose was acquire from Acros Organics (Geel, Belgium). 
 
3.1.2 Sample preparation and Data collection 
Three mixtures containing α-lactose monohydrate and HPMC were prepared with content percentage of α-
lactose monohydrate equal to 25%w/w, 50% w/w and 75%w/w by accurately weighting with micro-analytical 
Balance Mettler Toledo XPE26DR (6 decimal figures, Table 2). The standard mixtures have been blended in 
an agata mortar following the method of the geometric additions to reach homogeneous mixture. The mainly 
issue of the preparation of solid-state sample is the achievement of homogeneous mixtures, indeed different 
density, particle size and morphology of the powders impact the mixing and the inhomogeneity of the powdered 
standards may deeply affect the outcome of the quantitative method. To minimize the error due to the sampling, 
the mixtures have been prepared in small amount 50 mg and all the powder was measured at once.  
The standard mixtures and the pure reference standards of α-lactose monohydrate and HPMC, relevant 
respectively of 100% and 0% of crystalline content, have been analysed by X-Ray diffraction in transmission 
mode in Hilgenberg borosilicate glass 3.3 capillary diameter 0.5 mm and wall thickness = 0.01 mm. The 
patterns were collected on Panalytical X’Pert Pro equipped with a focusing Mirror and a Pixcel detector in the 
range 3-60°2θ. The samples have been analyzed in the same point six time, 30 minutes for single analysis. 
The diffraction pattern of empty capillary has been collected in the same condition. The mean of the six data 
has been calculated by HighScore software to improve the signal to noise ratio of the measurements.  
 
Table 2 Standard mixture of α lactose monohydrate and HPMC 
 STD 25% w/w STD 50% w/w STD 75% w/w 
HPMC (mg) 37.614 mg 25.412 mg 12.602 mg 
Monohydrate α lactose (mg) 12.642 mg 25.848 mg 37.696 mg 
% crystalline α lactose 25% w/w 50% w/w 75% w/w 
 
3.1.3 Crystallinity determination: USP Method 
The crystallinity degree of α-lactose monohydrate reference (100% crystalline) and standard mixtures was 
calculated using the USP method. 
The USP method require the determination of three areas: A due to the crystalline sample, B due the scattering 
of the amorphous powder and C is the background, due to the air scattering, sample holder etc. 
The C area was described by the pattern of the empty capillary. The amorphous was determined by the 
function “determine background” in Highscore Plus while the crystalline contribution is represented by the area 
of sharp peaks (area A). Hence, the three areas (A, B and C) were determined as following: 
• A XRPD pattern of samples 
• B background calculated using HighScore  
▪ Granularity 5 
▪ Bending 0 
▪ Use smoothed input data 





The intensity of the samples, the background lines and the capillary measure were elaborated using Excel 
software calculating the three areas and the crystalline percentage. Table 3 and Figure 4, Figure 5, Figure 6 
and Figure 7 report the results obtaining with USP method. The crystalline lactose reference considered as 
100% crystalline showed a crystallinity degree of 66%. To reach the actual crystalline percentage (100%) a 
correction factor of 1.51 was applied. The same value of correction factor was applied to the % crystalline of 
all the standard mixtures (see Table 3). It was observed general underestimation of the corrected % crystalline 
of the standard mixtures with negative absolute error of 4% for all the standards. Recovery % values were 
satisfactory, well as for the 25%w/w standard, which showed the lowest recovery % of 85%, even so in the 
acceptable range 80-120%. However, it is important to point out that the USP method is a comparative method.  
 
Table 3 α-Lactose-HPMC: USP method results 







% crystalline % crystalline 
100 66 66% 
1.51 
100 100% 
75 47 62% 71 94% 
50 31 61% 46 92% 






Figure 4 USP method results of α lactose monohydrate (100% crystalline) with blank capillary as constant 
background (blue area). The red and green area represent respectively the crystalline and amorphous area. 
 
Figure 5 USP method results of Std 75% w/w of α lactose monohydrate with blank capillary as constant 






Figure 6 USP method results of Std 50% w/w of α lactose monohydrate with blank capillary as constant 
background (blue area). The red and green area represent respectively the crystalline and amorphous area. 
 
 
Figure 7 USP method results of Std 25% w/w of α lactose monohydrate with blank capillary as constant 






The method DDQM is a new quantification method developed by Toraya and available by HighScore.42 It is 
based on the Intensity-composition (IC) equation that can determinate the weight fraction of the individual 
phases in a mixture using few input as such as the chemical formulas of the mixture’s constituents, 𝑆𝑘 sum of 
the observed powder diffraction intensities of each component, and 𝑎𝑘 the total scattering intensity per 




It requires the chemical formula of the phases and good description of experimental pattern to determine 𝑆𝑘 
and 𝑎𝑘.  
 
 
Where 𝐼𝑗𝑘 is the integrated intensity of j 
th reflection of K th component in a K-component mixture, 𝑀𝑘is the 
molecular weight, 𝑁𝑘
𝐴 is the number of atoms in the chemical formula unit, 𝑛𝑖𝑘 is the number of electrons 





Firstly, the capillary blank pattern was subtracted to patterns of references and standards to eliminate the 
contribution of the scattering of the sample holder, air and instrument. 
Then, the peaks of the pure crystalline α-lactose monohydrate were defined by a Pawley refinement. The cell 
parameters were retrieved by CSD44 (LACTOS03): 
Space Group Number: P21 (4) 
Crystal System: Monoclinic (beta) 
a [Å]:7.937 
b [Å]: 21.568 
c [Å]: 4.815 
α [°]:90 
β [°]: 109:77 
γ [°]:90 
Volume [Å3]: 778.521 
The profile was refined using pseudo Voigt function as profile fit function, Caglioti formula for the FWHM and 
the background was maintained flat at 0 cps. The refinement reached the value of Rwp=10.8, the deviation 
between calculated and experimental patterns was observed mainly in the description of peak intensity (Figure 
8). The determination of the peak list based on the cell parameters allow to detect also low intensity peaks, 
which can be missed by the “search peaks” procedure. 
The description of the amorphous hump was done by manually adding five peaks (Figure 9). The peaks’ profile 
was refined individually using the pseudo Voigt function and individual FWHMs function. The background was 
automatically set flat at 1.4 cps by HighScore and it was not changed during the fitting. The refinement reached 
the value of Rwp=2.7, good description of the amorphous pattern was achieved. 
The modelled pattern of crystalline and amorphous phases were used to fit the mixtures (see Figure 10, Figure 
11, Figure 12 and Figure 13). 





Red and blue line patterns represent experimental and calculated patterns, respectively. The plot in the bottom 
shows the difference between the experimental and calculated intensities. The area of crystalline peaks is 




Figure 8. Pawley refinement result of crystalline reference α lactose monohydrate. Red and blue line patterns 
represent experimental and calculated patterns, respectively. The plot in the bottom shows the difference 







Figure 9. Refinement result of amorphous reference HPMC. Red and blue line patterns represent experimental 
and calculated patterns, respectively. The plot in the bottom shows the difference between the experimental and 
calculated intensities. Blue area represents the amorphous area. 
 
Initially, the reference phases were scaled to describe the pattern of the mixture, then to improve the fitting, 
the crystalline peaks were refined as a group using Caglioti and pseudo Voigt function as profile function, while 
amorphous bands were individually refined using individual FWHMs and pseudo Voigt function as profile 
function. The background was refined using polynomial function with two coefficients. 
It is worth noting that the peak profile of the crystalline references usually shows a lower FWHM than the 
crystalline part in the mixtures. 
Observing the results reported in table below, underestimation of the crystalline % was noticed especially for 
standard with high content of crystalline phase. These results may be due to poor description of the 
background. Nevertheless, the method obtained satisfactory results with recovery % > 91% (see Table 4).  
 





Recovery% Rwp (%) 
25 25 100% 3.1 
50 48 96% 4.5 
75 70 93% 6.1 







Figure 10. Refinement of Std 25% w/w of α lactose monohydrate. Red and blue line patterns represent 
experimental and calculated patterns, respectively. The plot in the bottom shows the difference between the 
experimental and calculated intensities. The area of the crystalline and amorphous peaks is represented 







Figure 11. Refinement of Std 50% w/w of α lactose monohydrate. Red and blue line patterns represent 
experimental and calculated patterns, respectively. The plot in the bottom shows the difference between the 
experimental and calculated intensities. The area of the crystalline and amorphous peaks is represented 







Figure 12. Refinement of Std 75% w/w of α lactose monohydrate. Red and blue line patterns represent 
experimental and calculated patterns, respectively. The plot in the bottom shows the difference between the 
experimental and calculated intensities. The area of the crystalline and amorphous peaks is represented 







Figure 13. Refinement of Std 100% w/w of α lactose monohydrate. Red and blue line patterns represent 
experimental and calculated patterns, respectively. The plot in the bottom shows the difference between the 
experimental and calculated intensities. The area of the crystalline and amorphous peaks is represented 





3.1.5 Autoscale  
 
The utoscale method is a simple and fast semi-quantitative method available in HighScore software and it 
requires reference patterns to compare with the sample. The pure references of monohydrate α-lactose and 
HPMC were analyzed and use as standard for autoscale quantification. Obviously for this method the reference 
100% crystalline was not evaluated and compared with itself.  
The autoscale analysis gives back excellent recovery % values and good Rwp values, except for the 25% w/w 
standard, which showed recovery % of 84%, even so within the acceptable range 80-120% (see Table 5). 
Despite the good Rwp values, the difference graph showed a weak description of intensity of crystalline peaks 
in particular for the amorphous phase (see Figure 14, Figure 15 and Figure 16). Probably the over- and under-
estimation of the amorphous humps cancel the error, on the other hand the crystalline pattern is slightly 
affected by preferential orientation, which is mitigated in the mixtures, and prevents an exact match in the 
intensity of the crystalline part. Nevertheless, this method seems to work better in presence of high percentage 
of crystalline part. 
 





Recovery% Rwp (%) 
25 21 84 3.73 
50 49 98 3.25 
75 72 96 3.38 
 
 
Figure 14. Autoscale result of Std 25% w/w of α lactose monohydrate. The image in the top shows the XRPD 
pattern comparison between the Std 25% w/w in red, amorphous HPMC (blue line), and crystalline α lactose 







Figure 15. Autoscale result of Std 50% w/w of α lactose monohydrate. The image in the top shows the XRPD 
pattern comparison between the Std 50% w/w in red, amorphous HPMC (blue line), and crystalline α lactose 




Figure 16. Autoscale result of Std 75% w/w of α lactose monohydrate. The image in the top shows the XRPD 
pattern comparison between the Std 75% w/w in red, amorphous HPMC (blue line), and crystalline α lactose 




3.2 Drug Coated Balloon 
3.2.1 Material 
The manufacturing company of the drug-coated balloon catheter identity cannot be disclosed. The 
manufacturing company supplied the starting material and three balloon catheters with different batches 
labelled Test02, Test03 and Test04. The balloon catheter Test02 had swollen diameter of 5 mm, while the 
Test03 and Test04 had swollen diameter of 6 mm. The three devices diverged as well as for the length of the 
balloon catheter: Test02 and Test03 were 60mm long, whereas the Test04 was 200 mm long.  
The API is classified as High Potent, it is OEB 4 (control exposure to the range of 1ug/m3 to < 10ug/m3) and it 
is suspected of causing genetic defects (H341) and it may damage fertility and unborn child (H360FD). For 
safety reason the HPAPI was processed always in a confined environment. 
 
In the PolycrystalLine S.p.A. laboratories the pure crystalline and amorphous references of the API have been 
isolated. The amorphous reference has been obtained by evaporation at low pressure at 40°C of saturated 
solution in dichloromethane of anhydrous starting material. The crystalline reference has been isolated by 
slurry with two different experimental conditions labelled with EXP01 and EXP03: 
• EXP01: slurry in water HPLC grade at the concentration of 37.5 mg/mL for three days at temperature 
condition variable in the range 10-50°C.  
• EXP03: slurry in water HPLC grade at the concentration of 10 mg/mL for three days at room 
temperature. 
 
The samples have been analysed by X-Ray diffraction in transmission mode in Hilgenberg borosilicate glass 
3.3 capillary diameter Ø=0.5 mm and wall thickness=0.01 mm. The patterns were collected on Panalytical 
X’Pert Pro equipped with a focusing Mirror and a Pixcel detector in the range 3-50°2θ. 
It is worth noting that the powder is fluffy and sticky hence the preparation of the capillary is very challenging. 
It was possible to fill the capillary for about 1-1.5 cm with difficulties and the powder packing is not 
homogeneous. 
The crystalline references showed a crystalline pattern ascribable to the hemihydrate crystalline form retrieved 
from the CSD (Figure 18). No significant differences for the position and relative intensities of the peaks have 
been observed. Nevertheless, the crystalline_EXP03 showed lower intensity and signal to noise ratio. It was 
probably due to the lower amount of material present in the capillary, indeed the contribution of the capillary 
profile (grey line) appeared clear in all the patterns (Figure 17). 
The crystalline powder obtained by EXP01 was considered as the 100% crystalline reference. The XRPD 
pattern of EXP01 is comparable to the calculated pattern of hemihydrate form of the API. Nevertheless, it is 
worth to point out that in solid state quantification the 100% crystalline reference might be not achievable 






Figure 17. XRPD pattern comparison between crystalline references EXP01 (red line), EXP03 (green line), 
amorphous reference (blue line) and empty glass capillary (grey line) 
 
 
Figure 18. XRPD pattern comparison between crystalline references EXP01 (red line), EXP03 (green line) and 
calculated pattern from CSD of hemihydrate form 
 
3.2.2 Technique selection 
The balloon catheter holds 3.5 µg/mm2, indeed the diminished amount of the drug was one of the challenging 
of the quantitative method development. Further issue was the requirement of powder isolation due to the high 
potency of the drug. Therefore, the choice of the analytical technique and the analysis settings were relevant 
and preliminary test were performed to optimize the instrumental and measurement condition. The powder 
pattern was collected with different diffractometers with different set-ups to select the more effective option: 
• Micro-diffractometer (UNIFI) 
• Transmission diffractometer (UNIBO) 
o Soller 0.04 rad. 




In collaboration with the University of Firenze chemistry department “Ugo Schiff” Structural Crystallography 
(UNIFI-CRIST), the DCB sample Test 02 was analysed using micro-diffractometer Bruker D8 Venture 
equipped with IµS 3.0 micro focus X-ray source (Cu and Mo) and PHOTON III detector. The pattern was 
collected with Cu radiation and spot of the X-ray focus in the range of 100 µm.  
Three different patterns in three different point of the sample were collected using the micro-diffractometer in 
the range 4-36°2θ. The three XRPD patterns were comparable, denoting the homogeneity of the sample 
(Figure 19).  
 
Figure 19. XRPD pattern comparison between three different area of the drug powder capillary collected by 
UNIFI-CRIST 
 
At University of Bologna chemistry department “Giacomo Ciamician”, the powder patterns of all samples were 
collected with PANalytical X’pert Pro in transmission geometry equipped with a focusing Mirror and a Pixcel 
detector. Measurements in the range 3-40°2θ with both soller 0.02 rad. and soller 0.04 rad were performed. 
As expected, the pattern collected with soller 0.02 rad. showed less instrumental aberration and better resolved 
peaks (Figure 20). The pattern UNIBO_soller004 was scaled to appreciate the resolution difference of the two 
measurements settings.  
 
 
Figure 20. XRPD pattern comparison of the drug powder capillary collected by UNIBO with soller 0.04 rad (red 
line) and soller 0.02 rad. (blue line) 
 
The XRPD patterns collected with micro-diffractometer at UNIFI-CRIST and with transmission diffractometer 















FWHM due to instrumental aberration, while the patterns collected at UNIBO showed a remarkable resolution. 
Moreover, the X-ray beam irradiate a larger amount of sample increasing the representativeness of the 
measure (Figure 21). Additionally, the UNIBO analysis required less time for the results release. Therefore, 
the UNIBO transmission set up was chosen to analyse the samples for the significantly higher resolution, better 
statistic and representativity due to the amount of analysed sample and faster analysis procedure.   
 
 
Figure 21. XRPD pattern comparison between UNIFI-micro (red line) an UNIBO-transmission with soller 0.02 rad. 
(blue line) 
 
3.2.3 Sample preparation and Data collection 
During the manufacturing process of the drug coated balloon, the drug has been stored above inflated balloon. 
Successively, the balloon coated by the drug has been deflated and folded. To recover all the drug onto the 
balloon, it was inflated using water until pressure 10 bar as such all the surface of the balloon was exposed. 
The thin layer of powder deposited onto the balloon was gently scratched using a spatula avoiding the breaking 
of the balloon and water spill. It is was possible to recover about 10 mg of powder.  
The glass capillary for the X-ray measurements was filled with the recovered powder. 
All the balloon samples (Test 02, Test 03, and Test 04) and the crystalline and amorphous references were 
analysed into glass capillary by X-Ray diffraction in transmission mode with generator 40 kV and 40 mA in the 
range 3-50°2θ with step size 0.0131° and counting time 130 seconds. The pattern was collected four time to 
increase the signal to background ratio. Additionally, an empty capillary was measured in the same condition 
to describe the background.  
For all the data treatment the PANalytical HighScore 4.8 software was used.   
The DCB formulation contains a low amount of an excipient, that cannot be revealed. Nevertheless, any peak 
of the excipient was not detected in the XRPD pattern of the DCB sample Test 02, Test 03 and Test 04 (see 
Figure 22), probably because of the excipient is in very small amount or it is amorphous. Therefore, the 






Figure 22. Comparison between the mean XRPD pattern of the samples Test 02 (blue line), Test 03 (green line), 
Test 04 (pink line), blank analysis of glass capillary (cyan line) and references amorphous (orange line) and 
crystalline (red line) 
 
3.2.4 Crystallinity determination: USP method 
The crystallinity degree of crystalline API (100% crystalline) and the DCB samples was calculated using the 
USP method. 
As described before, this method requires the identification of the three different areas in the X-ray pattern: the 
background area (C in Figure 23) which is due to scattering of the air, instrument and sample holder, the 
Crystalline area (A) which is due to the crystalline phase present in the sample, normally is the area of the 






Figure 23. Example of USP method: graphical illustration of area A, B and C 
 
The identification of the three areas labelled as crystalline area (A), total area below the crystalline peaks (B) 
and background area (C) was delimitated as following: 
 
• A  XRPD pattern of samples 
• B  Background calculated using HighScore as following: 
▪ Granularity 12 
▪ Bending 0 
▪ Use smoothed input data 
• C  Empty capillary measure 
 
Figure 25, Figure 26, Figure 27 and Figure 28 reports the area determination for crystalline reference and DCB 
samples. The crystalline area A was composed by the area of the crystalline peaks (red area) and it was 
delimitated by the experimental XRPD pattern line (red line) and the background line (green line). All the area 
below the background line (green line) was identified as area B, which comprised the signal due to the 
amorphous component (green area) and background area (blue area). The background area (C) was included 
in the area B and it was identified with the area below the capillary blank pattern (blue area), it represents the 
signal due to capillary and instrument scattering (air scattering, fluorescence, equipment etc). The crystalline 
degree is calculated with the following formula: 
 
% 𝑐𝑟𝑦𝑠𝑡𝑎𝑙𝑙𝑖𝑛𝑖𝑡𝑦 = 100 ∗
𝐴
(𝐴 + 𝐵 − 𝐶)
 
 
In Figure 24 it can be noticed that crystalline reference pattern followed the contour of the capillary, indeed the 
crystalline reference did not show an amorphous contribute and it can be considered 100% crystalline.  
Nevertheless, applying the area determination described above, the crystalline reference crystallinity degree 
resulted to be 54.39%, considerably lower than the expected value, therefore it was necessary to apply a 
correction factor of 1.84 to reach the 100% of crystallinity degree in the crystalline reference. Supposing that 
the entity of the underestimation error was constant, the % crystalline of the DCB samples was calculated 
applying the correction factor. The corrected crystalline %, all the DCB samples showed high crystallinity 
degree, especially the sample Test 03 with 97%, regardless the samples Test 02 and Test 04 showed 
crystallinity degree higher than 80% (see Table 6).  
The results obtained reported only and indication and are comparative to the crystalline reference considering 
it 100% crystalline. It is important to point out that the USP method is a comparative method. Regrettably, in 
absence of a known sample of drug-coated balloon is unattainable to determine the accuracy of the results. 
The general underestimation of crystallinity is due to difficulties to distinguish in the amorphous hump the 
contribution of due to the instrument and capillary and the ones attributable to the amorphous content. 
Especially at high angle, the determination of the background line by HighScore, is placed at the bases of the 
peaks, which does not reflect the real situation. In fact, at high angle there is the overlap of several peaks, 
hence the base line should be lower.  
 
Table 6. USP method results of crystalline reference and DCB samples Test 02, Test 03 and Test 04 






Test 02 43.83 81 
Test 03 52.80 97 











Figure 25. USP method results of crystalline reference with blank capillary as constant background (blue area). 







Figure 26. USP method results of DCB sample Test 02 with blank capillary as constant background (blue area). 
The red and green area represent respectively the crystalline and amorphous area. 
 
 
Figure 27. USP method results of DCB sample Test 03 with blank capillary as constant background (blue area). 







Figure 28. USP method results of DCB sample Test 04 with blank capillary as constant background (blue area). 
The red and green area represent respectively the crystalline and amorphous area. 
 
3.2.5 DDQM 
The application of the DDQM method with the lactose-HPMC system was useful to obtain indication of the 
best approach to follow for the measurements of the challenging DCB samples. 
The raw patterns were analysed as following: 
 
1. Mean of the measurements (4 scans) 
2. Subtract of the capillary 
3. Define the reference phases  
4. Fit the samples using the reference phases 
 
The samples were evaluated in the range 3-35°2θ. The signal of the glass capillary was subtracted in order to 
eliminate the signal due to the sample holder, air scattering and instrumental contribution.  
The availability of pure reference patterns and of crystallographic structure for the crystalline phase was 
notably useful for the quantification method. Concerning the crystalline phase, the peak positions were 
determined on the basis of the cell parameters. This approach was preferred to the utilization of the function 
“search peaks”, which detected only the visible peaks and did not recognize the presence of overlapped peaks 
at high angle.  
The crystalline reference pattern was refined using the Pawley function starting with the unit cell parameters 
related to the crystalline form in the DCB samples:  
Space Group Number: P212121 (19) 
Crystal System: Orthorhombic 
a [Å]:9.689 
b [Å]: 28.076 








The profile was refined using pseudo Voigt function as profile fit function and Caglioti formula for the FWHM. 
The a, b, c [Å] values were refined and the background was refined using polynomial function with two 
coefficients. The refinement reached the value of Rwp=17.7. The achieved Rwp was high, although observing 
the difference plot (in the bottom of Figure 29) satisfactory description of the pattern was achieved in terms of 
peak position and profile, the deviation was observed merely for the intensity of the most intense peaks.  
The amorphous reference was described by manually adding three peaks and modelling them to simulate the 
experimental pattern. After that, the profile of the peaks was refined individually using the pseudo Voigt function 
and individual FWHMs function. The background was set flat at 0 cps (see Figure 30). The refinement reached 




Figure 29. Refinement result for the diffraction pattern of crystalline reference. Red and blue line patterns 
represent experimental and calculated patterns, respectively. The plot in the bottom shows the difference 
between the experimental and calculated intensities. The peak positions are represented by the short lines in 







Figure 30. Refinement result for the diffraction pattern of amorphous reference. Red and blue line patterns 
represent experimental and calculated patterns, respectively. The plot in the bottom shows the difference 
between the experimental and calculated intensities. The peak positions are represented by the short lines in 
the top, while the area of the crystalline peaks is represented by the blue area. 
 
The DCB samples were evaluated based on the refinement achieved for the crystalline and amorphous 
references. The cell and peak profile parameters refined against the reference were used as starting point in 
for the DCB samples. The comparison of the crystalline reference patterns with the DBC test pattern highlight 
some peak shift which suggest a slightly different cell parameters, which is not surprising, considering the 
nature of the molecule and its tendency to absorb small molecule as water and solvent (Figure 31). The Pawley 
refinement was applied to the DBC samples to evaluate potential small variations of cell parameters occur 
during the manufacturing process. The crystalline phase was refinement using Caglioti function and pseudo 
Voigt function as profile function and size and strain function was applied to consider the change of the profile 
compared to reference due to the manufacturing process of the DCB.   
The amorphous phase was refined using individual FWHMs and pseudo Voigt function as profile function. No 
size and strain functions were applied as we were facing to amorphous phase without crystalline order and 
defined structure. The background was refinement using polynomial function with two coefficients.  
Table 7 reports the comparison between the cell parameters of the DCB samples and the crystalline API 
reference after Pawley fit. All the samples showed cell parameters slightly different compared to the crystalline 
reference. The observed increase of the cell volume in the samples was probably ascribable to the nature of 
the molecule, which is inclined to absorb water molecules or small solvent molecules. The absorption of solvent 

















Test 02  
after DDQM 
evaluation 
Test 03  
after DDQM 
evaluation 
Test 04  
after DDQM 
evaluation 
a [Å] 9.676 9.657 9.624 9.637 9.658 
b [Å] 28.146 28.124 28.285 28.260 28.225 
c [Å] 33.664 33.520 33.929 33.855 33.839 
Volume [Å3] 9167.788 9103.814 9236.183 9219.658 9224.372 
 
 
Figure 31. XRPD patterns comparison between crystalline reference (black line) and DCB samples: Test 02 (blue 
line), Test 03 (red line) and Test 04 (green line) 
 
Figure 32, Figure 33, Figure 34 and Figure 35 show the crystalline determination by DDQM in crystalline 
reference and DCB samples Test 02, Test 03 and Test 04, respectively.  
The green area represents the crystalline area, while the blue one represents the amorphous area.  
Even the crystalline reference was refined as described above, it was used as control sample to have indication 
of the potency and accuracy of the method. The refinement of the crystalline reference gave back excellent 
results with crystallinity degree of 99.6%. Otherwise, it showed wide Rwp value of approx. 21% due to bad 
description of the intensity of the highest peaks (Figure 32). Nevertheless, the result obtained for the crystalline 
reference were really encouraging.  
The results for the DCB samples were comparable for samples Test 02 and Test 04, which showed crystallinity 
degree approx. 60% and Rwp value about 8%. The sample Test 03 showed higher crystallinity degree 70% and 
also Rwp = 10%. Nevertheless, the difference plot was satisfactory for all the samples (see Table 8).  
 
Table 8. DDQM results of crystalline reference and DCB samples Test 02, Test 03 and Test 04 
Sample % crystalline Rwp 
Crystalline reference 100% 20.90 
Test 02 59% 8.41 
Test 03 71% 10.15 







Figure 32. Refinement result for the diffraction pattern of crystalline reference. Red and blue line patterns 
represent experimental and calculated patterns, respectively. The plot in the bottom shows the difference 
between the experimental and calculated intensities. The peak positions are represented by the short lines in 
the top, while the area of the crystalline and amorphous peaks are represented respectively by the green area 







Figure 33. Refinement result for the diffraction pattern of DCB sample Test 02. Red and blue line patterns 
represent experimental and calculated patterns, respectively. The plot in the bottom shows the difference 
between the experimental and calculated intensities. The peak positions are represented by the short lines in 









Figure 34. Refinement result for the diffraction pattern of DCB sample Test 03. Red and blue line patterns 
represent experimental and calculated patterns, respectively. The plot in the bottom shows the difference 
between the experimental and calculated intensities. The peak positions are represented by the short lines in 









Figure 35. Refinement result for the diffraction pattern of DCB sample Test 04. Red and blue line patterns 
represent experimental and calculated patterns, respectively. The plot in the bottom shows the difference 
between the experimental and calculated intensities. The peak positions are represented by the short lines in 






3.2.6 Autoscale  
The pure references of crystalline and amorphous API were used as standard for autoscale quantification. All 
samples were analysed into glass capillary, on the assumption that the entity of the capillary signal is constant, 
the samples and the standards patterns were evaluated without the subtraction of the blank capillary measure. 
The autoscale is very quick and simply method. Nevertheless, it is important point out that it does not consider 
the difference in peak positions and profile due to the different cell parameters of the sample.  
Table 9 and Figure 36, Figure 37 and Figure 38 report the results obtained for the DCB samples. The autoscale 
method detected that all the sample were highly crystalline with the Rwp values in the range of 8-13%. However, 
observing the difference plot, the mismatch of the peak positions between the reference pattern and the DBC 
samples was not negligible.   
 
Table 9. Autoscale results of DCB samples Test 02, Test 03 and Test 04 
Sample % crystalline Rwp 
Test 02 100 9.38 
Test 03 97 8.43 





Figure 36. Autoscale result of DCB sample Test 02. The image in the top shows the XRPD pattern comparison 
between the DCB sample in red and the amorphous (blue line) and crystalline (green line) references. In the 







Figure 37. Autoscale result of DCB sample Test 03. The image in the top shows the XRPD pattern comparison 
between the DCB sample in red and the amorphous (blue line) and crystalline (green line) references. In the 







Figure 38. Autoscale result of DCB sample Test 04. The image in the top shows the XRPD pattern comparison 
between the DCB sample in red and the amorphous (blue line) and crystalline (green line) references. In the 






4 CONCLUSION  
The aim of this work was to determine the grade of crystallinity of formulation coated on Drug Coated Balloon 
by X-Ray powder Diffraction. The samples are challenging under different aspects: it is a High Potent classified 
OEB 4, only small amount of sample is available (around 10-15 mg), the reference and DBC patterns are 
slightly different due to different cell parameters. 
Many of the most common amorphous-crystalline quantitative methods, as such as RIR, PONKS, Rietveld and 
univariate method, cannot be applied. In fact, the lack of suitable amount of reference standard does not allow 
to prepare suitable standard mixtures for the quantification. Additionally, the poor amount of formulation does 
not allow to add correct amount of internal standard to the DCB samples. 
Three methods were pinpointed as suitable for the quantification of this problematic type of sample: USP 
method, DDQM and Autoscale.  
First, the three methods were evaluated by means of standard mixtures of α-lactose monohydrate (crystalline 
part) and HPMC (amorphous part), simulating the condition of the DCB samples like the analysis in confined 
condition (analysis in glass capillary), percentage of crystalline and amorphous phases.  
In the case of the USP method, the evaluation of the crystalline part gave good results only after the application 
of a correction factor which was determined on the 100% crystalline. On account of this, USP method can be 
utilized with at least a known sample or when the 100% of crystalline is available as reference standard. In this 
case, the capillary signal was considered as constant background (area C).  
The DDQM compares the area of the involved phases correlated with molecular weight and number of atoms. 
Hence, it can be applied with mixture of compound with different elemental composition. Additionally, DDQM 
is particularly interesting when the crystallographic parameters of the phase are known, the crystalline part 
can be described based on the crystalline structure parameters. The use of Pawley function allowed a better 
description of the crystalline phase thanks to good definition of the crystalline peaks. The capillary signal was 
subtracted by the sample measurement to evaluated exclusively the signal ascribable to the sample.  
The autoscale method is very simple method that requires purely two reference standards: in our case 100% 
crystalline and 100% amorphous. Nevertheless, it is less reliable when the crystalline phase slightly changed 
in the mixture. Although the Rwp values were low, the difference plots were very noisy, the results were due to 
the sum of positive and negative errors. For all the methods the results of crystallinity degree obtained for α-
lactose monohydrate and HPMC mixtures are comparable and satisfactory.  
The studies on the α-lactose-HPMC mixtures allowed us to optimize the data treatment and the background 
correction to apply in the DCB samples.  
The three DCB samples (Test 02, Test 03 and Test 04), present more difficulties respect to the standard 
mixture of α-lactose-HPMC: 1) the amount of powder for each sample is around 10-15mg so the filling of the 
capillary is a crucial step. Moreover, the powder did not properly pack inside the capillary, hence the amount 
of powder irradiated is quite variable; 2) the presence of an excipient, which has not been detected in the 
powder, so it was supposed to contribute to the amorphous hump; 3) the nature of API itself because it has 
non-stoichiometric hydrate behaviour, so the crystal structure can slightly change from sample to sample. In 
particularly it was not possible to obtain the reference sample 100% crystalline with peak in the same position 
as in the DCB samples. 
Visually, the samples Test 02, Test 03 and Test 04 were very similar in intensity and peak shape and they 
slightly differed from the crystalline API, which was characterized by sharper peaks and shifted in positions, in 
particularly, at high angle.  
The three quantitative methods gave back different results on the crystalline %. Concerning the autoscale 
method, all DCB samples showed crystallinity degree comparable to the crystalline reference however this 
method was not considered suitable method because the difference plot was very noisy due to the mismatch 
of the crystalline peak positions in the reference and the samples, that suggests unreliability of the results.  
USP method gave a crystallinity around the 81%-97%, while the DDQM gave a crystallinity between 59%-
71%. The results of USP method and DDQM method are not comparable between them but they are consistent 
inside the method. Both methods agree to determine the sample Test 03 as the most crystalline sample and 
the other sample Test 02 and Test 04 with a comparable crystallinity degree. Unfortunately, it is impossible to 
estimate the accuracy of each method because of lack of known DCB sample. The only available known 
sample determined with both the methods is the assume 100% crystalline reference standard, which did not 




percentage of the crystalline reference. In fact, for USP method needs a correction factor to reach the value 
of 100%. The reference was used to determine the value of this correction factor to determine crystallinity 
degree of the DCB sample on the assumption that there is a linear correlation. Differently, in DDQM method 
the reference 100% crystalline was firstly used to determine the crystalline phase. Successively, the crystalline 
API pattern was quantified as the same way of the other DCB sample given back excellent result of 100% 
crystalline without application of correction factor. Furthermore, DDQM sample allowed the application of 
Pawley function. Hence, it was possible to calculate the unit cell parameters of the DCB samples. Considering 
the nature of API molecule, which has non-stochiometric behaviour, it allows to supervise modification in the 
unit cell due to the manufacturing process. In fact, the Test 02, Test 03, and Test 04 showed unit cell 
parameters slightly different than the reference, especially with larger volume of the cell, indicating a 
modification in solvent content during the manufacturing process.  
In conclusion, considering the three quantitative methods evaluated, the DDQM is considered the best method 
to estimate the crystallinity degree of formulation onto DCB because of the directly determination without 
application of a correct factor and of the possible application of Pawley function and hence determination of 
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My PhD project is focused on crystal forms of API that are extremely important in pharmaceutical industry. 
Characterization and quantifications of polymorphs, solvates, and cocrystals are common requests from the 
regulatory bodies. In the chapter 2, I presented an interesting study on the cocrystal screening of Allantoin. 
Cocrystals are of particularly interest because of their potentially improvement in solubility and efficacy of 
drugs. The growing interest led the crystal engineering to develop statistical tools to identify molecular reactive 
sites, suitable coformers, and to evaluate the propensity to form cocrystal, as such as CSD-Materials module 
present within Mercury used for the study of Allantoin. The results obtained through CSD-Materials suggest 
propensity of Allantoin to form cocrystal with several molecules. Despite the favourable statistics, allantoin did 
not form cocrystal with any tested coformer. The allantoin’s small dimension and the presence of groups able 
to hydrogen bond interactions encourage the generation of cocrystals, but the high stability of the crystal form 
of Allantoin (until now the only one) prevents the formation of the cocrystals. These results should deserve 
further investigation to understand which step is fallacious: the prediction step, which misses some important 
descriptors or the experimental part where correct conditions to form cocrystal have not found yet. 
In chapter 3 I have described which are the source of errors and aberration which affect the analysis by X-ray 
powder Diffraction. The X-Ray diffraction is the lead technique for the study of the solid state because it 
provides easily and readily qualitative information about the polymorph. The knowledge of the source of errors 
and aberration in the analysis allows to optimize the measurement and prevent wrong conclusion. This 
technique is extremely useful also in case of quantitative analysis, as presented in chapter 4, in which several 
factors can be affected the analysis and the results as such as preferred orientation phenomenon, particle 
size, thickness, and amount of sample. Furthermore, the homogeneity of the calibration mixtures is extremely 
impacting and challenging aspect for solid-state quantification. The condition for successful quantitative 
method development is to obtain homogeneous mixture analysed using correct measurement settings. In 
chapter 5 I have compared the quantification by Standard Addition Method (SAM) with univariate and 
multivariate approach. Especially, the quantitative analysis of formulation and amorphous-crystalline are 
complicated, respectively due to the numerous peaks of excipients and the instability of the amorphous and 
the indirect quantification. In case of formulation the signal of the excipients was considered as matrix effect, 
inspired by the HPLC methods the standard addition method was used with satisfactory results. This method 
is extremely useful especially in case of no specific peaks, although it should be emphasised that this method 
requires preparation of standard addition mixtures and construction of calibration curve for each sample 
considerably extending the time of analysis.  
Determination of the Crystalline fraction has been a fundamental part of the thesis and chapter 6 and 7 present 
the evaluation of different method of quantification and their application in a real case. 
In case of amorphous-crystalline quantification it is important to monitor the eventually transition of the 
amorphous phase, for example promoted by mixing. Sometimes, the amorphous is not available for the 
preparation of mixture because of its instability. In these cases, the use of surrogate amorphous as such as 
hydroxypropyl methyl cellulose (HPMC) has demonstrated to be resolutive. It is worth noting to take in 
consideration the difference in mass absorption coefficient between surrogate amorphous and crystalline 
phase. The use of surrogate amorphous is recommended exclusively when real amorphous is unreachable.  
The study has evidenced the different response for various peaks in quantification with univariate analysis 
revealing that the choice of the quantification peak is significant. This aspect can be easily overcome using 
multivariate analysis that evaluates the whole pattern and unique specific peak is not necessary, extremely 
useful in case of formulation analysis. The PLS multivariate analysis has compensated the preferred 
orientation that slightly affect some peaks in crystalline lactose and the variability of the aliquots of the same 
standard mixtures. However, in X-Ray diffraction quantitative analysis it is recommended to use method based 
on whole pattern of this technique as such as direct derivation method. The direct derivation method is based 
on IC formula that can calculate the weight fraction of the individual phases in a mixture using only the chemical 
formulas of the mixture’s constituents. Although, it is advisable to apply the unit cell parameters when available, 
because the studies have revealed the improvement in accuracy of the results. The direct derivation method 
is extremely adaptable, simple, advantageous, readily, and single point method. Its execution was extremely 
useful in the determination of highly complex sample, as formulation into catheter balloon, when no other 
method was feasible.  
